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VOORWOORD  
Ouderen gebruiken meer geneesmiddelen dan om het even welke andere leeftijdsgroep. 
Ze hebben vaker langdurige, chronische ziekten en omdat vele ouderen aan meerdere 
ziekten lijden, gebruiken ze vaak verschillende geneesmiddelen tegelijkertijd. Ongeveer 
8% van de Belgische 65-plussers en 42% van de 85-plussers woont in een rust- of 
verzorgingstehuis. De kwaliteit van de geneesmiddelen die ouderen in de residentiële 
zorg gebruiken, vormt een belangrijke bekommernis voor het overheidsbeleid, gezien 
het toenemende aantal mensen in dit segment van de bevolking. De komende tien jaar 
zal het aantal 85-plussers in ons land stijgen van de huidige 180,000 tot 285,000.  
België heeft een vrij uniek model van residentiële zorg voor ouderen. Rust- en 
verzorgingstehuizen bieden een thuisvervangende omgeving wanneer de mogelijkheden 
inzake thuiszorg of transmurale zorg niet meer volstaan. Er wonen ouderen die licht tot 
sterk afhankelijk zijn en demente en niet-demente ouderen samen in één instelling. 
Ouderen kunnen overstappen van het éne zorgniveau naar het andere - van een 
rusthuis naar een verzorgingstehuis - zonder het gebouw te verlaten. De rust- en 
verzorgingstehuizen liggen over het hele land verspreid. Bijna elke gemeente heeft zijn 
eigen rust- of verzorgingstehuis.  
Het doel van deze studie was de kwaliteit van het geneesmiddelengebruik en van het 
voorschrijfgedrag in rust- en verzorgingstehuizen te onderzoeken en de mogelijke 
invloed van organisatiekenmerken van de instellingen na te gaan. Om op deze vragen te 
antwoorden, zijn betrouwbare gegevens over de instelling en over de resident 
onontbeerlijk. Als aanvulling op de informatie die in de beschikbare administratieve 
databanken, zoals Farmanet, aanwezig was, werd een veldstudie uitgevoerd in een 
selectie van instellingen en residenten in de provincies Antwerpen, Oost-Vlaanderen en 
Henegouwen. Onze welgemeende dank gaat dan ook uit naar de vele instellingen, hun 
coördinerend en raadgevend arts (CRA), de vele huisartsen en verder de 
verpleegkundigen en het verzorgend personeel die met het nodige enthousiasme 
meewerkten aan deze studie. Dit toont op de eerste plaats het engagement en 
bekommernis van alle betrokkenen om de zorgkwaliteit waar mogelijk te verbeteren. 
Dit rapport is het resultaat van een samenwerking tussen het KCE, het RIZIV en een 
consortium onder leiding van het Heymans Instituut voor Farmacologie (Gent). Het 
biedt aangrijpingspunten om de kwaliteit van het geneesmiddelengebruik in Belgische 
rust- en verzorgingstehuizen verder te blijven bewaken en te verbeteren. Dat zal een 
aanhoudende inspanning vergen. 
 
 
 
 
Jean-Pierre CLOSON    Dirk RAMAEKERS 
Adjunct algemeen directeur    Algemeen directeur 
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Executive summary 
INLEIDING 
Op 1 januari 2005 vertegenwoordigden de 65-plussers ongeveer 17.2% van de 
10.4 miljoen Belgische inwoners, 1.6 % was ouder dan 85. Ongeveer 8% van de 65-
plussers woont in een rusthuis of een rust- en verzorgingstehuis. De kwaliteit van de 
geneesmiddelen die ouderen in de residentiële zorg gebruiken, vormt een belangrijke 
bekommernis voor het overheidsbeleid, gezien dit segment van de bevolking toeneemt 
en veel geneesmiddelen gebruikt. Het is algemeen bekend dat oudere mensen meer 
geneesmiddelen nemen dan gelijk welke andere leeftijdsgroep. Ouderen hebben vaker 
langdurige, chronische ziektes dan jongere mensen. Omdat velen van hen meerdere 
ziektes of aandoeningen hebben, nemen ze ook meerdere geneesmiddelen tegelijk. 
In tegenstelling tot andere landen bestaat er weinig empirisch onderzoek naar de 
kwaliteit van het geneesmiddelengebruik en de kwaliteit van het voorschrijfgedrag in de 
residentiële zorg voor ouderen in België. Dit komt vooral door een gebrek aan vlot 
toegankelijke gegevens. Het doel van deze studie was de kwaliteit van het 
geneesmiddelengebruik en van het voorschrijfgedrag in de residentiële zorg voor 
ouderen te onderzoeken alsook de relatie met organisatiekenmerken. Deze ruime 
onderzoeksvraag werd vertaald naar een aantal meer specifieke vragen: Wat is de 
omvang van het geneesmiddelengebruik door ouderen in de langdurige residentiële zorg 
in België en welke kosten zijn eraan verbonden? Wat zijn de medische behoeften van 
geïnstitutionaliseerde ouderen? Welke kwaliteitsindicator(en) moet(en) worden 
aanbevolen als hulp bij de monitoring en verbetering van de kwaliteit van de zorg die 
worden verstrekt in Belgische rust- en verzorgingstehuizen? Welke zijn de algemene 
eigenschappen van het geneesmiddelenbeheer in Belgische rust- en verzorgingstehuizen? 
Welke organisatiekenmerken houden verband met de kwaliteit van het 
geneesmiddelengebruik? Aangezien de bestaande administratieve databases niet alle 
nodige informatie bevatten, werd een veldonderzoek gedaan bij een aantal 
verzorgingstehuizen en hun bewoners. 
ALGEMENE KENMERKEN VAN DE LANGDURIGE 
RESIDENTIËLE ZORG VOOR OUDEREN IN BELGIË 
België heeft een vrij uniek model van langdurige residentiële zorg voor ouderen. 
Rusthuizen (ROB) bieden een thuisvervangende omgeving wanneer de mogelijkheden 
inzake thuiszorg of korte intramurale zorg niet meer volstaan. Rust- en 
verzorgingstehuizen (RVT) zijn bedoeld voor patiënten die langdurige verzorging nodig 
hebben, en die voor hun dagelijkse activiteiten sterk afhangen van de hulp van anderen. 
In Belgische residentiële instellingen voor ouderen wonen zowel patiënten die licht als 
sterk afhankelijk zijn en demente en niet-demente patiënten samen in één instelling. 
Ouderen kunnen overstappen van het éne zorgniveau naar het andere - van een 
rusthuis naar een verzorgingstehuis - zonder het gebouw te verlaten. Op 31 december 
2004 waren er 665 zuivere rusthuizen, 970 gemengde instellingen (ROB/RVT) en 
45 zuivere verzorgingstehuizen. Ongeveer 150,000 ouderen verbleven in een rusthuis of 
een rust- of verzorgingstehuis in 2004. Meer dan 75% van hen waren vrouwen, 46% was 
ouder dan 85.  
De residentiële instellingen voor ouderen zijn over het hele land verspreid. Bijna elke 
gemeente heeft zijn eigen rust- of verzorgingstehuis. Toch bestaan er belangrijke 
verschillen tussen de provincies en binnen eenzelfde provincie wat betreft het aantal 
bedden in de instellingen. Op provinciaal niveau hebben Henegouwen en Luik veruit het 
grootste aantal leeftijd-gestratificeerde bedden voor ouderen (>4,099 bedden per 
100,000 inwoners vanaf 50 jaar), tegenover de provincies Limburg en Vlaams-Brabant 
die het laagste aantal hebben (<2,700 bedden).  
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GEAGGREGEERD GENEESMIDDELENGEBRUIK IN 
RUSTHUIZEN EN RUST- EN 
VERZORGINGSTEHUIZEN 
De meeste rust- en verzorgingstehuizen kopen hun geneesmiddelen via lokale 
apothekers. Geneesmiddelen worden terugbetaald op een betaling per prestatie basis in 
België. De Farmanet databank bevat gedetailleerde informatie over voorschriften die 
worden afgeleverd in lokale apotheken in België. Aangezien voorschriften die worden 
afgeleverd in ziekenhuisapotheken niet zijn opgenomen in Farmanet, zijn onze ramingen 
over het geneesmiddelengebruik lichtjes onderschat. De gegevens over het 
geneesmiddelengebruik worden ingedeeld volgens het Anatomical Therapeutic Chemical 
(ATC) classificatiesysteem. Om de verdeling van het geneesmiddelengebruik te 
berekenen, maken we gebruik van de Defined Daily Dose (DDD).  
De vier belangrijkste ATC1-groepen van geneesmiddelengebruik bij 
geïnstitutionaliseerde ouderen in België hebben betrekking op het cardiovasculaire, 
zenuw-, gastro-intestinaal en luchtwegenstelsel. Voor hart- en vaatziekten is 
molsidomine het meest voorgeschreven geneesmiddel, gevolgd door enkele middelen 
tegen hoge bloeddruk, tegen aritmie van klasse III en statines. De groep geneesmiddelen 
voor het zenuwstelsel wordt overheerst door antidepressiva, de tweede plaats wordt 
ingenomen door atypische antipsychotica. Bovendien wordt betahistine nog steeds in 
ruime mate gebruikt. Voor het maag- en darmstelsel zijn geneesmiddelen om peptische 
ziektes te behandelen het meest gebruikt. Bij de geneesmiddelen werkend op het 
metabolisme vormen de orale antidiabetica de grootste groep. Mucolytica worden nog 
in ruime mate gebruikt. Ze worden gevolgd door verschillende inhalatiepreparaten die 
worden gebruikt voor obstructieve longziektes. Er bestaan duidelijke geografische 
verschillen in het voorschrijven voor meerdere geneesmiddelenklassen. 
GEAGGREGEERDE UITGAVEN IN RUSTHUIZEN EN 
RUST- EN VERZORGINGSTEHUIZEN 
De totale uitgaven voor farmaceutische specialiteiten afgeleverd door lokale apotheken 
voor residentiële ouderen liepen op tot meer dan 130 miljoen € in 2004.  82% werd 
betaald door de ziekteverzekering, 18% door de bewoners zelf. Antidepressiva, 
antipsychotica en antitrombotische middelen zorgen voor de hoogste kosten voor de 
ziekteverzekering. Samen zijn de 10 meest voorgeschreven ATC3-klassen goed voor 
bijna de helft van het totale budget. De prijs van een individueel geneesmiddel is echter 
ook een belangrijke determinant van de budgetimpact voor de ziekteverzekering. 
Vooral geneesmiddelen die infectieziekten voorkomen of behandelen (griepvaccin, 
verschillende antibiotica en antimycotica) hebben een hogere individuele kost. 
Daarnaast is ook de individuele kost voor verschillende hormonen, geneesmiddelen 
tegen de ziekte van Alzheimer, antipsychotica en opioïden vrij hoog.                 
LITERATUUR OVER HET 
GENEESMIDDELENGEBRUIK IN 
VERZORGINGSTEHUIZEN VOOR OUDEREN 
De bespreking van de internationale literatuur over het geneesmiddelengebruik in 
verzorgingstehuizen maakt gebruik van MEDLINE, International Pharmaceutical 
Abstracts en EMBASE, met behulp van een zoekstrategie op basis van 6 reeksen 
sleutelwoorden. Er werden relevante referenties uit relevante artikelen gehaald 
(sneeuwbalmethode). Een beperkte reeks van 40 uiterst relevante artikelen werd als 
vertrekpunt gehanteerd om het “related articles” algoritme in Pubmed toe te passen en 
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om te zoeken in Web of Science. Deze strategie leidde uiteindelijk tot 170 relevante 
artikelen.  
Deze artikelen kwamen aan bod in een narratieve bespreking, niet in een systematische 
bespreking. De bedoeling hiervan was een breedschalig overzicht te geven van het 
onderwerp als voorbereiding op de veldstudie, om de nodige elementen te leveren om 
vragenlijsten op te stellen en om bestaande sets van kwaliteitsindicatoren te beoordelen 
op hun relevantie in het kader van verzorgingstehuizen voor ouderen. Er werden geen 
pogingen gedaan tot formele gegevensextractie voor het samenvoegen van gegevens.  
Het belangrijkste besluit van dit literatuuroverzicht is dat verschillende 
interventiestrategieën in verzorgingstehuizen de kwaliteit van het voorschrijfgedrag 
kunnen verbeteren. Er bestaat enig bewijs van de effectiviteit voor farmaceutische zorg 
en multidisciplinaire interventies, waarbij het hele team van zorgverleners betrokken is. 
De omvang, expertise en cultuur van het verplegend personeel is belangrijk voor de 
kwaliteit van de geneesmiddelenverstrekking en van de controleprocessen. Er is meer 
onderzoek nodig naar de implementatie van geneesmiddelenformularia in 
verzorgingstehuizen en naar het gebruik van informatietechnologieën om het 
geneesmiddelenbeheer te verbeteren.  
Bestaand onderzoek richt zich op structurele indicatoren (algemene eigenschappen van 
instellingen en de eigenschappen van hun geneesmiddelenbeheersystemen).  De impact 
van deze structurele indicatoren op het voorschrijfproces is onderzocht aan de hand 
van recent ontwikkelde procesindicatoren van de voorschrijfkwaliteit. Er worden 
verschillende sets van kwaliteitsindicatoren van het voorschrijven ontwikkeld voor 
verzorgingstehuizen, die elk verschillende aspecten van de voorschrijfkwaliteit meten. 
Geen ervan is volledig gevalideerd of is universeel toepasbaar. Bovendien ontbreekt het 
bewijs dat er een verband bestaat tussen structurele indicatoren, procesindicatoren en 
directe metingen van resultaten bij de bewoners.   
VELDONDERZOEK 
Rationale  
Uitgangspunt van het veldonderzoek was de vaststelling dat niet alle vragen die in dit 
rapport aan bod komen uitsluitend beantwoord kunnen worden op basis van de 
bestaande administratieve datasets, zoals Farmanet. Om de kwaliteit van het 
geneesmiddelengebruik van residentiële ouderen te beoordelen zijn betrouwbare 
gegevens over de instelling en over de resident onontbeerlijk. Een veldonderzoek 
ondervangt de meeste beperkingen van de administratieve datasets.   
Het belangrijkste doel van het veldonderzoek (PHEBE-onderzoek) was de relatie te 
onderzoeken tussen de institutionele eigenschappen, de 
geneesmiddelenbeheersystemen en de kwaliteit van het voorschrijfproces.  Daarnaast 
wilde het onderzoek bestaande sets van kwaliteitsindicatoren van het voorschrijven 
evalueren met betrekking tot hun geschiktheid om te worden toegepast in de Belgische 
context. 
Ontwerp en steekproefprocedure 
Het onderzoek werd uitgevoerd als een cross-sectioneel beschrijvend onderzoek van 
een representatieve steekproef van rust- en verzorgingstehuizen en hun inwoners. Rust- 
en verzorgingstehuizen (>30 bedden, RVT-bedden inbegrepen) werden willekeurig 
geselecteerd (N=76) in de provincies Antwerpen, Oost-Vlaanderen en Henegouwen op 
basis van een stratificatie volgens de grootte (tot 90 of meer dan 90 inwoners) en het 
type (openbaar, privé). In elke geselecteerde instelling werden 40 bewoners willekeurig 
geselecteerd. 
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Gegevensverzameling 
Op het niveau van het rust- en verzorgingstehuis werden gegevens ingezameld aan de 
hand van een gestructureerd interview met de directeur en één of twee 
hoofdverpleegsters. De gestructureerde vragenlijst richtte zich op de eigenschappen van 
het geneesmiddelenbeheersysteem. De organisatorische eigenschappen van het 
geneesmiddelenproces werden omgezet in een scoresysteem met een evaluatie van de 
kwaliteit van de verschillende aspecten van het geneesmiddelenbeheersysteem (gebruik 
van formularium, communicatie, bewaring, bereiding en toediening van geneesmiddelen). 
Op het niveau van de inwoners werden administratieve gegevens verzameld en er werd 
een kopie van de geneesmiddelenfiche genomen. De geneesmiddelen op de fiche 
werden ingevoerd in een database. Een afdruk werd verstuurd naar de behandelende 
arts met de vraag de geneesmiddelen te controleren en aan te vullen met informatie 
over klinische problemen en zorgproblemen van de bewoner. Op die manier kon de 
kwaliteit van het voorschrijfproces van geneesmiddelen worden beoordeeld. We 
gebruikten drie bestaande sets van kwaliteitsindicatoren van het voorschrijven, die 
speciaal waren aangepast aan de situatie van ouderen: de BEERS-criteria voor potentieel 
ongepast voorschrijven voor ouderen, de ACOVE-criteria voor onvoldoende 
voorschrijven voor ouderen en BEDNURS (Bergen District Nursing Home Studie). 
Daarnaast voegden we nog 2 andere kwaliteitsbenaderingen van het voorschrijfgedrag 
toe: gebruik van chronische benzodiazepines en Belgische geneesmiddelen met een lage 
baten/risicoverhouding. Dit onderzoek werd uitgevoerd in 76 willekeurig geselecteerde 
verzorgingstehuizen en bij 2,510 bewoners voor wie we over de administratieve 
gegevens en de geneesmiddelenfiche beschikten. 
Organisatiekenmerken van de verzorgingstehuizen  
De geselecteerde rust- en verzorgingstehuizen hadden een gemiddelde capaciteit van 
106 bedden (variërend tussen 35 - 306) en 1 tot 7 afdelingen, vooral met een gemengd 
karakter en open voor alle soorten bewoners. De grote meerderheid van de 
instellingen kocht de geneesmiddelen bij een lokale apotheek (83%), 1/4 met prijzen op 
basis van een openbare aanbesteding en 1/3 op basis van een informele overeenkomst. 
De meeste tehuizen werkten met een geneesmiddelenformularium, maar de mate van 
implementatie verschilde aanzienlijk. De gebruikte geneesmiddelenfiches werden in 21% 
van de instellingen nog met de hand geschreven.  Een of meer van de verplichte items 
op de kaart ontbrak in 30% van de instellingen. Kwaliteitsscores van het 
geneesmiddelenbeheersysteem toonden een ruime variatie in alle geëvalueerde 
domeinen. Voor de meeste domeinen lag de mediaanwaarde dicht bij nul, wat erop wijst 
dat alleen aan de wettelijke verplichting was voldaan.   
De kwaliteit van het geneesmiddelenbeheersysteem werd beïnvloed door de locatie van 
de instelling, de activiteiten van de lokale apotheker en vooral door de kwaliteit van het 
verplegend personeel (aantal bewoners behandeld per opgeleide verpleegster en 
percentage bachelorverpleegsters op het totale aantal verpleegsters). 
Eigenschappen van de bewoners 
De geselecteerde bewoners hadden een gemiddelde leeftijd van 85 jaar (variërend 
tussen 36 en 104), 77% van hen waren vrouwen. De score voor klinische problemen, 
opgetekend door de verantwoordelijke arts, lag tussen 0 en 12 (gemiddelde 2.7). Hart- 
en vaatziekten werden het meest vastgesteld. Daarenboven hadden de bewoners tussen 
0 en 15 zorgproblemen (gemiddelde 2.7). Van alle bewoners had 46% dementie en was 
35% depressief. 
Bewoners kregen tussen 0 en 22 geneesmiddelen, die vermeld stonden op hun 
geneesmiddelenfiche (gemiddelde 8.1). De meeste waren voor chronisch gebruik (88%), 
3% was acute medicatie en 9% “indien nodig”. Het hoogste verbruik werd vastgesteld 
voor psycholeptica (benzodiazepines of antipsychotica) (68% van de bewoners), laxativa 
(50%) en antidepressiva (46%). De totale gemiddelde uitgave per maand en per bewoner 
voor chronische medicatie werd geraamd op 140 €, waaronder een gemiddeld remgeld 
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van 23 € voor terugbetaalde medicatie en een gemiddelde eigen betaling van 27 € voor 
niet terugbetaalde geneesmiddelen. 
Kwaliteit van het voorschrijven van geneesmiddelen  
Bij de beoordeling van de kwaliteit van het voorschrijven werden de meeste problemen 
opgemerkt bij het gebruik van ACOVE-, BEDNURS- en BEERS-criteria. 
Onderbehandeling werd voornamelijk vastgesteld bij patiënten met hartstoornissen. 
BEDNURS scoorde bijzonder hoog voor de combinatie van psychotropische 
geneesmiddelen. BEERS stelde vooral het mogelijks ongepaste gebruik vast van digoxine, 
oxybutyine en amiodarone. De globale score voor problemen in voorschrijfkwaliteit lag 
tussen 0 tot 13 per bewoner (mediaan 2) en toonde een brede variatie tussen 
verzorgingstehuizen. 
De hoeveelheid gebruikte chronische geneesmiddelen werd voornamelijk beïnvloed 
door polypathologie en het aantal zorgproblemen van de bewoner. De hoeveelheid 
gebruikte geneesmiddelen was lager bij de oudsten, bij de demente populatie en in de 
laatste fasen van de palliatieve zorg. Op het niveau van de instelling was de hoeveelheid 
gebruikte medicatie in belangrijke mate beïnvloed door de inbreng van de lokale 
apotheker. Ze was het laagst in grote OCMW-verzorgingstehuizen.   
Institutionele eigenschappen hadden een belangrijke invloed op de uitgaven voor 
chronische geneesmiddelen. Het percentage goedkope geneesmiddelen werd beïnvloed 
door de locatie van het verzorgingstehuis, het gebruik van een 
geneesmiddelenformularium, de activiteiten van de coördinerende arts en de lokale 
apotheker en het bestaan van een systeem van prijsconcurrentie voor de aflevering van 
geneesmiddelen.  
De totale score van problemen in voorschrijfkwaliteit nam toe bij hogere polypathologie 
en bij grotere instellingen, en daalde bij een groter aantal bewoners dat werd behandeld 
door de CRA, een groter aantal activiteiten die de apotheker uitvoerde, een hogere 
gemiddelde leeftijd van de bewoners en een hoger percentage van dementie. 
DISCUSSIE EN ALGEMENE CONCLUSIES 
België heeft een goed uitgebouwd netwerk van rusthuizen en rust- en 
verzorgingstehuizen binnen zijn steden en dorpen, die worden geleid door de sociale 
diensten van de gemeente, door VZW’s en door privé-verenigingen met winstoogmerk. 
Rusthuizen en rust- en verzorgingstehuizen zijn niet gespecialiseerd in specifieke ziektes, 
maar bewoners met verschillende medische problemen wonen er samen in één 
instelling. Vele bewoners worden nog gevolgd door hun vroegere huisarts, maar in 
sommige rust- en verzorgingstehuizen is de coördinerende arts verantwoordelijk voor 
meer dan de helft van de bewoners van het tehuis.  
De grote meerderheid van rust- en verzorgingstehuizen wordt bediend door lokale 
apothekers, die zich weinig bezighouden met klinische apothekersactiviteiten. Zowat 
een op tien instellingen wordt bediend door een ziekenhuisapotheker. De 
geneesmiddelenbeheersystemen in de rust- en verzorgingstehuizen zijn slechts beperkt 
uitgebouwd en richten zich vooral op het distributieproces binnen de instelling, en 
minder op de kwaliteit van het voorschrijven. Weinig bewoners slagen erin enige vorm 
van autonomie te behouden over hun medicatie, behalve in instellingen met een 
beperkte personeelsbezetting en een slecht uitgebouwd distributiebeheer. Hoewel er 
sinds 2004 een formularium bestaat (RVT Formularium) voor rust- en 
verzorgingstehuizen als gids voor het nastreven van rationeel voorschrijfgedrag, lijkt de 
implementatie van dit formularium en de impact ervan op de keuze van geneesmiddelen 
van de bezoekende artsen beperkt. Verzorgingstehuizen die worden geleid door de 
sociale dienst van de gemeente (OCMW) hebben vaker een ziekenhuisapotheker die 
instaat voor de toelevering van geneesmiddelen aan de instelling, hebben vaker een 
coördinerende arts die een groot aantal bewoners binnen de instelling behandelt, en 
hebben ook vaker meer intense geneesmiddelenbeheersystemen.   
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Bewoners van rusthuizen en rust- en verzorgingstehuizen genereren aanzienlijke 
publieke uitgaven voor farmaceutische specialiteiten (123 miljoen € per jaar). Het 
veldonderzoek toonde aan dat bewoners ook grote bedragen zelf betalen voor het 
remgeld van terugbetaalde chronische geneesmiddelen, en voor betalingen aan de 
apotheker voor niet-terugbetaalde medicatie. Hoewel slechts 1.4% van de bevolking in 
een rusthuis of een rust- en verzorgingstehuis woont, wijzen de gegevens uit dit 
veldonderzoek en de gegevens van nationale facturatiedatases erop dat meer dan 5.6% 
van de publieke uitgaven voor geneesmiddelen (farmaceutische specialiteiten) worden 
gegenereerd door bewoners van residentiële instellingen voor ouderen.  
Met betrekking tot de voorschrijfkwaliteit stellen we aanzienlijke polyfarmacie vast bij 
de meeste bewoners. Het grote aantal geneesmiddelen en geneesmiddelencombinaties 
op zich zouden een reden voor bezorgdheid kunnen zijn. Anderzijds kampt de helft van 
de bewoners met minstens één potentieel probleem door het te weinig voorschrijven. 
Het chronische gebruik van benzodiazepines, antidepressiva en antipsychotica (vaak in 
combinatie) is echter opvallend hoog. Zowel de analyse van de nationale gegevens als 
het veldonderzoek toont aan dat er nog steeds verschillende verouderde 
geneesmiddelen of geneesmiddelen waarvan de klinische en kosteneffectiviteit in vraag 
moeten gesteld worden, in gebruik zijn.   
Het aantal vastgestelde kwaliteitsproblemen en de aanwezigheid van polypathologie zijn 
duidelijk gerelateerd. We stellen een daling vast in het aantal kwaliteitsproblemen in die 
instellingen waar de coördinerende arts een groot aantal patiënten behandelt en waar 
de lokale apotheker een actieve rol speelt in het geneesmiddelenbeheer. Om het 
verschil in de voorschrijfkwaliteit volledig te begrijpen, moet echter rekening worden 
gehouden met de sleutelrol van de voorschrijvende arts.  
Interventies om de kwaliteit en de betaalbaarheid van geneesmiddelen in rust- en 
verzorgingstehuizen te verhogen, zullen meer rendabel zijn als ze niet alleen een impact 
hebben op het keuzeproces van geneesmiddelen voor bewoners van rust- en 
verzorgingstehuizen, maar ook op het keuzeproces voor àlle oudere patiënten van de 
huisartsen.   
BELEIDSAANBEVELINGEN  
1. Sinds 2004 is er een wettelijke verplichting voor rust- en verzorgingstehuizen om een 
formularium te hebben als leidraad bij het rationeel voorschrijven. Er moeten 
maatregelen genomen worden om de implementatie te verbeteren en de impact in rust- 
en verzorgingstehuizen en rusthuizen te versterken. Op basis van de resultaten van deze 
studie moet hierin een grotere rol toebedeeld worden aan de coördinerende arts. Het 
formularium kan een sleutelrol spelen in de overdracht van kennis over “best practices” 
naar voorschrijvende artsen in rusthuizen en rust- en verzorgingstehuizen, in het lokaal 
implementeren van richtlijnen over farmacologie en van systemen van kwaliteitsbeheer. 
Een voortdurende nauwe samenwerking tussen de verschillende wetenschappelijke en 
professionele organisaties is van groot belang. De organisaties die onafhankelijke 
farmacotherapeutische informatie leveren en die instaan voor farmacovigilantie zouden 
in staat moeten gesteld worden hun inspanningen te vergroten om samenvattingen van 
de evidentie te maken over het gepast voorschrijven van geneesmiddelen en om het 
bewustzijn te vergroten van de risico’s verbonden aan het gebruik van geneesmiddelen 
bij ouderen.  
2. Lokale afspraken tussen instellingen, voorschrijvende artsen en apothekers over de 
concrete keuze van generische geneesmiddelen kunnen het gebruik ervan stimuleren. 
Momenteel kan de soms zeer ruime beschikbaarheid van verschillende moleculen en 
wisselingen in de toelevering naargelang de apotheker de praktische haalbaarheid van 
een keuze voor generische geneesmiddelen beperken. De mogelijkheden inzake 
toepassing van unit-dose waarbij geneesmiddelen per individuele patiënt verpakt 
worden, zouden moeten onderzocht worden. 
3. De traditionele opleiding van verpleegsters en apothekers dient, in samenwerking 
met de coördinerende arts, geheroriënteerd te worden naar de nieuwe rol van deze 
beroepen in beheersystemen voor medicatie in gezondheidsinstellingen. Betere training 
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van verpleegkundigen in farmacologie en een betere communicatie met de afleverende 
apotheker en voorschrijvende arts kunnen zorgen voor een betere kwaliteit van de 
farmaceutische zorgen in het rust -en verzorgingstehuis. Klinische apothekers kunnen 
hierbij helpen en deelnemen aan de organisatie van alle stadia van het proces van het 
geneesmiddelengebruik: het voorschrijven, aankopen, verpakken, administratie- en 
verdelingssysteem van geneesmiddelen en opvolgen van de werkzaamheid en veiligheid 
van de farmacotherapie.   
4. Geneesmiddelen die worden geleverd door de lokale apotheker worden momenteel 
terugbetaald op een fee-for-service basis. De voor- en nadelen van dit systeem zijn 
gekend. In een poging om stimulansen voor kwaliteitsverhoging en kostenbeheersing te 
combineren, zouden andere financieringssystemen moeten worden onderzocht. Case-
mix budgettering en referentieprijzen zijn twee mogelijke alternatieven die nader 
onderzocht moeten worden. 
5. Onderzoeksagenda: 
x Gegeven het aantal voorschriften voor bepaalde geneesmiddelen, zijn 
voor de volksgezondheid in sommige Belgische regio's verdere 
epidemiologische onderzoeken nodig over de incidentie en de 
prevalentie van aandoeningen zoals majeure depressie, gedragsmatige 
en psychologische symptomen van dementie, ziekte van Menière, diepe 
veneuze trombose, coronaire syndromen en angina pectoris. 
x Er is nood aan betrouwbare en hanteerbare schalen voor het bepalen 
van de zorgbehoefte van instellingen en de continue bepaling van de 
functionele en klinische status van individuele residenten. Gezien de 
aankomende digitale revolutie in de instellingen voor gezondheidszorg, 
kan onderzocht worden hoe de methodes voor gegevensverzameling 
voor farmaceutische en klinische gegevens die in dit onderzoek zijn 
gehanteerd, kunnen gebruikt worden voor continue, geautomatiseerde 
inzameling en het geven van feedback. Er is nood aan methodes die 
uitkomstgegevens (kwaliteit van leven, hospitalisaties en overlijdens, al 
dan niet gebonden aan geneesmiddelen) bepalen en deze integreren in 
het onderzoek naar de kwaliteit van het voorschrijven en van het 
beheer van de geneesmiddelen in de rust -en verzorgingstehuizen. 
x Een vergelijkbare epidemiologische studie van het 
geneesmiddelengebruik en van de kwaliteit van het voorschrijven zou 
moeten uitgevoerd worden bij kwetsbare ouderen in de thuiszorg. 
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1 ORGANIZATIONAL CHARACTERISTICS 
AND AGGREGATED MEDICATION USE IN 
BELGIAN REST AND NURSING HOMES 
Authors: Carine Van de Voorde, Stephan Devriese, Marc De Falleur, Dirk Ramaekers 
1.1 INTRODUCTION 
On January 1, 2005 the elderly (aged 65 and older) represented about 17.2% of the 
10.4 million Belgian inhabitants, 1.6% was over 85 years. Current demographic 
projections suggest that approximately 19% of Belgium’s population will be more than 
65 years by the year 2015, and that people more than 85 years will make up 2.7% of the 
total population. Furthermore it is projected that by the year 2030 almost 25% of the 
population will be aged 65 and older and 3.2% will be 85 or older.1 These projections 
mean that increasing numbers of Belgians will be “the oldest old”. The potential 
consequences of his demographic shift over the next decades for the organization and 
financing of long-term care are a major policy concern and research topic in Belgium 
and other countries facing the same demographic evolution.2 
Although the health care needs of many older people are not so different from those of 
the rest of the population, for the oldest old and those with chronic diseases or 
disability the prevalence rate of long-term care is high and increasing in Belgium.3, 2, 4, 5   
One element of caring for the elderly is by making sure they get the right medical care. 
The most common intervention that older people experience is the use of medication. 
It is well-known that older people consume more medication than any other age group. 
They tend to have more long-term, chronic illnesses such as arthritis, diabetes, high 
blood pressure and heart disease than do younger people. Since many elderly have a 
number of diseases or disabilities at the same time, it is common for them to take 
multiple medications at the same time. The hazards of prescribing many drugs, including 
side-effects, drug interactions, under-prescribing of potentially beneficial drugs and 
difficulties of compliance, have been recognized in the international literature as 
particular problems when prescribing for elderly people.  
The quality of medication use by residential elderly is a major concern because of an 
increasing number of people in this segment of the population and the fact that they are 
major consumers of medicines. The quality of medication use depends both on the 
quality of prescribing and the quality of medication management. The medication 
management includes the whole process from the prescribing of the medication, 
through the purchase, packaging, security, administration and distribution system, until 
the follow-up of pharmacotherapy. The determinants of prescribing and of the 
medication process for nursing home residents are not well understood, but 
organizational characteristics of residential settings are a plausible candidate. 
Identification of factors influencing the patterns of medication use in residential elderly 
could lead to development of strategies to optimize medication use with consequent 
improvement in residents' health. 
In other countries, an increasing number of studies were carried out on the quality of 
medication use in elderly residents during the last decade. In Belgium very little research 
has been conducted on this topic, mainly due to a lack of readily available data on the 
consumption and quality of medication. The use of medication and prescribing patterns 
in old age and in residential elderly are hardly documented.  
Belgium has rather limited experience with medication management in residential care 
for the elderly. Yet, during the last years some initiatives have been taken to improve 
the quality of the medication policy. Since 2000 each nursing home must have a medical 
coordinatora. This is a general practitioner, preferably with an additional formation in 
                                                     
a Royal Decree of June 24, 1999. Coördinerend en raadgevend arts (CRA) in Dutch, médecin 
coordinateur et conseiller (MCC) in French. 
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gerontology, who is responsible for the coordination of quality initiatives and for the 
training of the staff. Regarding medication policy the responsibility of the medical 
coordinator includes the development and use of a formulary. Since 2004 such a 
formulary (RVT Formulariumb) for nursing homes is available as a guide to pursuing 
rational prescribing. 
The objective of this study was to investigate the quality of medication use, prescribing 
and medication management in residential homes for the elderly in Belgium. Since the 
available administrative databases do not contain all the information needed, a field 
study was carried out in a selection of nursing homes and residents.   
This introductory chapter presents a general overview of the organization and financing 
of the Belgian residential long-term care for the elderly (section 1.2). Section 1.3 
specifies the research questions. Some previous studies on medication use in residential 
homes for the elderly in Belgium are summarized (section 1.4) and aggregate data on 
medications use and expenditures are provided (section 1.5). Section 1.6 introduces the 
rationale for the field study.  
Chapter 2 provides a report of an international literature search on the needs of 
nursing home residents, on the medication use in nursing homes and on organizational 
characteristics which may affect the quality of prescribing and the quality of medication 
management. 
Chapter 3 is the main part of the report and contains the setting, objectives, methods 
and results of the field study carried out in a selection of nursing homes and their 
residents. 
Chapter 4 discusses and concludes the findings of the report and presents the policy 
recommendations.   
1.2 A BRIEF DESCRIPTION OF THE BELGIAN RESIDENTIAL 
LONG-TERM CARE FOR THE ELDERLYc 
1.2.1 Residential long-term care settings 
“Long-term care” and “residential care” are not easy to define. However, defining the 
boundaries among primary, acute and long-term care and the role of residence for an 
elderly population go far beyond the limits of this study. Instead, we follow the 
definition of long-term residential care of the WHO6: “Institutional or residential long-
term care is defined as the provision of care to three or more unrelated people in the 
same place. Activities undertaken by formal caregivers “may be publicly financed and 
organized, but the services may be provided by governmental organizations, NGOs or 
by the private sector. Formal care is usually provided by professionals (doctors, nurses, 
social workers) and auxiliaries, such as personal care workers”. 
The Belgian elderly care infrastructure comprises at-home care and community 
services, short-term and long-term residential care and hospital care. Long-term 
residential care includes rest homes or homes for the elderlyd and nursing homese. 
A rest home (ROB) is defined as one or more buildings that functionally generate a 
collective residence in which elderly people live on a long-term basis. In the rest home, 
the usual family and household care is given completely or partlyf. The legislator defines 
elderly people as people aged 60 years and older. Younger people can be admitted only 
when approved in writing by the responsible authority. Rest homes offer a home-
                                                     
b See http://www.formularium.be/nl/formularium/frameset.htm for more information.  
c All results in section 1.2 were calculated using administrative databases made available by 
RIZIV/INAMI (National Institute for Sickness and Invalidity Insurance), unless mentioned otherwise. A 
description of the data and record-linkage are provided in the technical note in Appendix 1.  
d Rusthuis (ROB) in Dutch, Maison de repos pour personnes âgées (MRPA) in French. 
e Rust- en verzorgingstehuis (RVT) in Dutch, Maison de repos et de soins (MRS) in French. 
f Article 2, $6 of the Decree of the Flemish Government of December 18, 1991. Article 2 of the 
Decree of the French Region of June 5, 1997. 
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replacing environment when possibilities for long-term care at home or short-term 
residential care are not sufficient anymore.  
Medical characteristics of the residents differentiate rest homes from nursing homes. 
Nursing homes (or beds) are designed for patients with long-term care needs, who are 
heavily dependent on the help of others for the activities of daily living. Eligibility for 
admission to a nursing home rests on the following criteriag:7, 8 
1. The elderly person has undergone all active and reactivating treatment but has not   
regained full competency in activities of daily living (ADL). However, daily medical 
supervision or a specialized medical treatment is not necessary.  
2. All possibilities for at-home care have been explored so that a nursing home 
admission is needed.  
3. The general health status of the elderly person demands, apart from medical care 
provided by a general practitioner and nursing care, paramedical and/or 
physiotherapeutic care and help with activities of daily living.   
4. The elderly person has a degree of care dependency equal to B or C (see 
section 1.2.2.1).  
Rest homes and nursing homes can impose further criteria for admission. Some for 
example do not admit people suffering from dementia, while others exclusively admit 
people with a diagnosis of dementia.7 
For placement in both residential settings, an assessment with multi-disciplinary 
evaluation reports and standardized evaluation scales takes place (see section 1.2.2.1). 
The general practitioner or the nurse (providing hospital or at-home care) fill in the 
evaluation scale. This assessment together with an evaluation of social conditions 
determines eligibility for placement in a rest or nursing home.  
The first nursing homes were created in 1982 with the explicit intention to create an 
intermediary structure between a rest home and a hospital. Nowadays nursing home 
beds are in distinct parts of hospitals or rest homes. There is a merged system of rest 
home and nursing home, which means that the elderly can move between different 
levels of care without leaving the institution.  
The Belgian model of long-term residential care for the elderly is rather unique. Rest 
and nursing homes are not specialized in specific illnesses – except for dementia- but 
accept residents with different medical problems. Moreover, residential homes for the 
elderly are spread all over the country. Nearly every municipality has its own rest or 
nursing home.9 Although many homes have waiting lists, most elderly have the 
opportunity to go to a home in the municipality they live or a neighbouring municipality 
when moving into a residential care home.  
Rest and nursing homes are mainly run by community social services, by religious 
charities and to a more limited extent by private for-profit corporations. 
                                                     
g Article N1 – appendix 1 of the Royal Decree of September 21, 2004.  
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Terminology 
In chapter 1 we use ‘rest home’ to refer to that part of the institution or building with 
accredited rest beds (ROB-bedden). A ‘nursing home’ refers to the part with accredited 
nursing beds (RVT-bedden).  
In chapters 2 and 3 we use ‘nursing home’ for an institution with exclusively nursing 
beds or with rest and nursing beds. In this way the term ‘nursing home’ is used 
according to the international literature.  
1.2.1.1 The responsibilities of authorities for residential long-term care 
The responsibility for residential long-term care is shared between the federal and 
regional authoritiesh. 
The Federal Minister of Social Affairs and Public Health determines the planning and 
accreditation criteria for the nursing homes and the daily lump sum i  allocated by 
RIZIV/INAMI to rest and nursing homes. The Federal Minister of Economy, Energy, 
Foreign Trade and Science Policy fixes the price for hotel (accommodation) services to 
be paid by the resident (see section 1.2.2.2).  
The planning and accreditation criteria for the rest homes are determined by the 
communities (Flemish, French and German-speaking communities).  
The distribution of responsibilities between the different authorities is complicated. 
However, since 1997 three protocol agreements (1997, 2003 and 2005) between the 
federal government and the communities have formulated common objectives of elderly 
care. These agreements allow each authority to flesh out the common objectives 
autonomously according to the local demographic needs. 
1.2.1.2 Number of institutions 
There were 1,678 rest homes (ROB) and 1,015 nursing homes (RVT) with at least one 
bed on December 31, 2004. In a majority of the cases, an institution comprised both a 
rest home and a nursing home. In this way, 970 rest homes and 970 nursing homes 
were each part of a single institution. In other words, 708 rest homes and 45 nursing 
were single entities. The geographical distribution by province is shown in table 1.1.  
Table 1.1 : Number of residential homes by type and province on 
December 31, 2004 
Provinces in Flanders ROB1 RVT1 Total 
Antwerpen 197 162 359 
Vlaams-Brabant 116 83 199 
Limburg 74 55 129 
Oost-Vlaanderen 194 153 347 
West-Vlaanderen 163 150 313 
Provinces in Wallonia    
Hainaut 294 117 411 
Liège 220 107 327 
Namur 102 41 143 
Brabant wallon 68 28 96 
Luxembourg 50 20 70 
Brussels - Capital Region    
Brussels - Capital Region 200 99 299 
1 ROB: rest home; RVT: nursing home; Source: RIZIV/INAMI 
                                                     
h See Appendix 2 for more details on the responsibilities of the different authorities for residential 
long-term care in Belgium. Appendix 2 also provides a detailed overview of the data the rest and 
nursing homes have to report to the responsible authorities. 
i See section 1.2.2.1 for more details on the financing of residential long-term care. 
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1.2.1.3 Number of residential home beds 
On average, the distribution of number of beds for rest homes and for nursing homes is 
fairly similar (see table 1.2). About 25% of both rest homes and nursing homes had 
approximately 30 beds or less on December 31, 2004, while about 25% had more than 
60 beds.  
 
Table 1.2 : Descriptive statistics of the number of residential home beds by 
type of home on December 31, 2004  
  N Min Max Q1 Median Q3 Mean SD 
ROB 1,678 2 234 27 41 59 47.03 28.66 
RVT 1,015 1 347 25 37 58 46.73 28.91 
All 2,693 1 347 27 40 59 46.92 28.75 
Source: RIZIV/INAMI 
An age-stratified number of residential home beds by district suggests a larger potential 
of beds in the Walloon region and the Brussels-Capital region compared to the Flemish 
region (see figure 1.1). This tendency is more pronounced in the provinces of Limburg, 
Hainaut, Liège and Vlaams-Brabant. Although figure 1.1 reveals substantial differences in 
the number of residential home beds within one province and between the provinces, 
the differences between the regions dominate the picture. These regional differences in 
residential home beds for the elderly have to be compared with at-home care and 
community services and short-term residential care for the elderly in the different 
regions to get an overall picture of care infrastructure for the elderly. A typical example 
is the province of Limburg. While the number of residential home beds per 100,000 
inhabitants over 50 years is among the lowest in Limburg, the number of elderly making 
use of at-home care services is substantially larger than in the rest of Flanders.2 
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Figure 1.1 : Number of residential home beds per 100,000 inhabitants over 
50 years of age by district (2005) 
 
Source: RIZIV/INAMI (number of beds on December 31, 2004); FOD Economie - Algemene 
Directie Statistiek en Economische Informatie, Dienst Demografie (population on January 1, 2005)  
1.2.1.4 Number of patients 
The distribution by age and by gender indicates that elderly rest and nursing home 
residents are predominantly women above 80 years of age (table 1.3 j ). More than 
75 percent of residential elderly are women. There are some striking differences in the 
age distribution between men and women. Beneath the age of 80, the percentage of 
men in rest and nursing homes is larger than that of women. Above the age of 80 the 
opposite is true. This means that when abstracting from the total number of residential 
men and women, the male population is relatively younger than the female residential 
population. About 51 percent of residential elderly women are above the age of 85, 
while this is only the case for about 33 percent of menk.  
                                                     
j The results in table 1.3 were calculated using an administrative database made available by IMA 
(Intermutualistisch Agentschap- Agence Intermutualiste - Intermutualistic Agency). IMA is a non-profit 
institution with all Belgian sickness funds as its members. A description of the selection of patients is 
provided in the technical note in Appendix 3. 
k In Pacolet et al. 2004-p2082 the number of long-term residential elderly is substantially lower than in 
table 1.3. In the former study the number of residents is a picture on June 30 of each year, while in 
table 1.3 all residents for whom a rest or nursing home received a lump sum from RIZIV/INAMI (see 
section 1.2.2.1) during the year 2004 are included.  
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Table 1.3 : Age and gender distribution of elderly residents in rest and 
nursing homes (2004)  
Age groups Total  % Women  % Men  % 
Age 95+  10,227 6.8 8,948 7.9 1,279 3.5 
Age 90-94 28,784 19.2 24,009 21.3 4,775 12.9 
Age 85-89 30,435 20.3 24,430 21.6 6,005 16.2 
Age 80-84 38,661 25.8 29,398 26.0 9,263 25.0 
Age 75-79 20,849 13.9 14,732 13.0 6,117 16.5 
Age 70-74 9,916 6.6 6,066 5.4 3,850 10.4 
Age 65-69 4,902 3.3 2,579 2.3 2,323 6.3 
Age 60-64 2,574 1.7 1,213 1.1 1,361 3.7 
Age 55-59 1,726 1.2 761 0.7 965 2.6 
Age 50-54 983 0.7 413 0.4 570 1.5 
Age <50 854 0.6 351 0.3 503 1.4 
Totall 149,911 100.0 112,900 100.0 37,011 100.0 
Source: IMA  
Table 1.4 offers some insight in the rate of institutionalization of the elderly in Belgium. 
We compared the number of elderly women and men in rest and nursing homes (in 
2004) with the total population of the same age (on January 1, 2005). Approximately 8% 
of the 65+ and 42% of the 85+ elderly lived in a rest or nursing home in the course of 
2004m. Noticeable are the increase in the rate of institutionalization with higher age and 
the larger rate for women than for men.  
Table 1.4 : Institutionalization rate by age and gender (2004)  
Age groups Total (%)  Women (%) Men (%) 
Age 95+  82.8 85.7 66.9 
Age 90-94 54.6 59.1 39.6 
Age 85-89 30.3 34.5 20.2 
Age 80-84 13.7 16.3 9.1 
Age 75-79 5.4 6.4 3.9 
Age 70-74 2.4 2.3 1.8 
Age 65-69 1.0 1.0 1.0 
Age 60-64 0.5 0.5 0.6 
Age 50-59 0.2 0.2 0.2 
Totaln 4.1 5.7 2.2 
Source: IMA (residential elderly in 2004) and FOD Economie, Ecodata (elderly population by age 
and gender on January 1, 2005) 
1.2.2 Financing of rest homes and nursing homes 
Costs for staying in a rest or nursing home can be divided into two major categories: 
costs associated with hotel services versus medical and personal care costs. In general, 
the care costs are covered by the public health insurance scheme, hotel costs by the 
resident. In this section we do not take into account the costs for RIZIV/INAMI or for 
the resident associated with GP or specialist consultations, hospital admissions or 
medication. We also neglect subsidies for infrastructure. 
                                                     
l Missing values are not included. 
m The figures are not listed in table 1.4. The percentage at one moment in time is of course lower. 
n We neglect the institutionalized people younger than 50 years. 
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1.2.2.1 Cost for RIZIV/INAMIo 
The care costs are financed by the public health insurance scheme through an envelope 
funding mechanism. A pre-set per diem payment rate is allocated to rest homes and 
nursing homes by RIZIV/INAMI for each beneficiaryp depending on the care dependency 
of the beneficiaries.  
The degree of care dependency is assessed according to the Katz scaleq. There are six 
categories of dependency with a higher care profile receiving a higher per diem (see 
table 1.5).  
Table 1.5 : Dependency categories 
Dependency 
category 
Description 
O Physically independent / no dementia. 
A Physically dependent for personal hygiene or getting dressed; or physically 
independent but disoriented in time and space. 
B Physically dependent for personal hygiene and getting dressed, and for transfer or 
bathroom visits; or physically dependent for personal hygiene and getting dressed 
and disoriented in time and space. 
C Physically dependent for personal hygiene and getting dressed, and for transfer and 
bathroom visits, and to eat or because of incontinence. 
Cd C plus disoriented in time and space. 
Cc In a persistent vegetative state caused by an acute brain trauma followed by a 
coma. 
Source: art. 151 of Royal Decree dated July 3, 1996 on “rustoorden voor bejaarden, rust- en 
verzorgingstehuizen en centra voor dagverzorging” (homes for the aged, nursing homes, and day 
care centres); RIZIV circular 1307/AVB/omz-ROB-RVT2004/4 to the homes for the aged and 
nursing homes dated November 18, 2004.; art. 148 of Royal Decree dated July 3, 1996 on 
“uitvoering van de wet betreffende de verplichte verzekering voor geneeskundige verzorging en 
uitkeringen” (execution of the law concerning the compulsory insurance on health care and 
benefits). 
Before January 1, 2004 a rest or nursing home received a daily lump sum differentiated 
along the degree of dependency of the beneficiary. The new financing scheme allocates 
an average daily lump sum per beneficiary depending on the overall dependency rate of 
the institution. The lump sum covers care provided by nurses and caregivers, speech 
therapy, assistance in activities of daily living, activities of reactivation and social 
integration including occupational therapy, care materialr and staff training in palliative 
care. In nursing homes the daily lump sum also covers the physical therapist and the 
activities of the medical coordinator.  
Since January 1, 2004 the number of invoiced days for a calendar year (t+2) is based on 
a quota of days calculated during a reference period (from July 1, year t until June 30, 
year t+1). This quota is equal to the sum of the number of days of the beneficiaries 
charged to their sickness fund and the actual number of days of the other residents. 
This total is raised by 3 percent to meet an increase in the occupancy rate during the 
                                                     
o We describe the financing system into force since January 1, 2004. A detailed description of the new 
financing scheme can be found at RIZIV (2004).10 
p A beneficiary is a resident of a rest or nursing home whose care costs are financed by the per diem 
payment. Since the financing of rest and nursing homes is part of the compulsory health insurance 
system, it applies only to persons covered by this system. Some residents are not covered by the 
compulsory health insurance system for the care costs in a rest home (self-employed without a 
voluntary insurance for their minor risks) or in a rest home and nursing home (some foreign 
patients).  
q Since January 1, 2005 Mini Mental State Examination (MMSE) scores can be used to complete the 
Katz scores for persons disoriented in time and space. 
r As defined by article 147, $$ 1 and 2 of the Royal Decree of July 3, 1996. 
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reference period. The financing system also provides a partial contribution for days 
exceeding the quota.  
Most invoiced days per residential home bed in the last quarter of 2004 fall into 
dependency categories O and A for rest homes and in dependency categories Cd for 
nursing homes (see figure 1.2). Figure 1.2 must not be interpreted as depicting the use 
of available bed capacity because the number of beds represents a snapshot on 
December, 31 2004 and does not reflect changes in the number of beds during the last 
quarter of 2004. Invoiced days were divided by the number of beds only to correct for 
the size of the homes. Due to the legal definition of nursing homes, there are no 
invoiced days in dependency categories O and A. Similarly, there are no invoiced days in 
dependency category Cc for rest homes.  
Figure 1.2 : Number of invoiced days of residents divided by total number of 
beds per home in function of dependency and type of home (ROB: rest 
home, RVT: nursing home). 
 
Source: RIZIV/INAMI 
In general, the large majority of the residents in rest homes and nursing homes are 
beneficiaries. A marked difference between beneficiaries and non-beneficiaries is found 
for the distributions of invoiced days per residential home bed for all dependency 
categories except O, A, and Cc. The results suggest that most homes have little or no 
invoiced days per residential home bed of non-beneficiaries in dependency categories B, 
C, and Cd.   
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1.2.2.2 Private spending of residents for non-medical care 
The remaining costs, mainly for hotel services, are met by the residentss. These costs 
include food, administration and maintenance costs. They do not depend on the 
dependency category of the resident. The Federal Minister of Economy, Energy, Foreign 
Trade and Science Policy fixes the price for hotel services to be paid by the residentt. 
Table 1.6 learns that the daily price residents of rest and nursing homes have to pay for 
hotel services differs substantially between and within provinces. However, since the 
daily price is not an all-in price we should be cautious when comparing the daily prices 
between residential homes for the elderly. On top of the daily price homes may ask 
supplements or advances on behalf of a third partyu. In the agreement between the rest 
or nursing home and the resident the items included in the daily price and a list of extra 
charges must be explicitly mentioned.  
Table 1.6 : Daily price (in €) for hotel services in a single room in rest and 
nursing homes by province (2nd semester of 2005)  
Provinces in Flanders Mean Min Max 
Antwerpen 42.6 24.5 86.8 
Vlaams-Brabant 37.5 21.2 73.0 
Limburg 37.1 25.4 66.0 
Oost-Vlaanderen 37.6 18.0 125.0 
West-Vlaanderen 36.8 22.3 74.9 
Provinces in Wallonia    
Hainaut 31.3 18.0 75.4 
Liège 31.0 16.3 76.0 
Namur 30.3 18.8 75.5 
Brabant wallon 37.5 18.8 86.1 
Luxembourg 32.1 19.8 73.2 
Brussels - Capital Region    
Brussels - Capital Region 37.2 16.7 134.7 
Source: Ministerie van Economische Zaken, afdeling prijzen en mededinging 
On October 1, 2001 a long-term care insurance scheme was introduced in Flanders to 
compensate for some of the costs of non-medical care that emerge when people 
become aged or disabled. Since July 1, 2006 all residents of an accredited rest or nursing 
home receive a monthly lump sum of €125.  
1.2.3 Staff 
The regulation of staffing requirements was not changed under the new financing 
scheme in effect from January 1, 2004. All staffing standards are expressed as 1 FTE for 
each 30 beneficiaries. The distribution is given in table 1.7. 
                                                     
s Financial aid from the public municipal welfare centres (OCMW in Dutch, CPAS in French) or from 
the family of the resident is possible.  
t Ministerial Decree of August 12, 2005.  
u Voorschotten ten gunste van derden in Dutch, avances en faveur de tiers in French. When services 
are provided by third parties, the rest or nursing home first pays the third party and claims back the 
costs from the resident afterwards.  
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Table 1.7 : Staffing standards in rest and nursing homes, by type, 
occupational group and dependency category (in FTE/30 beneficiaries) 
Dependency category Occupational group ROB RVT 
O Nurse  0.25 Not relevant 
A Nurse  
Caregiver 
1.20 
0.80 
Not relevant 
Not relevant 
B Nurse 
Caregiver 
Reactivating personnel 
Physical therapist/speech 
therapist/occupational therapist 
2.10 
4.00 
0.35 
Not relevant 
5.00 
5.00 
Not relevant 
1.00 
 
C Nurse 
Caregiver 
Reactivating personnel 
Physical therapist/speech 
therapist/occupational therapist 
4.10 
5.06 
0.385 
Not relevant 
5.00 
6.00 
0.50 
1.00 
Cd Nurse 
Caregiver 
Reactivating personnel 
Physical therapist/speech 
therapist/occupational therapist 
4.10 
6.06 
0.385 
Not relevant 
5.00 
6.50 
0.50 
1.00 
Source: RIZIV/INAMI 
The difference between the actual number and the subsidized number of different 
categories of staff is paid by the rest or nursing home.  
Figure 1.3 shows the distribution of staff in FTE per bed and occupational groupv.  
Caregivers, other staff below level A2 and nurses comprise the largest occupational 
groups in rest homes and nursing homesw. The variation within each occupational group 
is due to the way rest and nursing home staff is financed. Not only the number of 
beneficiaries, but also their care need is taken into account. 
                                                     
v The occupational groups in figure 1.3 can be classified according to the groups in table 1.3. Nurse = 
nurse A1, nurse A2 and hospital assistant; other personnel A2, other personnel A1/univ. and other 
personnel <A2 are not financed by the lump sum. 
w Due to the nature of the data file, a distinction between the FTE distributions of rest and nursing 
homes was not possible. 
14  Medication use in Nursing Homes KCE reports 47 
 
Figure 1.3 : Distribution of staff in FTE per residential home bed and 
occupational group in the last quarter of 2004 
 
Source: RIZIV/INAMI 
When comparing the number of invoiced days per residential home against the FTE per 
home by occupational group, we found that for most occupational groups, the more 
days were invoiced per home, the larger the amount of FTE per home (see figure 1.3). 
Given that more invoiced days generally corresponded to a larger home and hence to 
more available staff, this finding seemed fairly obvious but for two reasons. Firstly, 
speech therapists, reactivating personnel, and to a lesser extent other personnel level 
A2, were exceptions. That is, a larger number of invoiced days did not necessarily 
correspond with more FTE and vice versa. Secondly, the relation between FTE and 
number of invoiced days was far from perfectly linear as evidenced by figure 1.3. An 
explanation for both phenomena might be the governmental financing of staff in homes. 
Not only the number of patients but also the need for care of the residents is taken 
into account in the attribution of the amount of FTE per homex.  However, a more 
extensive exploration of this topic is beyond the scope of this report. 
                                                     
x Ministerial order of 6 November 2003: “vaststelling van het bedrag en de voorwaarden voor de 
toekenning van de tegemoetkoming, bedoeld in artikel 37, § 12, van de wet betreffende de verplichte 
verzekering voor geneeskundige verzorging  
en uitkeringen, gecoördineerd op 14 juli 1994, in de rust- en verzorgingstehuizen en in de rustoorden 
voor bejaarden”; enactment of the amount and conditions of the attribution for the compensation, 
intended in art. 37, § 12 of the law regarding the mandatory health insurance and remunerations, 
coordinated on the 14th of July 1994 in the nursing homes and the rest homes 
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Figure 1.3. Number of invoiced days for the last quarter of 2004 in function 
of FTE by occupational group. Each panel has different scales. 
 
Source: RIZIV/INAMI 
1.3 RESEARCH QUESTIONS 
The main objective of this study was to investigate the quality of medication prescribing 
in residential long-term care for the elderly in Belgium and the relation with institutional 
characteristics, including the quality of the medication management systems. We 
translated this broad research question into the following specific questions. 
What is the magnitude of medication use and expenditures for long-term residential 
elderly in Belgium? The use and cost of medication in residential elderly are hardly 
documented in Belgium. We investigate the costs and use of prescribed medicines in all 
Belgian rest and nursing homes in 2004 using a large administrative database 
(Farmanet y ). In addition, we provide detailed information on the use and cost –
reimbursed and private- of prescribed and over-the-counter (OTC) medication in a 
selection of nursing homes. 
What are the medical needs of residential elderly? An assessment of clinical needs of 
nursing home residents is a prerequisite for any evaluation of the quality of prescribing. 
This assessment includes at least an evaluation of the resident’s risk profile and co-
morbidity.   
How can the quality of prescribing to elderly nursing home residents be measured? 
Although many explicit, evidence-based criteria to assess the quality of prescribing to 
elderly nursing home residents have been developed and evaluated, debate continues 
regarding which indicators are most appropriate. Which (adapted) indicators to 
measure prescribing medication are most suited in the Belgian geriatric context? Which 
                                                     
y See RIZIV (2005)11 for a description of the Farmanet database.  
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quality indicator(s) should be recommended to assist in monitoring and improving the 
quality of care provided to residents of Belgian nursing homes?  
What are the general characteristics of medication management in Belgian nursing 
homes? We examine the provision of pharmaceutical services, the organization of the 
medication process and the implementation of a formulary. 
Which organizational characteristics are associated with the quality of medication use? 
We examine the extent to which the quality of medication use varies across 
characteristics associated with the organizational structure such as ownership, size, 
type, financing (reimbursements and private spending), nurse staffing levels, case-mix 
and geographical locations.  
1.4 PREVIOUS STUDIES FOR BELGIUM 
Relatively few studies on the quality of medication use in Belgian rest and nursing homes 
have been carried out.  
In a recent study by the Christian Mutualities12 the cost and quality of medication use by 
residential elderlyz were analyzed. The study included a cohort of residential elderly 
with no change in dependency score in 2002, without a transfer from at-home care to 
residential care and who did not die during 2002 and 2003 (n=5,123). For this cohort a 
follow-up of one year was possible in the period 2002-2003. For some of the results, a 
comparison was made between rest and nursing home residents and a group of elderly 
receiving at-home care, selected on the basis of the same criteria (n=25.532). The data 
on medication prescription and cost are based on the Farmanet database, which only 
contains medication dispersed by community-based pharmacists. 
Table 1.8 shows the median cost of reimbursed medication for the health insurance 
(RIZIV/INAMI) and for the elderly in a rest or nursing home or elderly receiving at-
home care. In view of a comparison with the results of our study, we want to 
emphasize the specific study population in table 1.8.  
Table 1.8 : Cost of reimbursed medication for elderly in rest or nursing 
homes and elderly receiving at-home care 
Median medication costs  ROB/RVT At-home care  
Reimbursements by RIZIV/INAMI 480€ 538€  
Co-paymentsaa 115€ 121€  
Total 606€ 672€  
Source: Du Bois et al.12 
In table 1.9 the medication use for residents and elderly receiving at-home care is 
compared for medication groups or medication for specific diseases which account for a 
relatively large part of the cost for RIZIV/INAMI. For some medication groups the 
percentages of residential elderly and elderly receiving at-home care show substantial 
differences. However, cautious interpretation of these differences is crucial since these 
percentages only reflect the use of medication without correcting for differences 
in  (co-) morbidity between the two populations. 
                                                     
z Only members of the Alliance of Christian Sickness Funds were included in the study. The results 
were confirmed by one of the authors (M Du Bois). 
aa Remgeld in Dutch, ticket modérateur in French. A co-payment is a cost-sharing arrangement which 
requires the individual covered to pay part of the cost of care. A co-payment is a fixed fee (flat rate) 
per item or service. 
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Table 1.9 : Medication use by elderly in rest or nursing homes and elderly 
receiving at-home care, by medication group (% of elderly) 
Medication group or disease 
% of RIZIV/INAMI 
cost 
% of ROB/RVT 
elderly 
% of elderly with at-
home care 
Diabetes 3.1 12 15 
Thrombosis 2.1 18 32 
Diuretics 1.1 36 36 
Corticosteroids 1.0 15 18 
Antibiotics for systematic use 1.1 47 57 
Anti-inflammatory and anti-
rheumatic medication 
 
1.1 27 48 
Psycho-analeptics 2.8 36 31 
Anti-asthmatics 2.0 14 18 
Source: Du Bois et al.12 
Within the group of residential elderly (percentages in the column ROB/RVT of 
table 1.9) medication use was not uniform across the country. Table 1.10 shows the 
regional variation. Contrary to table 1.1, the provinces of Vlaams-Brabant (Flanders), 
Brabant wallon and the Brussels–Capital Region were taken together as one province. 
Understanding regional variation in the use of medication is complex and is far beyond 
the scope of this introductory chapter. Therefore we only point out some remarkable 
differences or similarities in medication use between provinces. The largest regional 
variation in medication use of elderly residents was found for psycho-analeptics with the 
largest percentage in the province of Namur (52%) and the smallest in Antwerpen 
(38%). Antibiotics for systematic use had a similar pattern: 58% in Namur versus 38% in 
Antwerpen. Within Flanders the province of Limburg shows the largest percentage of 
elderly residents for most medication groups. In the Walloon region this is the case for 
Namur, followed by Liège.  
In 2005 a study was carried out by the Limburgs Universitair Centrum (LUC)bb in a 
sample of Belgian rest and nursing homes.13 The central research question was closely 
related to the key research question of the present study, viz. an analysis of the 
medication policy of Belgian residential homes for the elderly. A questionnaire was sent 
to all Belgian rest and nursing homes (n=1,722). The response rate was 33.57%. In 
addition, 29 interviews were conducted to complement the written questionnairecc.    
The medication policy questionnaire and interviews revealed information about the 
prescribing, the purchase and stock of the medication, the formulary and cooperation. 
We only give some results, since it is very difficult to describe a study and its results 
solely on the basis of presentation slides. Nearly 98% of prescriptions were written by 
the family doctor, the other 2% by the medical coordinator. The distinction between 
prescription-bound and non prescription-bound medication determined to a large 
extent if the medication was obtained from a community pharmacy, a hospital pharmacy 
or from a wholesaler or manufacturer. Most rest and nursing homes purchased from 
only one pharmacy (69.5%), another 22.2% purchased its medication from multiple 
pharmacies in turn. Only 8.3% was serviced by multiple pharmacies at the same time. 
The most important criteria for choosing a medication supplier were good service 
(73.5%), proximity (11.3%) and cost of medication (8.1%). Almost 72% of the nursing 
homes had a formulary (with large differences between the three regions), which was 
used by 30% of the family physicians. The usage depended to a large extent on the 
origin of the formulary (from the government, own formulary, hospital formulary). 
                                                     
bb Since June 2005 the LUC is called Universiteit Hasselt. 
cc There is no information whether the results are representative for all Belgian rest and nursing 
homes.  
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An older study by Vander Stichele et al.14 investigated the medication use and 
knowledge of medication among residents of a sample of nursing homes in Flandersdd. In 
addition, the medication distribution and information activities inside the homes were 
described. The selection of nursing homes was based on the ‘selection’ of 
23 experienced nurses working in different nursing homes but meeting regularly for 
postgraduate training. In each of the nursing homes a random sample of ten residents 
was taken.  
The 23 nurses interviewed the nurse responsible for the selected resident and the 
resident, if possible. Eventually 198 residents (20 institutions) were included in the 
study, 128 of them could be interviewed directly. Although the average number of 
residents in the 20 institutions was somewhat larger than the Flemish average, the 
selected institutions were representative for Flanders. The residents had a mean of 
4.5 different medicines (range 0-12) on their medication chart. 4% did not take any 
medication, half of them because of therapeutic abstinence in terminal care. 47% had at 
least 5 medicines. The number of medicines increased with age (3.7 to 4.8 medicines 
between the age of 60 and 79), but stabilized from the age of 80 onwards 
(4.3 medicines). On average 19 different GPs attended residents.  
In Pitruzzella et al.15 the medication use in rest and nursing homes in the Walloon 
Region was analyzed for the year 2003 and compared with the results of a survey 
carried out in 1993. For a representative sample of elderly residents (2,343 elderly 
residing in 37 different institutions) the medication chart on a specific day 
(November 15, 2003) was analyzed. On that day a total of 16,808 medications or 7.19 
drugs per resident were registered with large differences between the institutions 
(range of 5.9-8.7). In 1993 this was only 5.04. Almost 19% of the residents received 
more than 10 drugs on one day, 19.4% received less than 5 drugs. Drugs related to the 
nervous system (n=5,410), the cardiovascular system (n=4,133), the gastrointestinal 
system (n=3,713) and blood and blood forming organs (n=1,257) represented the 
largest groups. Age, gender and the presence of dementia were found to be explaining 
factors.  
                                                     
dd As in chapters 2 and 3 we use the term ‘nursing home’ for an institution with exclusively nursing 
beds or with rest and nursing beds. 
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Table 1.10 : Medication use by elderly in rest or nursing homes, by medication group and by province (% of elderly residents)  
Medication group or disease Belgium Antwerpen Brabant Limburg Oost-Vl West-Vl Hainaut Liège Namur Luxemb 
Diabetes 12 9 11 19 11 15 11 12 9 16 
Thrombosis 18 15 16 22 17 15 21 22 23 19 
Diuretics 36 32 33 27 36 37 29 40 40 42 
Corticosteroids 15 11 16 15 13 12 17 18 18 15 
Antibiotics for systematic use 47 38 47 51 43 48 53 54 58 42 
Anti-inflammatory and anti-rheumatic medication 27 21 25 33 27 26 28 34 28 26 
Psycho-analeptics 36 28 38 39 28 32 41 44 52 45 
Anti-asthmatics 14 11 13 17 11 12 19 18 18 15 
Source: Du Bois et al.12 
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1.5 AGGREGATED DATA ON MEDICATION USE AND 
EXPENDITURES IN REST AND NURSING HOMES IN 
BELGIUM  
The Farmanet database contains prescriptions dispensed from community-based 
pharmacies in Belgium. Prescriptions dispensed from hospital pharmacies as well as 
expenditures for other categories of care can be obtained from the IMA-database with 
claims data on all expenditures categories. Both databases contain information on 
reimbursements of RIZIV/INAMI and out-of-pocket payments by the residents for 
prescription medication.   
The present study is the first to show national estimates of medication use and 
expenditures for elderly residents of rest and nursing homes in Belgium. Section 1.5.1 
provides data on medication use by major drug classes. In the Anatomical Therapeutic 
Chemical (ATC) Classification System drugs are classified into different groups 
according to the organ or system on which they act and their chemical, pharmacological 
and therapeutic properties. Drugs are divided into groups at 5 different levels ee . 
Section 1.5.2 gives a general overview of the expenditures of prescribed and reimbursed 
medication used by elderly residents of rest and nursing homes for the year 2004. We 
calculated the expenditures for the health insurance reimbursed by RIZIV/INAMI as well 
as the out-of-pocket payments for the residents.  Medicines are reimbursed on a fee-
for-service basis in Belgium ff . The basis for reimbursement is classification within 
categories fixed by Royal Decree. The classification reflects the social importance of the 
drug, pharmacotherapeutic criteria and price criteria. 
For this population-based description of medication use in Belgian rest and nursing 
homes, only the data of drugs sold by community pharmacists to these homes are taken 
into account. A minor part of homes buy their drugs through hospital pharmacies. The 
hospital pharmacy data did not allow us to distinguish in a reliable way between the 
medication prescribed in inpatient or day case treatment from the medication delivered 
to the rest or nursing home of the resident. Moreover, this latter category also contains 
the dispensing of some expensive drugs which is legally exclusively reserved for hospital 
pharmacies. This bias in our estimates will lead to a small underestimation of global 
medication use. The utilization data are not expected to be influenced by the retailer’s 
circuit chosen by homes. To estimate the distribution of drug utilization, the Defined 
Daily Dose (DDD) is used as estimate for the maintenance dose per day per drug used 
for its principal indications in adults.  In the Farmanet data, DDDs adapted to the 
Belgian situation are usedgg. To calculate the overall expenditures of prescribed and 
reimbursed medication, we include the hospital pharmacy data. 
1.5.1 Use of medication by different levels of ATC group  
The four main ATC1 classes of drug consumption in elderly people living in Belgian rest 
en nursing homes are related to the cardiovascular, nervous, gastrointestinal and 
respiratory system (figure 1.5). These four classes are described in more detail in this 
section.  A lengthy table containing the 100 most frequently used drugs (ATC5) is 
presented in Appendix 4 (table 4.1).  
                                                     
ee See http://www.whocc.no/atcddd/ for more information. 
ff Since July 1, 2006 a large part of hospital drugs are financed on a lump sum basis replacing the fee for 
service practice. 
gg See http://www.bcfi.be for more details. 
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Figure 1.5 : Number of medication prescriptions in Belgian rest and nursing 
homes, expressed in DDD for every main ATC class. 
Source: Farmanet 
In the drug class related to the cardiovascular system, molsidomine - a drug to treat 
angina - is most often prescribed (see Appendix 4 - table 4.2 for more details).  ACE-
inhibitors, drugs used in the treatment of heart failure and hypertension, are also widely 
used.  Angiotensin II antagonists, a more recent antihypertensive drug class, constitute 
28% of the amount of ACE-inhibitors prescribed.  This ratio is an underestimate, since 
part of ACE-inhibitor prescription will be done to treat heart failure or in the post 
myocardial infarction setting. Amlodipine, an antihypertensive drug from the Ca-
antagonist’s class, compared to other classes such as ACE-inhibitors, ATII antagonists 
and antihypertensive diuretics, accounts for about 1/3 of all prescriptions.  Class III anti-
arrhythmics such as amiodarone and sotalol are widely prescribed in this population.  
Compared to the class of selective beta-blockers, used as secondary prevention 
treatment for post-ischemic heart disease, heart failure, angina pectoris and atrial 
fibrillation, all largely prevalent in this population, it represents 64%.  Class I anti-
arrhythmics such as propafenon and flecainide are still used for chronic treatment. 
Simvastatin and atorvastatin are the most popular drugs to lower cholesterol and are 
used to the same extent as the selective beta-blockers.    
In the second ATC1 class, the nervous system, it should be stressed that the non-
reimbursed benzodiazepines are not present in the Farmanet data.  This second group is 
dominated by antidepressants: 71% are selective serotonin reuptake inhibitors, 5% 
mono-amine reuptake inhibitors and a large rest group of other molecules (see 
Appendix 4 - table 4.3 for more details). Of all antidepressants used in this patient 
population, citalopram is the most prescribed (26%), followed by sertraline (15%), 
escitalopram (13%), paroxetine (12%) and trazodon (10%). Next, antipsychotics are the 
second largest group of prescribed drugs in this class. Risperidon is the most prescribed 
(31%), followed by olanzapin (27%). Of the older antipsychotics, haloperidol is used 
most frequently (12%). Betahistine is still widely used to treat vertigo and possibly 
Menière’s syndrome. In the class of the Alzheimer drugs, donepezil is used in over half 
of prescriptions of this kind.  Noteworthy is the fact that gingko biloba is present in 
0.5% of cases, probably also for this indication.           
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In the third ATC1 class, drugs for the gastro-instestinal system, the largest group is the 
one with drugs to treat peptic disease (see Appendix 4 - table 4.4 for more details). 
Omeprazole, a proton pump inhibitor, is used in the majority of patients.  Ranitidine, a 
drug of the older H2-receptor blocker class, is still being used frequently. The second 
largest group in this class consists of several oral antidiabetics that add up to a total of 
more than 3.6 million DDDs, compared to over 2 million for subcutaneous insulins.  
Combinations are likely, so this number only represents market share and is not a 
proxy for the number of diabetic patients in this population. Metformin is the most 
prescribed oral antidiabetic drug. Otilinium is the most frequently used spasmolytic 
drug, followed by mebeverine. For the laxatives, it should be stressed that the majority 
of them are not reimbursed by health insurance.  Data in Farmanet are thus incomplete. 
In the ATC1 class of drugs for the respiratory system, the mucolytics represent the 
largest group (see Appendix 4 - table 4.5 for more details). For the drugs most 
frequently used for obstructive pulmonary disease COPD, the sympathomimetics make 
up the largest group of prescriptions. They are most frequently used in combination 
with inhalation preparations including an anticholinergic or corticosteroid. Taken 
together the pure formulations and the combinations, the long acting beta-agonists 
constitute about 42% of this type of drug prescriptions.  In the group of the H1-
antihistamics, levocetirizine has a market share of 30%.  
In the class of medication related to blood and blood forming organs, the heparines are 
clearly heading with more than 3.8 million DDDs. Enoxaparine and nadroparine have 
about an equal market share of 47% and 48% respectively. Next drug class are the 
thrombocytes aggregation inhibitors, with nearly 1.9 million DDDs of which clopidogrel 
represents 79%.  
In the class of drugs for the musculoskeletal system the bifosfonates, used to treat 
osteoporosis, lead the group with nearly 1.5 million DDDs.  However, all non-steroidal 
anti-inflammatory drugs together represent over 2.4 million DDDs. In general they are 
used to treat osteoarthritis and rheumatic disorders. The Cox-2 inhibitors represented 
about one fourth of all prescriptions in 2004.  Virtually all paracetamol is sold over-the-
counter without prescription, disabling an analysis of the use of analgetics and the 
pharmacological strategies used in this elderly population.   
The most frequently prescribed antibiotics for systemic use in rest en nursing homes is 
amoxicillin with a beta-lactamase enzyme inhibitor with over 750,000 DDDs.  Both 
nitrofuranes together add up to nearly the same amount.  The quinolones account for 
over 470,000 DDDs annually, followed by second generation cephalosporins 
(335,000 DDDs) and broad spectrum penicillins (278,000 DDDs).  99,000 influenza 
vaccines were reimbursed in 2004 in Belgian rest and nursing homes. 
In the class of the antineoplastic and immunomodulating agents, tamoxifen used as 
adjuvant therapy for breast cancer is prescribed most (330,000 DDDs), closely followed 
by the gonadoreline analogues mostly used for prostate cancer in this population with 
270,000 DDDs. In the group ‘various’, medicinal oxygen takes up 82,000 DDDs. 
Regional variation in medication use based on DDD was considered for the top 10 of 
most frequently used drug classes (ATC level 3).  Furthermore, the drugs classes that 
were used for the recent feedbacks of the RIZIV/INAMI for antihypertensive agents and 
antibiotics prescribed in general practice were assessed.  This resulted in geographical 
variation distributions for the following classes: antidepressants and antipsychotica 
(psychopharmaca); ace inhibitors, angiotensin II antagonists, diuretics and potassium-
sparing agents, and selective calcium channel blockers with mainly vascular effects 
(hypertensives); beta-lactam antibacterials and penicillins, macrolides, lincosamides, 
streptogramins, and quinolone antibacterials (antibiotics); drugs for peptic ulcer and 
gastro-oesophageal reflux disease, vasodilators used in cardiac diseases, antithrombotic 
agents, high ceiling diuretics, and beta blocking agents (see Appendix 5 for the Belgian 
maps). We found a marked but different regional variation for several medication 
groups. Apparently, no simple regional pattern across medication groups existed. For 
example, antidepressants and selective calcium channel blockers were used to a larger 
extent in Walloon provinces compared to Flemish provinces, while the opposite was 
true for beta blocking agents and diuretics and potassium-sparing agents. Several of 
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these drugs can be used for different indications. Since we did not dispose of other 
variables like clinical patient characteristics per medication group it is in general not 
warranted to interpret these results towards an under- or overuse of these classes and 
hence to appraise the drug utilization quality. We thus ascertain a clear regional 
variation but do not attempt to provide an explanation for these variations in this part 
of the report (see section 1.6 - rationale for a field study).   
1.5.2 Expenditures of prescribed medicines in Belgian rest and nursing homes 
In 2004 total expenditures on prescribed and reimbursed medication in Belgian rest and 
nursing homes amounted to almost 153 million € of which 88% was dispensed by the 
community pharmacy (table 1.11). As mentioned before, total expenditures on 
medication dispensed by the hospital pharmacy contain medication prescribed in day 
case treatment and the medication delivered to the rest or nursing home of the 
resident, including the dispensing of some expensive drugs.  
Our estimate of total expenditures on pharmaceutical specialties dispensed by the 
community pharmacy added up to more than 130 million € of which 82% was paid by 
the health insurance and 18% out of pocket by the residentshh. In addition, 2.8 million € 
was spent on magistral preparations (of which 83% by the health insurance) and another 
1.46 million € on special medical nutrition and wound material (of which 84% by the 
health insurance). In the rest of this section we focus on pharmaceutical specialties 
dispensed by the community pharmacy and neglect magistral preparations or special 
medical nutrition and wound material as well as medication dispensed by the hospital 
pharmacy. 
Table 1.11 : Expenditures on prescribed and reimbursed medication for 
health insurance and the resident, by type of medication and dispenser 
(2004) 
Dispenser 
Type of 
medication 
Health insurance cost (€) Out-of-pocket (€) Total (€) 
Hospital pharmacy Specialties 16,368,403* 1,652,954 18,021,357 
 Magistral 
preparations 
149,820 25,443 175,263 
 Medical 
nutrition 
and wound 
material 
69,171 36,377 105,548 
 Total 16,587,394 1,714,774 18,302,168 
Community pharmacy Specialties 106,839,205 23,516,627 130,355,832 
 Magistral 
preparations 
2,335,892 479,138 2,815,030 
 Medical 
nutrition 
and wound 
material 
1,235,698 
 
229,294 1,464,992 
 Total 110,410,795 24,225,059 134,635,854 
Total  126,998,189 25,939,833 152,938,022 
* About 55% of this amount was prescribed in residents of rest and nursing homes during 
inpatient treatment. Source: IMA 
Antidepressants, antipsychotics and antithrombotic agents are rivaling for the highest 
health insurance cost (table 1.12). Together, the 10 most prescribed ATC3 classes 
amount to almost half of the total budget.  However, the price of an individual drug is 
also a major determinant of the budgetary impact for health insurance (figure 1.6). 
Especially drugs used to prevent or treat infectious diseases represent a higher 
                                                     
hh The data are not corrected for reimbursements by the system of maximum billing (MaF).   
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individual cost: influenza vaccination, several antibiotics and antimycotic drugs. In 
addition, several hormones, anti-Alzheimer drugs, anti-psychotics and opioids represent 
a relatively high individual cost.          
Table 1.12 : DDD and expenditures by ATC-class (2004) 
 
ATC Class or non-proprietary name DDD 
Health 
insurance 
cost (€) 
Out-of-
pocket 
(€) 
1 N06A ANTIDEPRESSANTS 15,187,938 12,429,029 3,627,857 
2 N05A ANTIPSYCHOTICS 4,651,768 10,651,173 1,516,215 
3 B01A ANTITHROMBOTIC AGENTS 6,446,832 10,617,869 1,985,108 
4 A02B 
DRUGS FOR PEPTIC ULCER AND 
GASTRO-OESOPHAGEAL REFLUX 
DISEASE (GORD) 10,971,741 7,890,532 1,736,477 
5 C01D 
VASODILATORS USED IN CARDIAC 
DISEASES 15,769,367 5,894,855 1,365,843 
6 N02A OPIOIDS 2,502,729 5,026,818 1,344,979 
7 N06D ANTI-DEMENTIA DRUGS 1,356,858 3,714,205 371,777 
8 N04B 
DOPAMINERGIC AGENTS 
(PARKINSON) 2,529,695 3,363,585 639,078 
9 C08C 
SELECTIVE CALCIUM CHANNEL 
BLOCKERS (HYPERTENSION) 6,722,495 3,355,252 805,498 
10 R03A SYMPATHICOMIMETICS (INHALANTS) 2,918,707 3,245,897 643,113 
Source: Farmanet 
Figure 1.6 : Cost per DDD for health insurance for the most costly ATC3 
classes.  Classes with less than 10,000 DDD were omitted.  Influenza 
vaccination with a DDD of 1 is not represented in the graph. The class V03A 
is not represented.  It contains mainly oxygen with a cost per DDD of 22.5€.   
Source: Farmanet 
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To have some idea about the share of medication in total health insurance expenditures 
for elderly residents in rest and nursing homes, we calculated the most important cost 
components for this population group. Health insurance expenditures on medication 
dispensed by the community pharmacy accounted for about 6% of total RIZIV/INAMI 
reimbursements for this population in 2004 (table 1.13).  
Table 1.13 : Health insurance cost of residential elderly (2004) 
Type of cost Health insurance cost (€) % of total cost 
Lump sum for ROB 702,021,473 39.6 
Lump sum for RVT 616,518,522 34.8 
GP consultations and visits 59,899,446 3.4 
Hospitalization 18,837,080 1.1 
Physiotherapy (ROB) 26,167,075 1.5 
Medication from community pharmacy 110,526,192 6.2 
Medication from hospital pharmacy 16,587,394 0.9 
Total 1,773,499,831 100.0 
Source: IMA 
1.6 RATIONALE FOR A FIELD STUDY  
Some of the research questions addressed in this report cannot be answered solely on 
the basis of the available administrative datasets. Although Farmanet is a very rich 
database containing detailed information on prescribed medication, some essential 
information is missing. Firstly, in Farmanet only prescribed and reimbursable medication 
is included. Secondly, only medication of rest and nursing homes serviced by a 
community pharmacy is included. Those serviced by the hospital pharmacy are not.  
Thirdly, Farmanet does not include diagnostic codes providing possible explanations for 
prescription behavior. And fourthly, possible causal relationships between the local 
institutional setting and prescription behavior and other confounding local more 
qualitative factors cannot be explored in claims data. Although a linked database 
consisting of Farmanet and some datasets available at RIZIV/INAMI at the level of the 
institution (number of beds, number of residents, number of invoiced days, number of 
staff) or available at IMA (medication dispensed by the hospital pharmacy) would 
improve substantially the potential to answer the research questions, some crucial 
lacuna would still remain.  
To assess the quality of medication use of residential elderly, reliable data at the level of 
the institution and at the level of the resident are indispensable. A field study overcomes 
most of the limitations of the administrative datasets.   
A questionnaire-based field study was carried out in a selection of nursing homes and 
their residents in three provinces. The selected sample of nursing homes is not a 
random sample but follows the Rapid Assessment cluster method of the World Health 
Organizationii . The field study was complemented by some general analyses on the 
expenditures and use of medication based on administrative databases and by a review 
of the literature on the quality of medication use in nursing homes and the impact of 
organizational characteristics on the quality of prescribing and the medication process.  
                                                     
ii See section 3.3 for more details.  
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Keypoints 
x The Belgian model of long-term residential care for the elderly is rather 
unique. Rest and nursing homes are not specialized in specific illnesses - 
except sometimes for dementia - but accept residents with different medical 
problems. Moreover, residential homes for the elderly are spread all over 
the country. 
x About 150,000 elderly were resident in a rest or nursing home in the course 
of 2004. More than 75% of them were women, 46% was older than 85 years. 
x Although some studies on the use of medication in Belgian nursing homes 
exist, little is published on the relation between medication use and 
organizational characteristics and quality of prescribing.  
x Total expenditures on pharmaceutical specialties dispensed by community 
pharmacies added up to more than 130 million € of which 82% was paid by 
the health insurance and 18% out of pocket by the residents (2004). Another 
18 million € was dispensed by hospital pharmacies.  
x The four main ATC1 classes of drug consumption in elderly people living in 
Belgian rest en nursing facilities are cardiovascular, nervous, gastrointestinal 
and respiratory drugs. The group of drugs for the nervous system is largely 
dominated by antidepressants.  
x Although clear geographical variations exist for the prescription of several 
drug classes, no simple regional pattern across medication groups was found. 
x Antidepressants, antipsychotics and antithrombotic agents are rivaling for 
the highest health insurance cost.  Together, the 10 most prescribed ATC3 
classes amount to almost half of the total budget. 
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2 REVIEW OF THE INTERNATIONAL 
LITERATURE ON THE USE OF MEDICATION 
IN NURSING HOMES 
Authors: Charlotte Verrue, Marc Bauwens, Robert Vander Stichele 
2.1 OBJECTIVES OF THE LITERATURE REVIEW   
The aim of this review was to survey the current literature on the use of medication in 
nursing homes, with special focus on the impact of institutional characteristics (including 
medication management systems) on the quality of prescribing.   
2.2 METHODS OF THE REVIEW   
A computerized literature search was carried out starting with a search in Medline (US 
National Library of Medicine), based on search profiles in Medical Subject Headings 
(MeSH). The search strategy is given in Appendix 6. 
This review is a narrative review, not a systematic review. Its purpose was to provide a 
broad overview of the subject, in preparation to the field study, to provide the 
necessary elements for constructing questionnaires, and to review existing sets of 
prescribing quality indicators, pertinent to the setting of nursing homes. No attempts 
have been made at formal data extraction for pooling of data.   
In this review, we address the following questions: 
1. Why are elderly institutionalized? 
2. What are the most prevalent functional and clinical problems among 
residents? 
3. What are the most prevalent problems with regard to medication and 
how can the quality of prescribing be assessed? 
4. Which institutional characteristics are important for the quality of 
prescribing? 
5. What is the effectiveness of interventions (medication management 
systems) with regard to the quality of prescribing in nursing homes? 
For the assessment of prescribing quality, a description will be given of 5 sets of 
prescribing quality indicators: 
1. The indicators of underuse of medication within the ACOVE 
(Assessing Care of Vulnerable Elders) Quality Criteria 
2. The BEERS Criteria for potentially inappropriate medication use in 
older adults 
3. The BEDNURS Criteria for inappropriate medication use in nursing 
homes 
4. The Medication Appropriateness Index (MAI). 
5. UK Commission for Social Care Inspection National Minimum 
Standards on Medication Care Homes for Older People : Medication 
within the home 
In addition, a brief description is given of 5 instruments for the assessment of functional 
status, case mix or quality of care in nursing homes:  
1. Resource Utilization Groups Version III (RUG-III) 
2. Dutch Care Dependency Scale 
3. Functional Autonomy Measurement System 
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4. Resident Assessment Instrument for Nursing Homes (RAI) 
5. ACOVE (Assessing Care of Vulnerable Elders) Quality Criteria 
2.3 RESULTS OF THE LITERATURE REVIEW  
2.3.1 Why are elderly institutionalized? 
Nursing home placement is often the result of dementia, multiple illnesses, severe 
disease, or lack of social support. It is triggered by a sentinel event (e.g., major illness, 
accident, hospitalization). Wandering and disruptive behavioral problems are also 
significant factors leading to long-term care placement. Determining the specific 
circumstances that led to a nursing home admission is an important element of the 
initial evaluation.  
The most common diagnoses at nursing home admission are16: 
x Mental disorders  (dementia, depression)  
x Heart disease and cerebrovascular disease (heart failure, stroke) 
x Nervous system disorders  
x Injuries  
x Endocrine disorders (e.g., diabetes mellitus)  
x Respiratory tract disorders (e.g., chronic obstructive pulmonary 
disease)  
x Musculoskeletal disorders  
History taking at the moment of admission to the nursing home provides the 
opportunity to learn the most about residents, not only their medical condition but also 
their functional abilities, social background, support system, interests, hobbies, and 
previous daily routines. Inclusion of family members in the initial resident assessment 
can help allay anxiety or guilt feelings surrounding a nursing home admission and 
provide opportunities to discuss expectations regarding care and to establish treatment 
preferences. 
Dementia emerged as the most potent risk factor for institutionalization in a 12-year 
prospective population-based epidemiological study.17 Persons with dementia had nearly 
five times the risk of institutionalization as those who were not demented. At 3- and 12-
year follow-ups, 5.8% and 13.6%, respectively, of the cohort members had been 
institutionalized. Increasing age, impairment in ADL (activities of daily life) and less social 
support emerged as other less-critical risk factors in this study.  
Interestingly, the interaction between the number of prescription medications and 
dementia was significant in the model predicting institutionalization. Specifically, 
prescription medication count had less effect on institutionalization in those with 
dementia than in those without dementia. A likely explanation for this phenomenon is 
the clinical observation that cognitively intact persons are generally institutionalized for 
medical rehabilitation, whereas the potency of dementia as a risk factor far outweighs 
the effect of medical co-morbidity in the cognitively impaired.  
The burden of care to immediate care givers is a crucial element in the process 
of institutionalization. Often families are able to care for an elderly patient at home until 
he or she loses the ability to perform basic functions. The course of the events leading 
up to nursing home placement can provide insight into the patient's level of functioning 
and rate of decline. Research studies published between 1989 and 1995 were analyzed 
by Chenier18 to identify variables that led to caregiver burden and nursing home 
placement of non-demented elders. Although the variables impact each caregiving 
situation differently, decreased functional abilities of the care receiver, interrupted sleep 
of the caregiver or the presence of multiple factors within the caregiving situation were 
positively correlated with caregiver burden and increased risk of nursing home 
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placement. Increased awareness of these issues is essential to provide successfully for 
the aging population.  
Cost savings by postponing institutionalization 
Although expenditures did not increase with age for most services, the high personal 
cost for nursing home care among the oldest old underlines the need for increased 
efforts to support them in the community (USA).19 Greater spending by those in poor 
health highlights the importance of preventing age-related health conditions and their 
complications. Improved access to discretionary care among the oldest old may help to 
reduce the need for care in higher cost settings. The high prevalence of out-of-pocket 
prescription spending across the age range provides impetus for current efforts to 
reduce these costs.  
Canadian research examined the cost effectiveness of home care for seniors as a 
substitute for long-term institutional services. Chappell et al.20 computed the costs of 
formal care and informal care in both settings and ensured comparable groups of clients 
in both settings by comparing individuals at the same level of care. The results reveal 
that costs were significantly lower for community clients than for facility clients, 
regardless of whether costs only to the government were taken into account or 
whether both formal and informal costs were taken into account. When informal 
caregiver time is valued at either minimum wage or replacement wage, there was a 
substantial jump in the average annual costs for both community and facility clients 
relative to when informal caregiver time was valued at zero. Nevertheless, the results 
reveal that home care is significantly less costly than residential care even when informal 
caregiver time is valued at replacement wage. 
Loss of independence in older persons places considerable financial burden on them, 
their families, and the health care system.21 The Medicare Current Beneficiary Survey 
estimated the additional medical and long-term care costs that occur during the year 
when older persons make the transition to dependency at home or move to a nursing 
home. Average long-term care costs were $3,400 for persons who developed activities 
of daily living disability at home sometime during the year, $6,800 for those starting and 
ending the year with disability who remained at home, and more than $21,000 for those 
moving into a nursing home during the year.  
2.3.2 What are the most prevalent functional and clinical problems among 
residents? 
In order to assess properly the medication needs of nursing home residents, it is 
necessary to have an idea of the clinical problems common to this elderly population. 
We will address  
x Clinical Assessment  
x Functional Assessment 
x Nutritional assessment 
x Assessment of communication needs 
x Assessment of palliative care needs 
x Patient Autonomy 
2.3.2.1 Clinical assessment  
Heckman et al.22 found that heart failure is common in Canadian long-term care (LTC) 
facilities, but undertreated. The prevalence of heart failure was 20%. LTC residents with 
heart failure were older, more often women, and more functionally impaired and 
burdened by co-morbidity than were participants in heart failure trials. Documentation 
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supporting the heart failure diagnosis was inadequate, with some symptoms possibly 
misattributed to chronic obstructive pulmonary disease.  
Hass et al.23 determined in a retrospective population-based study in nursing homes 
(Rochester USA 1989-1994) that nursing home residents with major stroke were 
younger and more disabled and required more services than residents without stroke. 
Per diem Medicaid reimbursement was 11% higher for residents with major stroke 
compared with residents without stroke. Nursing home residents with minor stroke 
appeared similar to those without stroke with respect to time to admission, 
characteristics at first assessment and per diem Medicaid reimbursement. They 
concluded that lower incidence and severity of stroke (e.g. by better controlling 
diabetes and hypertension) may contribute to lower care needs and per diem cost.  
Rheumatic diseases are common in elderly people,24 are increasing in frequency and are 
undertreated. Extended care facilities have special needs and restrictions, making pain 
management more complicated. Understanding how to assess pain in a population at 
risk for poor pain control is vital. Treatment individualized to the patient's special 
circumstances where optimal care rarely means cure or complete relief of symptoms 
leads to improved function and quality of life. 
In a study of care homes in the UK, Sinclair et al.25 found a 12% prevalence of known 
diabetes. In the group of care home residents not known to have diabetes and able to 
undergo testing, a substantial proportion (14,7%) has undetected diabetes based on a 2-
h postglucose load. It is possible that residents with newly detected diabetes will benefit 
from early treatment of raised glucose levels by experiencing reduction of osmotic 
symptoms, improvement in cognition and assessment of any vascular complications. 
Whereas these actions are unlikely to lead to an increase in life expectancy of diabetic 
residents, they may add some value to their quality of life.  
To determine the magnitude and distribution of nosocomial infections in LTC 
institutions, the Norwegian Institute of Public Health initiated a surveillance system. The 
system is based on two annual one-day prevalence surveys recording the four most 
common nosocomial infections: urinary tract infections, lower respiratory tract 
infections, surgical-site infections and skin infections, as well as antibiotic use. The total 
prevalence of the four recorded nosocomial infections varied in 2004 between 6.6 and 
7.3%,26 whereas the lowest prevalence was found in special units for persons with 
dementia. In the survey the prevalence of the four recorded nosocomial infections was 
higher than the prevalence of patients receiving antibiotics. After the survey, the 
Norwegian Institute of Public Health recommended the implementation of infection 
control programs in facilities that had not yet done so, stated the importance of 
employing more nurses in long-term care facilities, and recommended training of 
unskilled personnel in basic infection prevention principles.  
The carriage of Methicillin Resistant Staphylococcus Aureus is increasing in nursing 
homes. The detection of MRSA carriers in nursing homes needs to be realized under 
particular conditions. Decolonization of carriers is absolutely essential.27 
Dementia, often the main cause for institutionalization, is common among nursing home 
residents. Measurement of cognitive ability should be performed with standardized, easy 
to administer instruments, such as the Mini-Mental State Examination (MMSE). Formal 
tests are useful because impressions based on conversations with the patient can be 
misleading. Patients who are aware of having a slight decline in mental processes may 
cope by redirecting conversations or making excuses for their memory loss in an 
attempt to create the impression that they have no impairment. In contrast, some 
patients may appear to be demented when, in fact, their function is limited by another 
physical or mental condition (e.g., decreased visual or hearing acuity, depression). Such 
patients may perform better on the MMSE than would be expected from conversations 
with them during history taking and physical examination. Therefore, measurement of 
cognitive skills with a standardized instrument is essential for establishing a baseline to 
assess changes or responses to therapeutic interventions. Wu N et al.28 found that both 
nursing home staff and study nurses recorded less frequent and less severe pain for 
residents with more severe cognitive impairment. Their results strongly support the 
notion that specialized pain assessment instruments are needed to adequately detect 
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pain for the large proportion of cognitive impaired nursing home residents. Ten percent 
of the dementias show language disturbances as the first sign. Language disturbances 
may exist for a long time, even before the onset of the memory impairment. The 
language disorder causes difficulty in proper judgment of memory. Logopaedic 
examination is necessary to diagnose the language disorder. Neuropsychological testing 
should take the language disorder into account. Diagnostic accuracy is important. 
Distinguishing dementia from a language disorder has implications for the judgment of 
the patient's (dis)abilities and management.29  
The prevalence of depression in the nursing home population is high.30 Whichever way 
defined, the prevalence rates found were three to four times higher than in the 
community-dwelling elderly. Age, pain, visual impairment, stroke, functional limitations, 
negative life events, loneliness, lack of social support and perceived inadequacy of care 
were found to be risk indicators for depression. Although depressive symptoms 
seriously affect the quality of life of a growing proportion of elderly people in residential 
care homes, many residents do not receive adequate antidepressant treatment. Lack of 
recognition of depressive symptoms and signs by the attending staff in the residential 
home is a major obstacle to the provision of adequate treatment. Eisses et al.31 
evaluated the effects of a program of care staff training in residential homes on the 
recognition of depression, the treatment rate and the prognosis of those with 
depression. Recognition of depression increased more in homes where staff received 
the training than in the control homes. Treatment rates also increased compared with 
control homes, but the increase was not significant. Residents with depressive 
symptoms had a more favourable course when staff had received training. Moreover, 
the prevalence of depressive symptoms decreased, but the decrease was not significant. 
2.3.2.2 Functional assessment  
Performing functional assessment of residents may have multiple purposes: 
x to reliably assess the status of the individual patient  
x to assess the burden of care within an institution (case-mix assessment) 
x to monitor the outcome of processes of care  
Functional level can be measured with low sophistication by two general purpose scales: 
Activities of Daily Living (ADLs) and Instrumental Activities of Daily Living (IADLs).  
In Appendix 7, a number of more sophisticated instruments are presented: 
x Resource Utilisation Version III (RUG-III) 
x Dutch Care Dependency Scale 
x Functional Autonomy Measurement System 
x Residents Assessment Instrument for Nursing Homes (RAI)  
In nursing homes, some aspects of functional status are particularly important:  
x Visual impairment  
x Hearing handicap  
x Oral health problems 
x Incontinence 
Vision impairment is a contributing cause of disability and activity limitation among the 
nation’s elderly, and can have profound implications for their quality of life.32 Diminishing 
eyesight contributes to a reduction in their physical, functional, and emotional well 
being, even after controlling for gender, cognitive status, and baseline function. 
Furthermore, visual impairment has been related to increased risk of falls and hip 
fractures, depression, and cognitive decline leading to disruptive behaviors. An expert 
nursing home panel within The Assessing Care of Vulnerable Elders (ACOVE) study 
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identified 13 quality indicators relative to vision impairment that were felt valid and 
feasible in nursing home residents. 
Garahan et al.33 found that self-assessments of hearing handicap by residents, together 
with audiometric findings and expressed interest in a hearing aid, were more useful 
guides for aural rehabilitation needs than were nurses' assessments of residents' 
handicaps. Medical records failed to identify 48% of residents with moderate to severe 
hearing losses. They concluded that residents should have hearing evaluations with 
documentation of results on admission and periodically under the direction of a nurse 
trained as a hearing specialist.  
Evaluating the realistic oral treatment need in a population in southern Sweden enrolled 
in long-term care, in nursing homes or home care, including dental status, oral mucosal 
status, oral hygiene status, oral mucosal inflammation and oral mucosal friction, Isaksson 
et al.34 found that 61% of the sample had a need not just for an oral health evaluation 
but also for additional dental treatment. The results indicate that realistic oral treatment 
need, taking their medical condition into consideration, is modest in this population, but 
that regular oral screening is mandatory. 
Urinary incontinence is a common but challenging problem in the long-term care 
environment plagued by rising costs, limited resources, and high rates of staff turnover. 
Successful management of incontinence in the nursing home is possible but it requires a 
comprehensive evaluation of the resident and a formalized plan of care that is 
individualized to the resident’s unique needs.35 Cardiovascular disease, mental disorders, 
and endocrine disease such as diabetes and hypothyroidism (all common afflictions in 
nursing homes) are all risk factors for incontinence. 
2.3.2.3 Nutritional assessment 
Patient's nutritional status should be systematically assessed, because more than one 
third of persons over age 75 are underweight. A weight loss of 5% in 1 month or 10% in 
6 months is considered significant.16 Many factors place older patients at risk for poor 
nutrition. For example, the inability to feed oneself can result in inadequate caloric 
intake. Mechanical causes of eating difficulty (e.g., ill-fitting dentures, swallowing 
difficulties due to stroke) should be sought and appropriate evaluative or therapeutic 
measures undertaken. Also, nausea or loss of appetite resulting from use of certain 
medications (e.g., digoxin, antidepressants) can affect patients' nutritional status. 
Deficiencies of specific nutrients, such as calcium, zinc, selenium, magnesium, vitamin D, 
vitamin B12, and folate, are important to consider in nursing home residents. Because 
many elderly patients have poor calcium intake and calcium supplementation is usually 
well tolerated, supplementation with calcium and vitamin D is advocated. 
2.3.2.4 Assessment of communication needs  
Residents' limited opportunities for communication with staff are primarily focused on 
care tasks. Conversations in staff-resident interaction focus on activities of daily living 
(ADLs), personal-social care, technical care, and health assessment. Williams et al.36 
described an intervention which leads to increased communication awareness among 
staff, with an increased ability to modify conversational topics to better meet older 
adults' psychosocial needs. 
2.3.2.5 Assessment of palliative care needs 
Discussion of future care plans and advance directives should be part of care planning 
for all elderly patients admitted to an extended-care facility. This discussion can help 
clarify concerns patients and families may have regarding the meaning of such decisions. 
By assisting patients or their designated guardians in clearly spelling out their wishes 
about end-of-life care, physicians can help them avoid the need to make these critical 
decisions in a moment of crisis. 
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2.3.2.6 Patient autonomy  
Faced with the challenge of respecting resident autonomy and simultaneously adhering 
to nursing home standards, nursing home staff often experiences a frustrating ethical 
conflict.  
Scott et al.37 explored patient autonomy, privacy and informed consent in the care of 
elderly people in long-stay care facilities. Results indicated marked differences between 
staff's and residents' responses on three of the four dimensions explored: information-
giving, opportunity to participate in decision-making about care and consent. There was 
much closer agreement between staff's and residents' responses regarding protection of 
patient privacy. Findings suggest there is still a significant need to educate staff 
concerning ethical awareness and sensitivity to the dignity and rights of patients.  
Schnelle et al.38 investigated the use of restraining in nursing homes. Residents in high-
restraint homes were in bed more often during the day, often associated with poor 
feeding assistance, reflecting important differences in quality of care between homes.  
Butterworth39 explored the concept of consent and proposed that consent for older 
people in long-term care is not a discrete episode requiring a consent form, but is one 
aspect of the process of including service users in decisions about their care.  
No formal instruments to measure patient autonomy have been developed for the 
setting of nursing homes.   
Particularly in relation with medication, the question of patient autonomy is important. 
Most nursing homes have developed a rigorous distribution system for medication, to 
minimize medication errors. This distribution system is often forced on all residents, 
regardless of their cognitive status.40 Nurses and managers may be reluctant to grant 
exceptions for autonomous patients, who are capable of taking responsibility for their 
own medication management.  
2.3.3 What are the problems with medication usage and how can quality of 
prescribing be assessed in nursing homes? 
2.3.3.1 Current problems with medication prescribing in nursing homes 
To be at high-quality level, medication management in nursing homes should insure that 
the residents gain the maximum therapeutic benefit from their medication in order to 
maintain or improve the quality and duration of life, and do no suffer unnecessarily from 
illness caused by excessive, inappropriate or inadequate consumption of medicines.  
Concern has been expressed about the quality of drug treatment in nursing homes. 
Anxiety about the risk of excessive prescribing of, for example, inappropriate 
neuroleptic drugs, is matched by concern about the consequences of underprescribing 
potentially beneficial drugs. Other factors impeding the quality of drug treatment in 
nursing homes are the prescription of contra-indicated drugs, chemical restraint of 
residents and drug-related hospital admissions. The latter aspect may be caused partly 
by medication errors, a form of system failure more related to the distribution of 
medicines to and inside the institutions than to the quality of prescribing.  
Finally, nursing home directions should also pay more attention to the financial aspect of 
drug treatment. 
Overprescribing 
The elderly in general use more medications than any other age group. This high rate of 
drug use has been attributed in part to the accumulation of diseases with ageing41, but 
also to the inappropriate prescribing of medications outside the bounds of accepted 
medical standards.42  
A 2000 study of nursing homes revealed that individual nursing home residents receive 
an average of 6.7 routine prescription medications per day and 2.7 additional 
medications on an “as needed” basis. It is not surprising that nursing home residents 
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receive more medications than the community dwelling elderly.43, 44 For example, a 
study on 1,106 residents in 12 nursing homes of a large city in the US showed residents 
are on an average of 7.2 medications.45 Furthermore, as people age, pharmacokinetic 
and pharmacodynamic changes occur that can affect the disposition of medications in 
the body. This combination of polypharmacy and pharmacokinetic and 
pharmacodynamic changes lead to an increased risk of adverse drug reactions (ADR), 
defined as an injury from medication. There is a linear relationship between the number 
of drugs taken and the increased potential for ADR.46 The nursing home residents are 
the frailest segment of the geriatric population, using the highest number of medications 
compared to the non-institutionalized elderly, thus having the highest risk for an ADR. 
Further complicating this issue, ADR are often interpreted as a disease of old age 
resulting in another drug added to the patient’s therapy by the doctor.47 
Misprescribing  
Certain drugs should be avoided in older adults or should only be used under certain 
circumstances, since their potential risk outweighs the potential benefit.48 The 
prescription of such contraindicated drugs also represents an area of concern in the 
medication use of nursing home residents, as it can lead to morbidity, mortality and 
increased costs of care.49  
The quality of drug management in nursing homes is also affected by the inappropriate 
use of psychoactive drugs to control problematic behaviors and induce sedation of the 
residents (“chemical restraint”). The effectiveness of psychotropic drugs to treat 
disruptive behavior remains uncertain because most episodes are self-limited. Research 
has shown that not only are the drugs often ineffective, but they may actually precipitate 
an agitated state.50  
Underprescribing  
Another important and increasingly recognized problem in nursing home residents is 
undertreatment, defined as the omission of drug therapy that is indicated for the 
treatment or prevention of a disease or condition. Undertreatment has been reported 
for diseases as asthma, cardiovascular disease, dyslipidemia, osteoporosis, pain, 
hypertension and depression, and underuse of angiotensin-converting enzyme (ACE) 
inhibitor medications in patients with congestive heart failure, anticoagulation in elderly 
patients with atrial fibrillation, and preventive therapy after myocardial infarction.51, 42, 52 
Undertreatment may have an important relationship with negative health outcomes in 
the elderly, including disability, death and health services use.42 
Drug-related hospital admissions  
Many studies have shown that a high number of geriatric patients experience drug-
related problems leading to hospital admission.53-62 However, the definition of the 
problems investigated in these studies varies markedly from study to study. In all the 
publications mentioned in the reference list, we found that adverse drug reactions 
(ADRs) were considered; in some publications non-compliance, improper drug 
selection, untreated indications and drug use without indication were also considered. 
These last problems can be defined as drug therapy failures (DTFs).  
The frequency of hospital admissions due to drug-related problems in the elderly is 
found to be 10 to 30%. The majority of these problems seem to be adverse drug 
reactions. Difference in incidence can be explained by a different classification system of 
type of problems, and of contribution to hospital admission.  
Several studies have investigated the preventability of drug-related problems in the 
elderly, which is found to be substantial, varying from 50% to 97%.53, 55, 57, 59, 61, 63 From 
those studies criteria for inappropriate medication use in geriatric patients can be 
defined, with medications that should be avoided generally in the elderly, or in the 
presence of specific co-morbidities, or when dosages or frequencies may exceed 
tolerable levels.64, 48, 65-69 The drugs concerned are central nervous drugs, drugs with 
anticholinergic properties, drugs with a narrow therapeutic-toxic range, slow release 
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preparations… When taking these criteria into account, many drug-related problems in 
the elderly could be avoided. Most of the studies described above study the elderly in 
general and few studies specific for the nursing home setting exist. 
Expenditures for medication in nursing homes  
For a variety of reasons the management of prescription drugs in nursing homes is now 
poised to emerge as a critical policy issue.70 Awareness of drug spending in nursing 
homes has grown as budget problems have forced increasingly aggressive cost 
containment policies. Second, as pharmaceutical innovation continues, new and 
expensive medications are rapidly being developed for the elderly population. 
Avery et al.71 compared the costs of prescribing, the number of items on prescription 
and the types of drugs prescribed for older people in nursing homes with older people 
living at home by means of a retrospective case-control study. The mean cost of 
prescriptions per patient-month was almost three times higher for nursing home 
patients than controls (45.27£ compared to 16.46£). The mean number of items 
prescribed per patient-month was also higher in nursing home patients (5.60 compared 
to 2.55). There were differences in the types of medication prescribed between the two 
groups, including considerably higher costs for central nervous system drugs, ulcer 
healing drugs, laxatives and enteral nutrition in nursing home residents.  
O'Neill et al.72 examined variations in prescribing costs associated with nursing home 
patients and patients matched by age and sex living in the community (UK). They 
concluded that the ability of the multivariate models they used to explain variations in 
prescribing costs among a group of elderly patients is poor. Adjusting weighted 
capitation formulae with respect to older patients to take account of such information 
or referring to it in negotiations on prescribing budgets would not appear to be 
warranted. 
There are markedly different financing structures to reimburse for drugs:  
x Institutions subsidized on the basis of discounted price for drugs on a 
per-drug basis 
x Imposing financial risk on nursing homes by including drugs in the 
prospective payment rate 
x Residents paying out-of-pocket a non-discounted price for drugs on a 
per-drug basis. 
2.3.3.2 How can the quality of medication usage in nursing homes be assessed? 
Medications are a very important aspect of the care of nursing home residents. 
Therefore, medication use provides an ideal opportunity for monitoring the quality of 
care. Explicit or implicit, evidence-based criteria for inappropriate medication use such 
as the Beers criteria and the Medication Appropriateness Index (MAI) are well known 
and implemented. However research is still ongoing in the area of the development of 
new quality indicators specific for the nursing home population. Prescription data are 
frequently used as indicators, but an important limitation is that they do not take into 
account information about disease and patient factors important for judging the quality 
of prescribing.73   
The most widely known explicit indicator for appropriate medication use in nursing 
homes is the Beers list, developed in 1991 in the US by a group of 13 national experts. 
This list included 19 medications that should be avoided, as well as 11 doses, 
frequencies or durations of medication prescriptions that should not be exceeded.  The 
list was updated both in 1997 and 2003.74 Drug-disease interactions and severity 
rankings have also been added. This type of indicators is subject to several limitations, 
such as a poor specificity, a not established reliability and the fact that they are not to 
be generalized to other countries.  
The Medication Appropriateness Index (MAI) evaluates for individual patients each 
medication using 10 criteria that take into account efficacy, safety and cost aspects of 
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appropriateness.75 These 10 ratings can be combined to produce a weighted score per 
medication. The MAI is a time-consuming instrument, but is currently the most 
comprehensive instrument to measure appropriateness of prescribing in the elderly.   
In Norway, a comprehensive set of prescribing quality indicators was developed, based 
on data from the health care record and medication charts of institutionalized elderly.76 
More details on this list are given in the method section and the result section of this 
report.  
The ACOVE Project (Assessing Care Of the Vulnerable Elder) used systematic 
literature reviews, expert opinions and the guidance of expert groups and stakeholders 
in the US to develop a comprehensive set of quality-of-care indicators that are relevant 
to vulnerable elders.77 About a third of the indicators refer to medication. As part of 
the ACOVE project, Knight & Avorn78 developed quality indicators for appropriate 
medication use in vulnerable elders using a systematic literature review and expert 
panel considerations. On the basis of the literature review and the authors’ expertise, 
16 potential quality indicators were proposed to the expert panel. 12 of them were 
judged to be valid.  
Elliott et al.68 developed a set of indicators of prescribing quality for elderly in Australian 
hospitals. These indicators were based on a set of indicators developed previously in 
the UK and were piloted at nine Australian hospitals. The indicators were divided in 3 
groups: 1) summarising general prescribing activity, 2) assessing prescribing based on 
prescription data only, and 3) assessing prescribing based on prescription and clinical 
data. 24 indicators were developed and applied on the prescriptions of 1,416 patients. 
Following pilot audits, 5 indicators were deleted, resulting in a final set of 19 indicators. 
The review of prescription by 2 pharmacists (n=66) showed also a good inter-rate 
reliability. The developed indicators provide a tool that can be used to assess, monitor, 
benchmark and improve prescribing for the age. 
Oborne et al.79 aimed to modify previously developed indicators and algorithms from 
the hospital setting for use in nursing homes, and to apply these indicators in the 
nursing home setting. 13 indicators were successfully modified and applied on 934 
residents in 22 nursing homes in the UK. These objective, evidence-based and simple to 
use prescribing appropriateness criteria provide an objective audit tool that can be of 
use in comparing prescribing between units and to enhance prescribing quality.  
A remark on outcomes  
The above described sets of quality of prescribing are all measures of the quality of 
process to achieve better outcome among patients. They are not direct measures of 
outcome such as mortality, morbidity, hospital admissions, or quality of life. Few studies 
on inappropriate prescribing look directly at health outcomes. Only preliminary 
attempts to link outcomes, measured by the Resident Assessment Instrument with drug 
utilization data, have been published.80, 81 The measurement of quality of life may be 
difficult to measure with generic instruments, given the high prevalence of cognitive 
disabilities and disabilities of the senses.  
2.3.4 Which institutional characteristics are important for the quality of 
prescribing? 
The organizational characteristics of nursing homes can substantially influence the 
quality of prescribing in nursing homes. This chapter will give an overview of the nursing 
home characteristics and their impact upon quality of prescribing (expressed by volume, 
expenditures and appropriateness of prescribing). Only studies explicitly exploring the 
relationship between institutional characteristics and quality of prescribing are listed. 
We examined the following characteristics: 
x Size and type of the institution 
x Case-mix of the institution 
x Staffing within the institution 
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x General approach to management of care processes 
x Approach to medication management  
2.3.4.1 Size and type of the institution (public, private not-for-profit, private for profit)  
There is some evidence that organizational factors can have a significant impact on both 
the quantity and quality of psychotropic drug use in nursing homes. However, the 
relationships are complex and poorly understood. A few studies found higher rates of 
drug use in larger facilities and for-profit facilities, but other studies found that facility 
size and ownership had no effect.82-86 
2.3.4.2 Case-mix 
In the sample of Schmidt et al.,86 all nursing homes were non-profit and operated by 
public municipalities and there was no functional difference in financial status among the 
residents -all were covered by the Swedish universal health care insurance plan. 
Residents' clinical and demographic characteristics did not account for variations of drug 
use from one facility to another, suggesting that facility differences are not due simply to 
resident mix. 
Mylotte et al.87 determined significant correlations between the antibiotic use and cost 
indicators, overall infection rate and case-mix index at the facility level, between 11 
long-term care facilities (USA). There was no correlation between the CMI of the RUGs 
II system as a measure of functional status and infection rate. Nevertheless, there was a 
trend toward a significant correlation between mean facility CMI and mean facility 
incidence of antibiotic use (AUR antibiotic utilization ratio), and cost per RCD (resident 
care day). 
2.3.4.3 Staffing 
Shorr et al.88  found more extensive antipsychotic drug use in those Tennessee homes 
with poorer third-shift staffing. Svarstad et al.89 used a more refined measure of home 
staffing in their study of private- and public-pay residents in Wisconsin homes. As 
predicted, residents in homes with less adequate nurse staffing and resources were 
more likely to have an order for an antipsychotic or anxiolytic medication, more likely 
to receive such medications, and more likely to have inappropriate use, even after 
controlling for residents' clinical and demographic characteristics. The hypotheses 
suggest that home differences in drug use are due largely to organizational factors such 
as: resource availability and demand (low/high nurse staffing; low/high resident 
functioning); caregiver communication (presence/absence of intervention team 
meetings); facility size (small/large number of beds; reflecting a measure of institutional 
environment). 
Mullins et al.90 examined nursing home personnel's perceptions of patient autonomy in 
their home. Findings indicated staff members' education and race had the greatest effect 
on their perceptions of personal autonomy. Somewhat surprisingly, staffing levels, 
turnover rates, and restraint usage did not affect their views of autonomy (“whether the 
resident would be allowed to make his or her own decisions or whether the nursing 
home staff would decide for the resident”).  
Schnelle et al.38 compared nursing homes that report different staffing statistics on 
quality of care. Staff in the highest staffed homes (California), according to state cost 
reports, reported significantly lower resident care loads during onsite interviews across 
day and evening shifts (7.6 residents per nurse aide [NA]) compared to the remaining 
homes that reported between 9 to 10 residents per NA). The highest-staffed homes 
performed significantly better on 13 of 16 care processes implemented by NAs 
compared to lower-staffed homes. 
Castle et al.91  examined the association between nurse aide (NA) plus licensed practical 
nurse (LPN) and registered nurse (RN) turnover and quality indicators in nursing 
homes. Indicators of care quality used are the rates of physical restraint use, catheter 
use, contractures, pressure ulcers, psychoactive drug use, and certification survey 
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quality of care deficiencies. In addition, they used a quality index combining these 
indicators. Turnover information came from primary data collected from 354 facilities in 
4 states and other information came from the 2003 Online Survey, Certification and 
Reporting data (OSCAR). The turnover rates were grouped into 3 categories, low, 
medium, and high, defined as 0% to 20%, 21% to 50%, and greater than 50% turnover, 
respectively. The average 1-year turnover rates identified in this study were high at 
85.8% for NAs and LPNs and 55.4% for RNs. Multivariate analysis showed that 
decreases in quality are associated with increases in RN turnover, especially increases 
from low-to-moderate levels of turnover, and with increases in NA and LPN turnover, 
especially increases from moderate-to-high levels of turnover. These findings are 
significant because the belief that staff turnover influences quality is pervasive. The 
cross-sectional results are only able to show associations, nonetheless, few empirical 
studies in the literature have shown this relationship. 
2.3.4.4 General approach to management of care processes  
Increasingly, health care providers are acknowledging that organizational culture is 
crucial to understanding and managing the complex demands of a health care 
organization. The definition of organizational culture may include the social climate, 
quality of communication among staff, and informal values, norms, beliefs and attitudes 
shared by members of the organization. It has been shown that an organizational culture 
based on a teamwork approach (as opposed to a traditional hierarchy of authority) can 
significantly improve patient outcomes.92  
Co-ordination of care can be considered as one of the three dimensions of quality of 
nursing care in nursing homes. The other two dimensions are instrumental care and the 
quality of the social climate and living environment. In this concept, co-ordination of 
care is one of the aspects of quality of care. 
Holtkamp et al.93 investigated the quality of co-ordination of care and the way it is 
related to gaps between needs and care supply, the quality of life and health status of 
residents living in Dutch nursing homes. The results of this investigation showed a 
relation between the co-ordination of care and care discrepancies; the higher the quality 
of co-ordination of care, the fewer the gaps between residents' needs and the care they 
received. The psycho-social aspects in particular showed a gap between the needs and 
care supply. As regards the relation between co-ordination of care and quality of life, 
the strongest positive relations were found between taking case histories, patient 
allocation and dimensions of quality of life. No direct relations were found between the 
co-ordination of care and care discrepancies on the one hand and the health status of 
the residents on the other. In conclusion, this study showed that the quality of co-
ordination of care can affect the perceived quality of life of nursing home residents. The 
relation is even stronger when the unmet needs of the residents are also taken into 
account. To meet the residents' needs it is important to assess their physical and 
psycho-social needs accurately. An integrated instrument such as the Resident 
Assessment Instrument (RAI) in which the physical and psycho-social assessment 
procedures are both represented may help nurses to complete the assessment of 
residents’ needs. In a review Wagner et al.94 identified 21 empirical studies concerning 
quality system activities such as the implementation of guidelines; providing feedback on 
outcomes; assessment of the needs of residents by means of care planning, internal 
audits and tuition and an ombudsman for residents. The effects on care processes and 
the health outcomes of long term care residents were inconsistent, but there was some 
evidence that specific training and guidelines can influence the outcomes at the patient 
level. The design of most of the studies meant that it was not possible to attribute the 
results entirely to the newly implemented quality system.  
A nursing home that creates a culture that supports open communication and 
relationships, based on trust, respect, and leadership, ensures that staff members have 
the environment and resources to make and sustain improvement.95  However 
communication and relationships remain a concern, with more than 50% of staff 
suggesting that communication is not open, accurate, timely, or understandable. 
Although less has been learned about management infrastructure, there is no question 
that traditional management practices also send mixed messages and do not support an 
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environment where high-performing teams feel confident and supported. Information 
mastery is an evolving skill in the nursing home setting with high performing teams 
needing access to information, guidance in how to process information, and the ability 
to make an impact once they have used this information to fuel quality improvement 
efforts. Nurse leaders must carefully assess their personal preparation and 
understanding how they do partner with their administrators and other key leaders to 
create an environment that supports and values the voice of staff and the use of high 
performing teams as the main engine of improvement in their nursing home. This 
sustained improvement will ensure the best possible care of the frailest citizens for 
years to come. 
Some institutions have a culture of inaccurate documentation, often created by a 
discrepancy between care expectations placed on nursing homes by regulatory 
guidelines and inadequate reimbursement to fulfil these expectations. Nursing home 
staff has little incentive to implement the technologies necessary to audit and assure 
data quality if accurate documentation reveals that care consistent with regulatory 
guidelines is not or cannot be provided. Schnelle et al.38 reviewed methods to improve 
the accuracy of nursing home medical record documentation and to create data systems 
useful for staff training and management. 
Identification of residential care as a separate quality domain is important conceptually 
and pragmatically. Conceptually, it acknowledges the nursing home as the resident’s 
home and the consequent importance of the ongoing interaction between care 
providers and residents. It also distinguishes residential care as a key factor among the 
many that determine residents’ quality of life. The interactions of nursing home staff 
with residents powerfully determine residents’ quality of life. The residential care 
process measures developed by Saliba et al.96  are intended to measure the manner in 
which, or the extent to which, need is met on a day-to-day basis. Experts identified 
19 specific care processes as valid and important measures of the quality of nursing 
home residential care. Nine of these quality indicators may be measured best by direct 
observation of nursing home care, rather than by interviews or review of existing 
nursing home records. Almost half of the quality indicators were viewed as 
discriminating between better and average nursing homes. 
Pressure ulcers, a prevalent healthcare problem in long-term care homes are useful 
indicators of nursing home quality. Pressure ulcers are associated with considerable 
morbidity, mortality, and cost. In addition, nursing homes with high pressure ulcer 
prevalence are likely to have problems with other quality measures. Identifying LTC 
residents who are at risk for pressure ulcers is important because the Centers for 
Medicare and Medicaid Services consider a pressure ulcer to be a sentinel event in 
someone who has been assessed as low risk. Although researchers have examined skin 
conditions using the MDS, the relationship between risk assessment and pressure ulcer 
quality indicator scores from the MDS has not been evaluated. Wipke-Tevis et al.97 
measured pressure ulcer quality indicator scores and pressure ulcer prevention and 
treatment practices in long-term care facilities in Missouri. Fewer than 13% of homes 
used the Agency for Health Care Policy and Research pressure ulcer prevention and 
treatment guidelines. No relationship was found between the number of prevention 
strategies or the number of treatment strategies and the pressure ulcer quality indicator 
scores. Valid and reliable pressure ulcer risk assessment tools are seriously underused. 
Evidence-based pressure ulcer prevention and treatment guidelines appear to be rarely 
implemented. This study provides a basis for developing educational and quality 
improvement programs. 
Excessive time in bed has negative effects on both physical conditioning and functioning. 
There are no data or practice guidelines relevant to how nurses should manage the in-
bed times of nursing home residents, although all nursing homes receive a bedfast 
prevalence quality indicator report generated from the Minimum Data Set. Bates-Jensen 
et al.98 found significant differences between upper (i.e., higher prevalence of bedfast 
residents) and lower quartile nursing homes in the proportion of time residents were 
observed in bed (43% vs. 34%, respectively; p =.007), and in the proportion of residents 
who spent more than 22 hours in bed per day (18% vs. 8%, respectively; p =.002). All 
nursing homes underestimated the number of bedfast residents. The residents of upper 
40  Medication use in Nursing Homes KCE reports 47 
 
quartile homes showed more activity episodes and reported receiving more walking 
assistance than the residents of lower quartile homes. Minimum Data Set bedfast quality 
indicator identified nursing homes in which residents spent more time in bed, but did 
not reflect differences in activity and mobility care. In fact, upper quartile homes 
provided more activity and mobility care than lower quartile homes. Across all the 
nursing homes, most of the residents spent at least 17 hours a day in bed. Further study 
of activity and mobility care and bedfast outcomes in nursing homes is needed, and 
nurses need to note the amount of time nursing home residents spend in bed. 
Wagner et al.99 described a method for measuring and reporting the costs of quality 
management in a national survey in 489 organizations providing long-term care (nursing 
homes, home health care organizations, and homes for the elderly). Site visits and a 
questionnaire were used to measure the existence of quality management activities and 
investigate the costs per quality management activity in more detail. Health care 
organizations differentiate between regular activities and quality management activities. 
The costs of quality management activities were found to vary between 0.3% and 3.5% 
of the budget in three nursing homes. An extrapolation of the costs of quality 
management activities to the entire sector shows that the long-term care sector spent 
between 0.8% and 3.5% of the overall budget for quality management in 1999. The costs 
of developing and implementing quality management activities are higher than the costs 
of monitoring. Most long-term care organizations have no insight into failure costs (i.e. 
the costs of quality deviations). This makes it impossible for health care organizations to 
draw conclusions about the cost-effectiveness of quality management. Understanding 
how quality improvement affects costs is important. Lee et al.100 built on the principles 
of process improvement to develop a costing strategy. Process-based costing has 
4 steps: developing a flowchart, estimating resource use, valuing resources, and 
calculating direct costs. The researchers conclude that process-based costing is easy to 
implement, generates reliable, valid data and allows nursing managers to assess the costs 
of new or modified processes. 
Finally, there are some indications in the literature that there is a positive relationship 
between the level of subsidizing or payment rate of the institution and the quality of 
processes and better outcomes in nursing homes.101 The results from this analysis imply 
that a 10 percent increase in Medicaid payment was associated with a 1.5 percent 
decrease in the incidence of risk-adjusted pressure ulcers. These findings provide 
support for the idea that increased reimbursement may be an effective means toward 
improving nursing home quality. 
2.3.4.5 Approach to medication management systems 
Different initiatives have been taken in order to manage the quality of the drug 
consumption in nursing homes. We will review the literature on approaches to improve 
the quality of drug consumption in nursing homes:  
x The implementation of drug formularies 
x Organization of the medication distribution  
x Informatization of this medication distribution process 
x Pharmaceutical care in the nursing homes  
x An example of a quality management intervention: multidisciplinary 
case conferences in nursing homes 
In the next section we will review the literature on the evaluation of the effectiveness of 
these approaches to enhance the quality of prescribing. 
Medication management is closely related to other clinical activities such as screening 
activities (see the sections on clinical assessment) and preventive medicine activities 
such as vaccination.  Vaccinations for pneumonia and influenza are well accepted by 
patients and help prevent respiratory tract illness that can lead to hospitalization or 
premature death. On nursing home admission, the patient's record of these vaccinations 
should be reviewed and diphtheria-tetanus immunization updated.16 
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2.3.5 What is the effectiveness of interventions (medication management 
systems) with regard to the quality of prescribing in nursing homes? 
2.3.5.1 Implementation of formularies in nursing homes 
Little is known about the implementation of formularies in nursing homes. The 
published papers mostly refer to formularies as known in the US insurance system (the 
third-tier does not reimburse all of the drug-related expenses made, but only the ones 
that refer to the formulary accepted by the insurance). On the other hand, geriatric 
formularies for nursing homes are standard lists with affordable, safe and active 
medicines for the most frequently occurring diseases.102 The aim for implementation of 
this kind of formulary can be an increased safety, disposing of a list of always available 
medication, disposing of a list with the cheapest medication or an evidence-based 
prescribing behavior.  
Drug formularies have long been used and accepted in hospitals, but the concept is still 
quite new in nursing homes. A possible explanation is that nursing homes lack the 
organizational structure and communication systems that would cause the visiting 
physicians to meet and discuss an issue as a drug formulary. Therefore, the Pharmacy 
Corporation of America (PCA) decided to offer an open formulary specific to geriatric 
population to all medical directors, key attending physicians and directors of nursing in 
more than 2,000 nursing homes served by PCA. The formulary is presented in a 
handbook complete with monographs. The monographs display clinical dosing 
information, note federal and state nursing home regulations that apply, and list special 
considerations for geriatric patients, such as drug half-time or alternative dosage forms. 
PCA consultant pharmacists reported that the formulary served as an excellent starting 
point for developing a closed, limited formulary.103  
Drug formularies can theoretically increase the quality of prescribing and reduce the 
costs of prescription drug therapy. But Gross104 found that formularies do not actually 
enhance the quality of care. Neither do they adversely affect the quality of care, but 
more research is required.  
Peer-reviewed publications evaluating the impact of drug formulary use in nursing 
homes on the cost of care could not be found.  
2.3.5.2 Organization of the medication process 
Two studies conducted by Gurwitz et al.105, 106 showed that errors occurred most 
commonly at the ordering and monitoring stages of the medication process and less 
commonly at the dispensing and administration stages. Nevertheless, the dispensing and 
administration stages are problematic essentially for two reasons. Medications can be 
split or otherwise altered during the dispensing stage, and covertly (unknown to the 
resident) administered. Evidence shows that both practices are widespread in nursing 
homes and are potentially problematic.107-110 
Medication splitting or alteration is usually performed by the nurse in charge of the 
dispensing. Even with appropriate devices, the splitting practice does not produce equal 
halves.111 The dose can deviate by more than 20% from the intended one.112, 113 
Inaccurate dosing may result in ineffective disease management.107 Moreover, when 
tablets are split or otherwise altered, the effects of specific tablet formulations (such as 
enteric coated or sustained release formulations) may be negated and the drugs may be 
subject to increased degradation as a result of exposure to air.111, 114 Therefore, 
guidelines outlining best practice for the alteration and administration of medication in 
nursing homes are required. Accurate and up-to-date information needs to be available, 
detailing those medications which should not be altered, the potential risk of altering 
medicines and possible alternatives.108  
Covert administration of medications is also common practice in nursing homes. But 
most concerning are the poor recording and the secrecy around it.115, 110 The practice is 
found to be paternalistic and rarely ethically justifiable.116 It could be acceptable in 
extreme circumstances, for example if patients suffer from permanent mental incapacity 
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and refuse needed treatment.115, 117 But disguising medication simply for the convenience 
of the healthcare team is totally unacceptable.118  
2.3.5.3 Informatization in nursing homes  
Prescribing for elderly people is problematic for numerous reasons. The information 
necessary to general practitioners is usually fragmented across many isolated sources 
(different specialists, hospitals, nursing home records) and most records are still paper-
based. Moreover, drug treatment of elderly is a complex issue requiring dose 
adjustments, specific attention for interactions and for the ability of the patients to 
actually take the medications as prescribed.  
A computerized prescription order entry (CPOE) system equipped with a clinical 
decision support (CDS) module is a potentially powerful tool to prevent medication 
errors.119 CPOE and CDS systems have already been implemented successfully in a 
hospital setting. However, few descriptions of their use in nursing homes are 
available.120, 121 
Evidence indicated that computer support reduces serious prescribing errors by 55% 
and overall prescribing errors by about 83%.122 Also a significant decrease in medication 
error rates was observed. This reduction can be ascribed to the prevention of errors 
and adverse events, the facilitation of a more rapid response after an adverse event has 
occurred, the tracking of adverse events and the provision of feedback about these 
adverse events.123 However, the CPOE system also has several limitations. First of all, 
CPOE systems are challenging to implement in nursing homes.124 In order to facilitate 
the overall implementation of electronic prescribing, a few improvements of the system 
are also necessary: the user interface should be adapted, structured drug databases 
should be constructed, the system should have the capacity to generate both criticisms 
and suggestions during the prescription, and software for retrospective analysis of the 
prescribing habits should be developed.119 Medications differ from country to country, 
making it impossible to just take over an existing system and implement it abroad.  
Besides, CPOE systems have been designed for use in adults in general and need to be 
adapted to the specific needs of the geriatric population.121 Moreover, as CPOE systems 
are implemented, attention must be paid to the errors that these systems can possibly 
cause and not only to the errors that they prevent.125 For elderly with multiple medical 
conditions and polypharmacy, too many unimportant recommendations are made, by 
which important warnings may be ignored.126, 127  
In the light of the success in hospital settings, the implementation of a CPOE system in a 
long-term care facility has been studied. These studies agreed that the CPOE system is a 
very promising new technology that may be very useful in nursing homes. But a change 
in mentality and full facility commitment are needed to implement such a major change 
as the switch to electronic prescribing.126, 128, 129 
Whenever organizations finally decide to take the big step and adopt electronic 
prescribing, they can select from a wide variety of commercial systems. These systems 
are often complex and heterogeneous. That is why a conceptual framework for 
evaluating electronic prescribing systems as developed for outpatient settings by Bell et 
al.130 could be of great help.   
Information technologies can also provide a great support during the monitoring stages 
of the medication process. A computerized monthly drug regimen review can help the 
pharmacist in reducing the number of medications per patient, which in turn decreases 
the costs for the residents.131 A computerized system can also detect some adverse 
events in a timely and cost-effective way. This has mainly been tested in hospital 
settings, but could also be applied to nursing homes.132  
Another way of preventing medication errors is the implementation of a ‘closed loop 
system’ as described by Lenderink & Egberts.133 The essence of this system is that at the 
moment of medication administration, the medicine that is about to be given to the 
patient is verified against the medication order with respect to the necessary medicine 
characteristics (name, form, dose) and time. In order to make this possible, automated 
bar coding seems to be the most feasible instrument. This means that there should be a 
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specific barcode as well on each medicine as on a wristband that each patient should 
wear. A disadvantage is that mobile registration equipment is needed. The system was 
successfully tested in different wards of a hospital, and in a nursing home.  
2.3.5.4 Pharmaceutical care in nursing homes 
For a long time, the role of the community pharmacist was purely limited to 
compounding, packaging and dispensing medications, and advising about over-the-
counter drugs. Recently, this role has evolved, in some European countries and mainly 
in the US, to become one of pharmaceutical care provider. The American Society of 
Hospital Pharmacists (ASHP) defines pharmaceutical care as “the direct, responsible 
provision of medication-related care for the purpose of achieving definite outcomes that 
improve patient’s quality of life”.134 Pharmaceutical care involves pharmacists taking 
responsibility, in conjunction with physicians and patients, for the outcomes of drug 
treatment and not simply for the accurate dispensing of medications. This increased 
responsibility would require pharmacists to take a more active role in assuring that 
therapy is appropriate, that patients understand regimes, and that therapeutic outcomes 
are met. Improving drug therapy of elderly in nursing homes (e.g. by identifying, 
resolving and preventing drug-related problems) could form part of this reorientation of 
the pharmacy profession.  
Pharmaceutical care was implemented in the USA about 35 years ago. As a result of 
increasing public concern about the overuse of neuroleptics in nursing homes, the US-
government passed in 1987 the Omnibus Budget Reconciliation Act (OBRA-87), a law 
creating a set of national minimum standards of care and rights for people living in 
certified nursing facilities. One of the changes OBRA-87 brought to nursing home care 
was a mandatory monthly medication regimen review performed by a consultant 
pharmacist. But already before 1987, the effects of a drug regimen review were 
investigated. Cooper135 showed that the consultant pharmacist had an effect on drug 
costs in long-term care, which was reversed when the drug regimen review was 
removed and renewed when services were reinitiated. The provided pharmaceutical 
care also frequently included advice to GPs about choice and duration of drug therapy, 
as well as the participation in staff education about medication.  
In Europe (except in the UK), pharmaceutical care services are not so widespread. The 
services provided to nursing homes are primary the dispensing of medication and the 
provision of basic advice about documentation and storage.136, 137 
Different studies have explored what potential roles of a pharmacist can be. Pharmacists 
can promote safer prescribing practices, provide additional information to the nursing 
home staff, and identify potential adverse drug reactions and interactions. Some 
community pharmacists provide pharmaceutical advice and services to residential and 
nursing homes such as the management of repeat prescriptions and the monitoring of 
treatment. But they also can assist GPs with medication reviews, provide information to 
prescribing committees and compile drug formularies.138 Crotty et al.139 assessed the 
effects of a pharmacist as transition coordinator for transfers from a hospital to a long-
term care facility. The use of a pharmacist as transition coordinator improved the 
appropriateness of medication use across health sectors. Therefore, pharmacists should 
not restrain their activities to what happens inside the walls of the nursing home.  
Most studies are very positive about the effects of pharmaceutical care provided to 
nursing homes. Drug use decreases, which results in a decrease of the costs for both 
the residents and the government, without affecting the morbidity or mortality of the 
residents.140-144 However, one should be careful with the interpretation of such results. 
Majumdar & Soumerai145 argue that the often chosen goal of reduction of the number of 
prescribed medication is misdirected. It should actually be abandoned as a measure of 
quality, since underuse of medication and undertreatment are also common in nursing 
homes. In this case, the pharmacist’s intervention does not increase the number of 
prescribed drugs (which would be interpreted as a negative result), but does increase 
the quality of care.  Harjivan & Lyles146 state that although the purpose of monthly drug 
regimen reviews is to improve drug use and to avoid adverse drug events, the current 
guidelines focus on a limited selection of medications and indications rather than on 
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patient outcomes. Therefore, the pharmacist’s role should be more one of a clinical 
pharmacist than of a simple consultant pharmacist.  
But not all studies are positive about the effects of pharmaceutical care. A randomised 
controlled trial in primary care showed that the pharmacist intervention did not have a 
significant effect on patient outcomes.147 A study by Crotty et al.148 focused on stroke 
prevention and fall reduction rather than on a decrease in medication use. This study 
showed no change in prescribing patterns of the GPs, even if they were receptive to the 
idea of pharmaceutical care.  
Briesacher et al.149 argue that the effectiveness of drug use reviews in improving patient 
safety in nursing homes is actually unclear, even though state and federal agencies in the 
USA have widely adopted this strategy.  
2.3.5.5 Multidisciplinary case conferences in nursing homes (an example of a quality 
management intervention) 
Pharmacists can not improve the quality of medication use in nursing homes all by 
themselves.150 Collaboration between different healthcare providers and nursing home 
staff is required in order to modify suboptimal drug use in older people.151 The quality 
of drug use is indeed positively associated with the quality of communication between 
healthcare providers.138, 152  
Multidisciplinary teams seem to be useful for various aspects of the care process. The 
teams reduce the number of inappropriate medications, decrease the number of 
medication orders and increase the staff knowledge about drug therapy in the elderly. 
The composition of those teams is not a constant and varies from nursing home to 
nursing home. However, GPs, a pharmacist and nursing staff are almost always involved.  
But the team can also involve physicians specialized in a specific area (geriatrician, 
neurologist, neuro-psychiatrist, clinical pharmacologist, …) or other members of the 
nursing home healthcare team (dietitian, dentist, rehabilitation therapist, social worker, 
activities coordinator), sometimes under the supervision of the management.153  
These multidisciplinary teams meet on a regular basis in order to discuss the different 
aspects of care for the elderly in the nursing home, or the medication in particular. 
Medication errors or inappropriate medication use can thus be identified.  
Most studies showed positive results on the quality of prescribing, and thus benefits for 
the residents.86, 154, 49, 155, 152, 156-158 One study was rather sceptical because interventions 
with a multi-speciality group showed no effect other than the decrease of the number 
of prescribed drugs.153 However, no negative results were found.  
2.3.5.6 Changing organizational culture 
Svarstad et al.159 hypothesized that reduction in use of antipsychotic drugs was more 
likely to occur in homes with a resident-centered culture emphasizing psychosocial care, 
avoidance of psychotropic drugs, pharmacist feedback, and involvement of mental health 
workers. In this study, they examined four types of factors that can influence an 
organization’s ability or motivation to change: need, structure, capacity, and culture. The 
results of the study suggested that homes with higher reimbursement and stable nursing 
leadership are more responsive to new drug guidelines. How do these factors actually 
influence a home’s response? One obvious hypothesis is that better funding and 
leadership produce better nurse staffing, which is essential for improving care. In 
addition, directors of nursing with longer tenure may acquire the experience or 
legitimacy needed to identify appropriate tools, mobilize staff, and facilitate 
communication between nurses and other providers.  
Schmidt et al.152 explored the impact of the quality of nurse–physician communication on 
the quality of psychotropic drug use in Swedish nursing homes, while controlling for 
resident mix and other nursing home characteristics. The quality of drug use was 
positively associated with the quality of nurse–physician communication and with regular 
multidisciplinary team discussions addressing drug therapy and negatively associated 
with prevalence of behavioral disturbances among residents. Facility size, level of 
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staffing, resident’s diagnostic mix, and demographic mix were unrelated to the two drug 
quality measures.  
Manias et al.160 examined the extent of adherence to various protocols in relation to 
medication activities and determined how the ward environment impacts on graduate 
nurses’ use of protocols to manage patients’ medications. Such protocols included 
guiding statements for preparing medication for administration, assessing patients before 
administering medication, checking the patient’s identity before giving medication, the 
process for administering medication, evaluating desired and adverse effects, checking 
specific medications with other nurses before giving and the desired times of day to 
administer medication. The study showed that graduate nurses adhered to protocols if 
they were perceived not to impede with other nursing activities; were more likely to 
follow protocols if they felt encouraged to make their own decisions – “effective and 
safe medication management involves creating the appropriate balance between 
standardizing practice in protocols and allowing flexibility and autonomy to take 
responsibility”-; were reluctant to follow protocols about documenting medication 
errors if there was a likelihood that disciplinary action would be involved.  
A special study report from the UK Commission for Social Care Inspection (CSCI 112 
February 2006) revisited the management of medication to find out whether homes had 
improved their performance (see Appendix 8). It used statistical information that the 
Commission gathers from rating homes against national standards and enhanced this 
with qualitative data from inspectors to highlight best and poor practice. The report 
shows that there has been some slight improvement in performance overall (since 
March 2004), with the exception of nursing homes for older people. But the rate of 
improvement in such a crucial area of care has been disappointingly slow, with nearly 
half the care homes for older people still not meeting the minimum standard relating to 
medication. Of particular concern is the very high percentage of homes, which having 
achieved the minimum standard, then slip back and fail. The broad range of evidence 
used for this report has strengthened the finding that homes need to address core 
management issues – such as training of staff and the development and monitoring of 
practices and procedures – to safeguard residents from abuse through medication 
mismanagement and to maximize their wellbeing.  
2.4 DISCUSSION AND CONCLUSION OF THE LITERATURE 
REVIEW 
The major conclusion of this literature overview is that different intervention strategies 
in nursing homes have the potential to increase the quality of prescribing. Some 
evidence of effectiveness is available for pharmaceutical care and multidisciplinary 
interventions, involving the whole team of caregivers. The size, expertise and culture of 
the nursing staff are important for the quality of medication distribution and monitoring 
processes. Medication errors occurring during the medication distribution process may 
have important clinical consequences. Preventing medication errors may have a great 
potential for improvement in outcomes. However, interventions to prevent medication 
errors differ from interventions to improve the quality of prescribing. More research is 
needed on the implementation of drug formularies in nursing homes and on how to use 
information technologies in order to enhance medication management.  
Existing research focuses on structural indicators (general characteristics of institutions 
and the characteristics of their medication management systems).  The impact of these 
structural indicators on the process of prescribing has been studied through recently 
developed process indicators of prescribing quality. Several sets of prescribing quality 
indicators have been developed for nursing homes, each measuring different aspects of 
prescribing quality and none of them fully validated or universally applicable. Moreover, 
evidence is lacking on the link between structural indicators, process indicators and 
direct measurements of outcome at resident level. 
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3 FIELD STUDY: PRESCRIBING IN HOMES FOR 
THE ELDERLY IN BELGIUM (PHEBE) 
Authors: Robert  Vander Stichele, Monique Elseviers, Charlotte Verrue, Kris Soenen, 
Mike Smet, Mirko Petrovic, Pierre Chevalier, Tom De Floor, Els Mehuys, 
Annemie Somers, Micheline Gobert, Anne Spinewine, Stephan Devriese 
3.1 SETTING 
The study was conducted in Belgium, an industrialized Western-European country with 
10.4 million inhabitants, with 17.2% elderly (65+), of which 8% live in nursing homes in 
the course of one year. Belgium is divided in 10 provinces (5 Dutch-speaking and 5 
French-speaking) and Brussels-Capital Region. Nursing homes are multifunctional 
institutions, where residents are often treated by their former GP, and where one of 
the attending general practitioners has a role of coordinating physicianjj.  
3.2 OBJECTIVES 
The aim of this study was to investigate the relation between institutional characteristics 
(including the characteristics of the medication management system) and the quality of 
medication prescribing. 
The secondary aim of the study was to evaluate existing sets of prescribing quality 
indicators with regard to their suitability for application in the Belgian context. 
3.3 METHODS 
3.3.1 Design  
This study was a cross-sectional, descriptive study of a representative sample of nursing 
homes and residents with an exploratory analysis of the relation between institutional 
characteristics and prescribing quality. 
3.3.2 Sampling procedure   
We selected three provinces for participation in the study: Oost-Vlaanderen, 
Antwerpen (both Dutch-speaking) and Hainaut (French-speaking). In each of these 
provinces a two-stage (institutions and residents) sampling procedure was used, based 
on the Rapid Assessment approach of the World Health Organization.  
In the first stage of sampling the population of institutions was defined. Only institutions 
with at least 30 beds and having a certification for high intensity care beds (RVT beds) 
were eligible for selection. Nursing homes were selected in 4 strata based on size (up to 
90 or more than 90 residents) and type of nursing homes (public, private), with a 
random selection of 5 institutions per stratum in each province. Hence, in each of the 
3 participating provinces, 20 institutions (and 5 reserves) were selected with this 
stratified random selection procedure. In the sample of the province of Hainaut, 4 
institutions of Brussels were included. 
In the second stage of sampling, in each of selected institutions, first the coordinating 
physician of the nursing home (CRA) was contacted to ask for participation. Then, 
written consent of the management of the nursing home was asked. Umbrella 
organizations of CRAs and nursing homes were contacted to stimulate participation. 
Refusals were replaced by a new random selection within the same stratum. Per 
province, refusals ranged from 0 to 3 nursing homes per stratum. 
In the second stage of sampling, residents were selected in the selected institutions. In 
each of the participating institutions, 30 residents (and 10 reserves) were randomly 
selected. The treating physician of each selected resident was contacted by the CRA to 
                                                     
jj The Dutch acronym CRA for ‘’coördinerende, raadgevende arts’’ will be used hereafter. 
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ask for participation. In case of refusal, a new resident, treated by another GP, was 
selected.   
Random selection was performed by the research team based on a numbered list of all 
eligible residents of a nursing home, with random computer generated selection of 
20+10 residents. Researchers were blinded for the responsible GP of selected 
residents.  All contacts with GPs were handled by the CRA of the participating nursing 
home. All contacts with the CRAs were coordinated by one of their peers, who had a 
representative function at the provincial level for nursing home health care policy. 
3.3.3 Data collection at the level of the nursing homes  
Junior researchers of the department of Pharmacy of the University of Gent and Master 
students of the department of Pharmacy of the Catholic University of Louvain visited all 
participating nursing homes. They first interviewed the director or a member of the 
management team using a structured questionnaire. Data collection focused on general 
characteristics of the nursing home (number of beds, number and type of wards), 
general care management (presence of a quality coordinator and quality management 
handbook), the medication management systems (presence and use of a drug formulary, 
organization of the medication distribution process, handling of medication errors), and 
the pharmaceutical care activities of supplying pharmacists. 
Additionally, they interviewed the head nurse of one or two wards. If two wards were 
available, preferentially one ward for residents with good cognitive functions and one 
for demented residents were selected. Data collection concentrated on the different 
aspects of the medication distribution process (registration, storage, distribution and 
intake control of medication). 
3.3.4 Data collection at the level of residents 
Master students of nursing sciences of the Universities of Gent and Antwerpen visited 
all Dutch-speaking participating institutions and master students of the Public Health 
Department of the University of Louvain visited the institutions in the French-speaking 
Province of Hainaut, to collect administrative data of selected residents (age, gender, 
WIGW/VIPOkk, OCMW/CPAS and Katz scale). They obtained a copy of the medication 
chart of selected residents. These copies were put into an electronic format with 
automatic assignment of ATC/DDDll to estimate the volume of medicine consumed and 
the expenditures at ex-pharmacy retail price (the fixed total price paid by patients in the 
community pharmacy, including 6% VAT) and the out-of-pocket expenditures (co-
payment for reimbursed medicines, payment for non-reimbursed prescription 
medication and payment for over-the-counter (OTC) medication). 
Special procedures were used to transfer the data from the collected medication charts 
into computerized databases. A data entry program was written allowing trained 
pharmaceutical and medical personnel to recognize brand names on the medication 
chart, assure correct data entry of brand, strength and pack size, posology and status of 
the medication (chronic use, acute use, use on an ”as needed” basis). Entry lines on the 
medication chart not referring to officially registered medication were entered in free 
text (including prescriptions for magistral preparations by pharmacists). Posologies of 
anticoagulantia, insulin therapy and topical treatment were not recorded in detail. Data 
entry for registered medication was based on recognition of the unique medicinal 
product package (defined uniquely by the active substance, strength, pack size, 
pharmaceutical form and marketing authorization holder). Identification of the medicinal 
product package was facilitated by a quick search entry facility where each additional 
letter limited the choice possibilities down to a small list of possibilities from which the 
right package could be easily picked. Positive identification was then confirmed, initiating 
a procedure to get from a supporting database the unique identification code of the 
medicinal product package, the number of the international classification for medicines, 
namely the Anatomical Therapeutic and Chemical Classification (ATC). In addition, the 
                                                     
kk WIGW/VIPO pay lower co-payments.  
ll Anatomical Therapeutic and Chemical Classification/ Defined Daily Dose 
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appropriate reference measure for volume, the Defined Daily Dose (DDD) was added, 
as well as the prescription status, the ex-pharmacy retail price (including VAT), and the 
co-payment price in case of reimbursed medication.  
Data from the provinces of Antwerpen and Gent were entered by a team of highly 
specialized data encoders from a billing service of the association of community 
pharmacists. Data from the province of Hainaut were entered by the master students 
who were also responsible for data collection. The students received a formal training 
with exercise before entering the data. The information on posology (number and 
strength of dose units per day or per week) was combined with the standard price for 
daily consumption to calculate the expenditures per month for chronic medication. For 
anticoagulantia and insulin therapy (for which no individual posology was recorded) a 
standard Defined Daily Dose of 1 was assumed. Expenditures per treatment course for 
acute medication were calculated assuming 7 days per treatment course, with more or 
less days for some predefined specific treatment courses (e.g. one day for one shot 
treatment of urinary or vaginal infection). No attempt was made to calculate 
expenditures for medication on an “as needed” basis.  
Once the data were entered, a thorough process of data cleaning commenced with 
identification of those magistral preparations which mimic existing, officially registered 
medications. 
The finalized medication database was then printed out again on preformatted double 
pages, mimicking a medication chart. This outprint was double checked against the 
original medication chart based on anonymized patient codes. A computer program 
generated preformulated questions added to the appropriate medicines, to ask more 
detailed information on indication (only when the medication had multiple common 
indications), to ask for missing information on posology or the status of the medicine 
(chronic, acute or “as needed”). This double-sided outprint was put in a sealed and 
coded envelope, together with a one page questionnaire. On this questionnaire, a 
number of common diagnoses and care problems were listed to be ticked when 
appropriate. The envelope was sent to the CRA of each participating nursing home, 
with the request to distribute the correct envelope to the treating physician of the 
resident. This triage was performed by the CRA based on a list of patient codes (with 
the coordination physician blinded to the identity of the patient and the content of the 
envelope) matching with the name and address of the treating physician.  
The responsible GP was asked to control the prescribed medication, to confirm the 
chronic, acute of ‘’as needed’’ nature of the medication, to specify the indication for 
medication with multiple possible indications, and to provide clinical characteristics by 
ticking a checklist of common pathologies and care problems, and to specify whether 
the patient was or was not in palliative or terminal care. 
Completed forms were sent back in a prepaid envelope directly to the researchers with 
no identification but the patient code. The CRAs assured the necessary reminders by 
mail, telephone, and e-mail, if necessary.  
On the basis of the returned medication outprints, the existing medication database was 
amended and augmented, when necessary, and the clinical data were added to the 
resident database.  
3.3.5 Construction of databases 
3.3.5.1 Level of the medication chart 
The first database was constructed at the level of separate entry lines on the medication 
chart and contained name, dose and frequency, type of medication and ATC/DDD 
code, as well as the code of the resident to whom this medication was prescribed. For 
chronic medication, full expenditures at ex-pharmacy retail prices and out-of-pocket 
expenditures per month per resident were calculated. For acute medication, cost was 
expressed as the expenditures for one complete treatment for the main indication.  
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3.3.5.2 Residents’ level 
At the level of residents, the database consisted of administrative data and clinical 
characteristics of all sampled residents, as recorded from the questionnaires to the 
direction and the treating family physicians.   
A number of data from secondary analyses were added: 
x the scores of each resident on the separate prescribing quality 
indicators (and several sum-scores for each set of prescribing quality 
indicators and overall sum-score); 
x the aggregated medication data from the medication chart database; 
x the main characteristics of the nursing home in which the resident 
resided. 
3.3.5.3 Institution level 
This database contained the results of the institution questionnaire and the calculated 
institutional quality scores of medication care. The institution database was completed 
with  
x descriptive institutional characteristics derived from external 
administrative databases of RIZIV/INAMI (size, case mix, personnel); 
x aggregated data from the residents’ database describing clinical 
characteristics, medication use and prescribing quality of included 
residents. 
3.3.5.4 Ward level  
This database contained  
x the results of the ward questionnaire; 
x the results of the institution questionnaire; 
x the calculated institutional quality scores of the medication 
management systems;   
x aggregated data from the residents’ database describing clinical 
characteristics, medication use and prescribing quality of included 
residents.  
3.3.6 Construction of quality scores 
3.3.6.1 Quality of medication management systems 
In order to link the quality of the medication management system with the quality of 
prescribing, the organizational characteristics of the medication process were translated 
into a score. The practical organization of the medication process in each nursing home 
was assessed via a semi-structured interview with both the nursing home director (or 
another member of the nursing home management) and the senior nurses of the 
selected wards. The topics investigated in this interview were categorized in different 
domains: medication management, formulary and pharmacy for the nursing home 
management; work procedures, communication, medication chart, medication storage, 
residents’ medication autonomy, preparation of medication, administration of 
medication and information about medication for the divisional head (see table 3.1 for a 
more detailed description of the domains). Per investigated topic, a score was attributed 
to the different answering possibilities by a panel consisting of field experts: 1 nursing 
home director, 1 medical coordinator, 3 head nurses, 1 nursing director, 3 pharmacists, 
1 epidemiologist and 1 social worker.  To each answering possibility a score ranging 
from – 3 to + 3 was attributed by the panel. The 0 was chosen whenever the answer 
reflected a legal obligation or a situation without impact on the quality of care. The 
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gradations 1, 2 and 3 (positive or negative) respectively reflected a small, moderate or 
serious impact on the quality of provided care. The individual domain scores were 
summed to a total score for both the wards and the nursing home management. The 
total score, which is a sum-score of all the different domain scores, reflects the quality 
of the medication process in the nursing home. 
Table 3.1: Domains of medication management systems 
Institution  Level    
 Pharmacy Aspects of delivery of medications from the pharmacy to 
the nursing home  
 Formulary  Availability of the formulary in the institution  
 Medication Management The procedures pertaining to quality management and 
evaluation 
Ward Level    
 Information  The extent to which medication related information is 
given or easily available for residents and nursing staff 
 Administration  The extent to which the administration of medicines to 
residents by nurses is organized and controlled 
 Preparation  The extent to which the preparation of the 
administration of medicines (reading from the 
medication chart and fetching from the drug stock) is 
organized and controlled 
 Resident Autonomy  The extent to which the resident is allowed autonomy in 
the management of his/her medication  
 Storage The precautions taken for keeping medicines 
 Medication Records The amount of and the maintenance of information on 
medicines in the nursing record. 
 Communication The extent to which communication about medicines 
and residents’ health is going on between nurses and 
physicians.  
 Formulary  The extent to which a drug formulary is available and 
promoted 
 Work Procedures  The extent to which the process of the medication 
distribution is explicitly described in written procedures 
 
One week before the consensus meeting, all experts received an electronic copy of the 
PowerPoint presentation supporting the discussion as well as the questionnaire used 
during the interviews. In preparation of the meeting, a preliminary score was attributed 
by 2 members of the PHEBE team (2 pharmacists who had also assisted with the 
literature search, the elaboration of the questionnaire and with the interviews in the 
nursing homes). Their reasoning behind this score was also provided to the panel in the 
presentation. This method was used in order to initiate and facilitate possible 
discussions. On each topic, the panel discussed the given scores and reasoned until a 
consensus was reached. The whole scoring procedure took about 3 hours. The details 
are shown in Appendix 9. 
3.3.6.2  Prescribing quality scores 
The procedure described above provided information on the medications used by each 
individual resident and his or her relevant clinical diagnoses and care problems. With 
this limited amount of information it is possible to assess to a certain extent the quality 
of the process of prescribing medicines, focusing on the drug choice process of the 
physicians. 
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We used three existing sets of prescribing quality indicators, specially adapted to the 
setting of the elderly in general and the residents of nursing homes in particular:  
x The BEERS criteria of potentially inappropriate prescribing in the 
elderly 
x The ACOVE Criteria of underprescribing in the elderly 
x The BEDNURS (Bergen District Nursing Home Study)  
In addition, we added 2 other approaches to quality of prescribing: 
x Chronic use of benzodiazepines 
x Belgian medication with low benefit/risk ratio 
We will describe in more detail the three international sets of prescribing quality 
indicators and how these were adapted for this project in Belgium, as well as the two 
other approaches.  
The BEERS Criteria  
Beers and colleagues developed in 1997 explicit criteria for potentially inappropriate 
drug prescribing in ambulatory older adults aged 65 and over. These criteria were 
widely used to estimate the prevalence of inappropriate drugs. At first, the Beers list of 
inappropriate medicines was a list of medicines which use should be avoided in elderly, 
whatever their indication. The Beers List was updated in 2002. Some medicines were 
deleted and other added to this list in the 2002 update with 48 individual medications or 
classes of medication that should generally be avoided in persons 65 years or older 
because they are either ineffective or they pose unnecessarily high risk for older 
persons and a safer alternative is available. In addition, for some medicines dose and co-
morbidity were considered. For 8 medicines the inappropriateness of the medicine was 
conditioned by exceeding a maximal appropriate dose. The most important change was 
the production of a list of 20 medical conditions with a formal list of drugs that should 
not be used in patients having these conditions.  
We experience a number of problems when adopting this list to the Belgian situation. 
First, 10 of the 48 potentially inappropriate medications were not registered on the 
Belgian market, and another 25 have a very limited consumption. Second, programming 
the list of contra-indicated medicines for some medical conditions proved to be 
cumbersome as some very broad or ill-defined classes of drugs were used. Examples of 
broad classes are “drugs with high salt content” or anticholinergic drugs. This is difficult 
to program for identification based on individual medicinal product packages. Examples 
of ill-defined classes are “anticholinergic antidepressants”. Some of the medical 
conditions in the updated list were not on our questionnaire of clinical data (e.g. atrial 
arrhythmia, bladder obstruction).  Third, some of inappropriate medications registered 
in Belgium, are not registered in the US, and hence, not considered in the BEERS list 
(e.g. a number of long acting benzodiazepines, such as flunitrazepam).  
Hence, we limited the use of the BEERS criteria to the potentially inappropriate 
medication with a substantial usage in Belgium. This approach makes our data on 
prescribing quality not suitable for international comparisons.  However, the items we 
retained provide a partial but valid contribution to our attempt to quantify prescribing 
quality problems. 
The ACOVE criteria of underprescribing   
We wanted to include in our analysis of prescribing quality the dimension of 
underprescribing. For this purpose, we turned to the Assessing Care of Vulnerable 
Elders (ACOVE) project. This is a set of 203 quality indicators for care of 22 conditions 
(including geriatric syndromes and 11 associated diseases) and 6 domains of care 
(screening, prevention, diagnosis, treatment, follow-up, and continuity).  Fourteen types 
of medical intervention were considered, one of which was medication (with 68 
indicators pertaining to pharmaceutical intervention). Nine of these indicators were 
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related to underprescribing of medicines. All these indicators have the form of 
IF/THEN/UNLESS. IF specifies the clinical condition to which the quality indicator 
pertains. THEN specifies the medical act that should be performed. UNLESS lists the 
exceptions to the rule. An example of an underprescribing quality indicator is: if the 
patient has diabetes, then low dose aspirin should be prescribed, unless there is a 
contra-indication for aspirin. These criteria were designed to be assessed by 
pharmacists, performing a clinical review of the residents and their medication, with full 
access to the medical record of the patients. 
We were able to program seven of the nine ACOVE underprescribing quality 
indicators. Two criteria could not be assessed because they pertained to patients with 
atrial fibrillation, a condition which was not on our checklist in the clinical questionnaire. 
The remaining 7 quality criteria were programmed for the IF/THEN conditions. The 
UNLESS statements (with the list of exceptions) were too complex to program and 
could not be assessed in a valid way, given the limited nature of the data we collected. 
Again, this limits the validity of our data for international comparison.  
The criteria from the BEDNURS study 
In this approach, the occurrence of potential medical problems is investigated using an 
extensive physician/pharmacist medication review. The study focused on cardiovascular 
and central nervous problems. It addresses indication, dosage and duration of 
treatment, as well as safety, drug-drug and drug-disease interactions, duplication and 
underprescribing.  
We were able to program most (31) of the potential medication problems of the 
BEDNURSE approach into criteria, which could be generated by a computer analysis 
(see full list in results section). Dropped items were:  Vitamin C for cystitis prophylaxis, 
nutritional supplements for iron deficiency anaemia. Some items were slightly simplified: 
use of antipsychotics in non-psychotic patients was simplified to use of antipsychotics, 
because we did not know whether our patients were psychotic or not. Concomitant 
use of central nervous system drugs was simplified to concomitant use of ATC class 
N05 (psycholeptics) and N06 (psychoanaleptics) in three different combinations. 
Chronic use of benzodiazepines 
All patients with chronic use of benzodiazepines (and related substances), whether used 
as sedative or hypnotic, were recorded.  We decided to include a flag for usage of any 
benzodiazepine or derivative, as studies have shown increased risk for falls and/or hip 
fracture for benzodiazepines with very short, short half-lives as well as long-acting 
benzodiazepines, regardless whether these products were used as hypnotics or 
sedatives. 
Belgian medications with low benefit/risk ratio 
A list of medication with low benefit/risk ratio of the Belgian Drug Information Center 
was used. These are officially registered medicines in Belgium with poor evidence of 
efficacy, or with too many active substances combined. These medications can be 
recognized on the web site of the centre (www.bcfi.be), because no recommendations 
for posology are made for these medicines.  
3.3.7 Statistical analysis 
Data analysis was performed with the statistical package SPSS version 12.0.  A p-value of 
p<.05 was used as the significance level.  The conceptual framework of the analyses 
performed is shown in table 3.3. 
3.3.7.1  Descriptive analysis 
First, a general exploration of the databases was performed using descriptive statistical 
techniques. At the level of residents, inclusion for description of administrative 
characteristics and medication usage was limited to residents with administrative data 
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and a medication chart available. For description of quality prescribing parameters, only 
residents with clinical parameters available (i.e. medication form returned by responsible 
GP) and not in need for palliative care were included.  
Before using analytic statistical methods, parameters of prescribing quality were 
carefully tested, investigating their internal relationship, their predictive value and their 
coverage of different aspects of quality (see table 3.2).   
Table 3.2 : Operationalization of quality of prescribing in this research 
VOLUME Number of medications on the medication chart 
  Number of systemic chronic medications  
EXPENDITURES Public expenditures for reimbursed chronic medication (RIZIV/INAMI) 
 Co-payment for reimbursed chronic medication  
  Payments for non-reimbursed medication (at ex-pharmacy retail price, VAT 
6% incl.) 
APPROPRIATENESS  SUMSCORE of Potential Prescribing Quality Problems 
3.3.7.2  Univariate analysis 
Univariate analysis was performed at the level of residents exploring the relationship 
between patient and institution characteristics and the quality of prescribing. Univariate 
analyses were also performed at the level of the institution and the level of the ward to 
investigate the internal dependency between patient and institution characteristics and 
their relationship with the parameters of prescribing quality. Also the relationship 
between characteristics of medication management and quality of prescribing was first 
explored using univariate statistical techniques (bivariate regression analysis, one-way 
ANOVA). We preferred to use the non-parametric Spearman Rank Correlation Test 
(indicated by rs) because of the semi-quantitative nature of the data (quality scores) or 
the skewness of their distribution (expenditures). 
To answer the specific research question on the relationship between institutional 
medication management and the quality of prescribing, multivariate analysis at the 
institution level was performed using multiple regressions.  In table 3.3 an overview is 
given of the regression analyses performed at the different levels of analysis in univariate 
and in multivariate approach.  
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Table 3.3 : Conceptual framework of the analysis 
 
3.3.7.3 Multivariate analysis 
Since differences in individual consumption and prescribing quality could be explained 
both by resident and/or nursing home characteristics, it is important to include both 
individual as well as organizational characteristics simultaneously in the analyses in order 
to disentangle both sets of variables on prescribing quality. 
Multivariate data analysis techniques such as regression analysis allow to separate these 
effects and to identify their distinct impact on drug consumption.  A number of 
RESIDENT 
LEVEL         
(N=2510 OR 
N=1730)
WARD LEVEL  
(N=112)
UNIVARIATE UNIVARIATE UNIVARIATE MULTIVARIATE
Size in Beds
Size in Wards
Type
Stratum
Province
Price Competition 
Delivering Pharmacists
Price Competition 
Monopoloy in delivery
percent RVT beds
Percent billing private exp.
Percent OCMW-patients
CRA-activity
Number of GPs visiting
Residents per nursing staff
Residents per A1+A2
Percent A1
Manag
Form 
Pharm
Procedures
Pharmacist
Communication
Medical record
Storage
Self Medication
Preparation medication
Administration
Information
SUMSCORE MMS
Age
Sex
Dependency score (Katz)
Dementia
Number of diagnoses
Number of care problems
Impact on 
prescribing 
quality 
Impact on 
prescribing quality 
Impact on 
prescribing quality 
Impact on 
prescribing quality 
INSTITUTION LEVEL          
(N=76, 74 OR 72)
Impact on 
prescribing 
quality and 
medication 
management 
systems
Impact on 
prescribing 
quality 
Impact on 
prescribing quality 
Staffing characteristics 
Medication management systems at 
the institution level 
Medication management systemts at 
the ward level 
Residents characteristics 
(Demographics and case mix)
General Institutional Characteristics 
Impact on 
prescribing 
quality and 
medication 
management 
Impact on 
prescribing quality 
Impact on 
prescribing 
quality 
Impact on 
prescribing quality 
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dimensions of prescribing quality (averages at nursing home level) will be used as 
endogenous variable in the regressions. The aim is to identity the impact of resident and 
nursing home characteristics on three dimensions of prescribing quality: volume of 
usage (average number of medications per resident, average number of chronic systemic 
drugs per resident); expenditures (average ex-pharmacy expenditures of reimbursed 
chronic drugs per month per resident, average co-payment for chronic reimbursed 
drugs per month per resident, average out-of-pocket payment of non-reimbursed drugs 
per month per resident, percentage of cheap drugs), and appropriateness of prescribing 
(average sum-score of prescribing quality problems).  
Descriptive statistics of these endogenous (or dependent) variables (including Box plots 
and histograms and Box plots) and descriptives per stratum and province of these 
variables are reported in Appendices 11 and 12.   
These variables are the result of an aggregation process of resident variables (expressing 
quality of prescribing) to the level of the institution. Per institution the mean of all 
residents per institution is given. Consequently these data cannot be considered as ratio 
variables (or integer or count variables). Hence, we opted for regression techniques 
based on Ordinary Least Square methods, and not on binomial or Poisson approaches. 
We refrained from performing multivariate, multilevel regression techniques at the level 
of the residents, because most data on medication management systems were recorded 
at ward level and not at institutional level. Ward data could not be reliably attributed to 
the resident level, as there was no certainty that the resident belonged to either one of 
the surveyed wards.  
In the following sections, the 7 outcome variables presented on the previous pages will 
be used as endogenous variables in regressions.   Possible explanatory variables are 
listed in table 3.4.  All regression models start with a full model in which all variables 
listed in the table are used as exogenous variables. 
Table 3.4 Variables included in the full model 
GENERAL INSTITUTIONAL CHARACTERISTICS  
 LOCATION  Province 
 TYPE Public / Private not-for-profit / private for profit 
 SIZE Number of beds, number of wards 
 MEDICAL STAFF Number of residents per visiting general practitioner, Percentage 
of residents treated by the coordination physician  
 DELIVERING PHARMACIST Type of pharmacy,  Single or multiple delivering pharmacies 
 NURSING STAFF Number of residents per nursing staff, per nurse, per nurse 
bachelor level 
  BILLING TO RESIDENTS Percentage of residents with separate bill for private expenditures  
MEDICATION MANAGEMENT SYSTEMS 
  At management level (3 items), At ward level (8 items) 
CASE-MIX   
 Age  
 Percentage of female residents 
 Percentage of  beds certified as highly dependent (RVT) 
 Percentage of residents with dependency score C  
 Percentage of residents with dementia 
 Number of clinical problems, number of care problems 
  Percentage of residents living on local social welfare 
 
The following procedure was used for all 7 outcome variables. First, a “Full model” was 
estimated (using Ordinary Least Squares (OLS)) in which all exogenous variables from 
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table 3.4 were included. Residuals were examined to detect possible bias due to 
misspecification of the model. 
Examining individual significance of the variables included in these full model regressions 
revealed that a number of them were not estimated significantly different from zero and 
did therefore not contribute to explaining differences in the endogenous variable.   
These variables were iteratively omitted from the regression, starting with the least 
significant one (i.e. the variable with the smallest partial correlation with the dependent 
variable). After the removal of the least significant variable, the equation was re-
estimated and the variable with the smallest partial correlation was considered next. 
The procedure stopped when there were no variables in the equation that satisfied the 
removal criterion (t-statistic smaller than 0.75 (in absolute value)). Thus the remaining 
variables in the equation all have t-statistics larger than 0.75 (in absolute values). 
3.3.8 Ethical considerations 
Before the start of the study, the project proposal was presented at the Regional 
Organizations of Nursing Homes and the provincial CRAs. The protocol of this study 
was submitted to and approved by the ethical commission of the scientific organization 
of general practitioners of Flanders (WVVH). Informed consent was asked to the 
directors of selected nursing homes and of treating physicians. All data were collected 
anonymously. It was the exclusive task of the CRA of the participating nursing homes to 
anonymize the data for the researchers and to unlock the identity of the GPs to send 
them the print out of the medication charts.   
3.4 RESULTS 
This study was performed in 76 randomly selected nursing homes located in the 
provinces of Antwerpen, Oost-Vlaanderen and Hainaut, including 2,510 residents with 
administrative data and a medication chart available.   
3.4.1 Representativity of the sample 
In Belgium, 1,722 nursing homes with 126,346 beds were registered in 2004. Among 
them 970 were nursing homes with at least 30 beds and with a mixed character having 
available both ROB beds (beds for healthy elderly) as well as RVT beds (beds for elderly 
in need for nursing care). Out of the latter group, institutions were randomly selected 
in 3 provinces using a stratification system based on size (less or more than 90 beds) 
and type (OCMW/CPAS or private).  
In table 3.5, basic characteristics of the eligible Belgian institutions and the PHEBE 
participating institutions are compared, showing an acceptable fit between both.    
Table 3.5: Comparison of basic characteristics of the sampled nursing homes 
with the population of Belgian nursing homes 
 
Approximately 8% of the Belgian population over 65 is living in a nursing home. In 2004, 
institutionalized elderly had a mean age of 84.9 and 76.9% of them were female. 
Included residents in our sample had a mean age of 84.8 and 77.4% were female. 
Hence, we concluded that our sample of residents was representative for the 
population of residents in Belgian nursing homes. The size of our sampled institutions 
was slightly larger, private institutions were somewhat underrepresented in the 
province of Antwerpen and somewhat overrepresented in the province of Hainaut.  
Province Total In study Total In study Total In study Total % private In study % private
Antw 159 27 (17%) 104 108 49 48 65 52
OostVl 152 25 (16%) 100 105 45 46 57 56
Heneg 115 24 (21%) 102 115 50 51 61 70
Belgium 987 76 (8%) 97 108 48 48 61 58
*including only mixed ROB/RVT nursing homes with at least 30 beds
Number Mean size (in beds) % RVT beds Type (OCMW-privé)
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3.4.2 Description of participating nursing homes 
The selected nursing homes had a mean capacity of 106 beds (range: 35 - 306) and a 
mean number of wards of 2.6 (range: 1 - 7). The distribution of the type of wards is 
shown in figure 3.1. The wards were mainly (68.0%) ‘open mixed’, meaning that they are 
open for all kinds of residents, even those with beginning dementia. The rest of the 
wards were ‘closed’ (=closed ward only for demented residents; 17.2%), ‘closed-mixed’ 
(=closed ward for demented as well as non-demented residents; 9.9%) or ‘open’ (=open 
ward only for non-demented elderly; 4.9%).  
Figure 3.1: Distribution of type of wards in included nursing homes in 
Belgium (N=112) 
Included nursing homes had 20 to 153 RVT beds (mean percentage of RVT beds 48%). 
Mean age of their residents was 85 (range 79-89) with 77% of females (range 59-86%). 
Case-mix according to the Katz score revealed that 20% of their residents had Katz 0, 
15% Katz A, 20% Katz B and 45% Katz C.   
Participating nursing homes had between 35 and 249 staff members including 
approximately 65% of nursing staff. Resident/nursing staff ratio ranged from 2.0 to 6.2 
(mean 3.2 residents per nursing staff member). Only 37% of nursing staff was qualified as 
a nurse (13% bachelors and 24% qualified nurses). Distribution of nursing personnel 
according to qualification is shown in figure 3.2. Per nursing home, a mean of 
31.8 visiting GPs was identified (range: 7 - 115). On average, the CRA was the treating 
doctor for 23.9% of the residents (range: 0 – 86.0%). 
0 10 20 30 40 50 60 70 80
open mixed
closed
closed mixed
open 
  
% of total number of wards
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Figure 3.2: Mean proportional distribution of bachelors, qualified nurses and 
nurse assistants in included nursing homes (n=76) 
 
3.4.3 Description of the medication management system at the level of the 
institution 
3.4.3.1 Medication management 
The vast majority of the nursing homes had a quality coordinator (88.2%) and a quality 
handbook (84.2%). A quality coordinator is responsible for good quality of services 
provided in the nursing home, by coordinating all quality related activities (care, 
medication, food and hotel services) and contributing to the development of a general 
quality handbook and work procedures. 81.6% (62/76) of the nursing home directors 
had made written agreements with their staff on the practical organization of the 
medication process. These agreements were written down (not necessarily signed) in 
the general quality handbook (64.5%) and/or in separate work procedures (53.2%). 
Table 3.6 gives an overview of the different aspects of the medication process whereof 
written agreements were made. The number of written agreements per nursing home 
was distributed as follows: 16.1% made 1 to 4 written agreements, 41.9% made 5 to 9 
and 41.9% made 10 or more. 
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Table 3.6: Written agreements regarding the medication process 
Topic % of nursing homes that 
made written agreements 
on this topic 
engagements with the delivering pharmacy 64.5% 
engagements with the GPs concerning the prescription of 
medication or the modification of therapy 
61.3% 
the drawing up of medication charts 74.2% 
the correct way to order medication 74.2% 
the management and storage of medication 66.1% 
the disposal of excess or expired medication 53.2% 
the management of narcotics 67.7% 
the dispensing of medication 80.6% 
the administration of medication 79.0% 
the administration of injections 54.8% 
the administration of over-the-counter medication 66.1% 
the administration of prescription medication in acute situations 
without consulting the GP 
67.7% 
To minimize the risk of medication related errors in nursing homes, a proactive 
evaluation of the medication process is advisable. However, only one in five (21.1%) of 
the investigated nursing homes evaluated the medication process on a regular basis (at 
least every 6 months). 39.5% of the nursing homes performed such evaluation annually, 
while 39.5% never (or less than once a year) evaluated the medication process. A self-
reporting medication error system, whereby the staff records all medication errors 
throughout the entire nursing home, can be very useful to identify errors and unsafe 
conditions. Such self-reporting medication error system had been set up in 69.7% 
(53/76) of the investigated nursing homes and in most of these nursing homes (48/53) 
this resulted in actions taken to prevent these errors in future. Also about half (13/23) 
of the nursing homes not having a self-reporting medication error system, proclaimed 
to make interventions to reduce medication errors. 
3.4.3.2 Formulary 
A drug formulary tailored to the special needs of elderly patients can be a very useful 
tool to improve the quality of prescribing in nursing homes. Almost all of the selected 
nursing homes (94.7%) had a drug formulary, whereby the national formulary for 
nursing homes (‘Nationaal RVT Formularium’) was the most frequently used (78.9%). 
Surprisingly, 5.3% (4/76) of the nursing home directors declared not to have a formulary 
in their institution despite the fact that this is legally obliged and that every nursing 
home in Belgium annually receives a free copy of the national formulary for nursing 
homes. 31.6% of the nursing homes (24/76) used an electronic prescribing system, for 
about half of them (11/24) the formulary was electronically available and for one third 
(8/24) the formulary drugs popped up as first choice during the electronic prescribing 
process.   
3.4.3.3  Pharmacy 
Nursing homes purchased their medication from a community pharmacy (82.9%), a 
hospital pharmacy (13.2%) or a wholesaler (3.9%). 63.4% of the nursing homes 
purchasing medication in a community pharmacy worked with only 1 community 
pharmacy, 28.6% with 2 or 3, and 7.9% with 3 or more community pharmacies (see 
figure 3.3). For nursing homes working with more than 1 pharmacy, medication was 
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delivered by turns (81.8%) or simultaneously (18.2%) by the different pharmacies. For 
the purchase of prescription drugs, 22.7% of the nursing homes had made a public 
tender and 33.3% made an informal agreement with the pharmacy. For over-the-
counter medication, these percentages were 22.7% and 34.8%, respectively. 
The pharmacist delivered the medication packaged per resident with the resident’s 
name on each box (which is the method described by law) (50%), in one bag for the 
ward with the resident’s name on each box (43.4%), per resident without name (3.9%) 
or in one bag for the ward without names (2.6%) (see figure 3.4). In addition to 
dispensing medication, the pharmacist also provided an overview of the delivered 
medication (94.7%), provided drug information (63.2%), consulted with the nursing 
home management about the medication process (42.1%), assisted with the evaluation 
of the medication process (26.3%), gave advice about the medication process (38.2%), 
controlled the expiration dates of the drugs (11.8%) or provided other services (27.6%) 
such as the management of an emergency kit. This is shown in figure 3.5.  
Figure 3.3: Type and number of delivering pharmacies 
Figure 3.4: How is the medication delivered? 
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Figure 3.5: Services provided by the pharmacy 
 
3.4.3.4 Autonomy of residents in medication management 
More than half of the nursing homes (57.9%) forbade the storage of prescription drugs 
in the resident’s room, with 74.9% of them never and 25.1% sometimes making 
exceptions on this prohibition. Regarding over-the-counter medication, only 30.3% of 
the nursing homes forbade storage in the resident’s room.   
3.4.4 Description of the medication management system at the level of the 
wards 
The medication process is the process starting from the moment of prescription, 
through the purchase, storage, preparation and administration of medication, until the 
follow-up of pharmacotherapy. Figure 3.6 schematically describes the organization of 
the medication process in a nursing home. In order to provide a clear overview of all 
medication-related activities in the investigated nursing homes, the results of this survey 
are described per step in the medication process. 
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Figure 3.6: Schematic overview of the medication process in nursing 
homes 
 
3.4.4.1 Drug formulary 
In order to ensure rational prescribing in nursing homes, the use of a drug formulary 
(for elderly) is advisable. According to the senior nurses, a drug formulary was present in 
91.1% (102/112) of the wards, but was only used in 63.7% (65/102) of them. This 
formulary was visibly present at the place where the prescription was made in 66.6% 
(68/102) of the wards. Surprisingly, one of the interviewed divisional heads declared to 
use the formulary while no formulary was present on the ward.  
Senior nurses sporadically (19.6%) or systematically (41.1%) encouraged new GPs to use 
the formulary. Such stimulation of formulary use seems advisable since nursing homes 
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are visited by numerous GPs, each having their own prescription pattern. In the 
majority of the wards (91.1%), the drug formulary was not binding, meaning that GPs 
can prescribe non-formulary drugs without having to motivate their choice. Nurses 
sporadically pointed the GP at prescription of non-formulary drugs in 26.8% of the 
wards. This happened systematically in 8% of the cases. At the moment of prescription, 
nurses actually presented the formulary to all GPs in 14.3% of the wards, while in 4.5% 
of the wards, nurses only presented it to GPs receptive to formulary use. The policy 
about drug formulary use is shown in figure 3.7.   
After the prescription was made, the GP always handed over the prescription form to a 
nurse, who made sure that it was forwarded to the pharmacy. In about two thirds of 
the wards (69.6%), nurses did not wait for a prescription before ordering chronic 
medication implying that the doctor had to prescribe the medication afterwards. This 
can have severe consequences such as the continuation of not further indicated 
medication.  
Figure 3.7: Policy about drug formulary use 
 
3.4.4.2 Medication record 
At admission of a new resident, an anamnesis of the used medication needs to be 
performed. This was the task of the head nurse (60.7%), the general practitioner 
(43.8%), the nurse responsible for the resident (43.8%), or another person (9.8%, mainly 
the nurse present at the admission time or the social services). This anamnesis was used 
to draw up a medication chart, which was done for every single resident in the nursing 
home on a standard form (the medication form was standardized in 98.7% of the 
nursing homes). This medication chart was still handwritten in 21.4% of the wards. The 
majority (88.6%) of the wards disposed of an electronic medication chart, which was a 
self developed model (e.g. Excel file) in one third of the cases or developed by a 
software company in two thirds. In 55% of the wards, the entire patient nursing record 
(including a copy of the medication chart and the nursing file, the care plan, a diary ...) 
was computerized.  
Medication charts can contain up to 13 items: brand name, generic name, dose, galenic 
form, administration route, administration frequency (times per day), administration 
time, administration moment (before or after a meal), a blank for specific instructions, 
start date, stop date, the difference between chronic and acute medication, and PRN 
(pro re nata, “as needed”) medication. 9 of these 13 items are legally mandatory, 4 
(generic name, administration moment, the difference between chronic and acute 
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medication and the blank for specific instructions) are optional. In 30.4% of the wards, 
the chart contained less than the 9 mandatory items. The other 69.6% had even more 
items than the 9 mandatory ones on the medication charts. The most frequently 
omitted items were the generic name (absent in 71.4%) and the difference between 
chronic and acute medication (absent in 68.8%). Next to the daily oral medication, 
medication charts could also list medication that needs to be taken once a week (100%), 
ear or eye drops (92.9%), injections (99.1%), dermatologic preparations (67.9%) and 
rectal medication (93.8%). In 57.1% of the wards, medication charts were controlled on 
completeness and correctness by a third person.  
At every new prescription, the GP filled in the prescribed medication in the medical file 
of the resident (in 93.8% of the cases) while the nurse did the same in the nursing file 
(95.5%). The medication chart was also adjusted at every new prescription. A new 
handwritten medication chart was filled in: at each change in the therapy (12%), weekly 
(12%), twice a month (8%), monthly (52%) or less than once a month (16%). A new 
electronic medication chart was filled in and printed out: at each change in the therapy 
(3.4%), weekly (17%), twice a month (33%), monthly (45.5%) or less than once in a 
month (1.1%).  
3.4.4.3 Medication delivery 
For more details on the dispensing pharmacy and on how the medication was delivered 
to the nursing home, we refer to subheading 3.4.3.3. The delivered medication was 
checked on correctness in 88.4% of the nursing homes. This happened mainly at the 
moment of delivery (79.5%), using either the order form (59.8%) or the prescription 
form (16.1%). 
3.4.4.4 Medication storage 
In 35.5% of the nursing homes, medication was stocked in one central location in the 
nursing home. By coincidence, this central location could happen to be on the 
interviewed ward, which resulted in 98.2% of the wards stating to have a storage place 
for the medication of the residents. In 32.7% of the cases, this was in a separate room 
only for the purpose of storing drugs. To prevent misuse, the medication should not be 
accessible for residents. In spite of this common sense, the medication room was never 
locked in 25.9% of the cases and in 30.4% the cupboard where the drugs were stored 
was never locked. In 6.3% of the wards, neither the storage room nor the cupboard 
was locked. Most of the wards had a separate storage place for narcotics at their 
disposal (88.4%) as well as a fridge used for drugs requiring cool storage (81.3%). The 
amount of available stock (81.3%) and the expiration dates of the drugs (88.4%) were 
controlled on a regular basis by nurses.  
In 46.4% of the wards, there was a back-up stock of medication while 30.4% of the 
wards could use a back-up stock available for the entire nursing home. When such 
stock existed, there was a responsible in 79.1% of the cases. These stocks were 
originated from orders to the pharmacy (16.3%), excess medication (93%), free samples 
(3.5%) or from deceased residents (22.3%).  In 24.4%, there was a logbook in order to 
register incoming and outgoing medication from this back-up stock. The amount of 
available stock and the expiration dates of the drugs were checked just as for the 
regular medication, in 59.3% and 94.2% of the wards respectively.  
85.7% of the wards had an emergency kit containing life saving medication. In 93.8% of 
the cases, a responsible for this emergency reserve had been assigned. Emergency kits 
were composed by the medical coordinator (“CRA”) (75.9%), the GPs (6.3%), the 
pharmacist(s) (20.5%) and the senior nurses (35.7%).  The results of the topic of 
medication storage are shown in figure 3.8.  
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Figure 3.8: Medication storage 
 
3.4.4.5 Preparation of the medication     
Before dispensing to the residents, the medication was prepared (meaning that tablets 
were taken out of their packages and were put on a tray per resident in order to 
facilitate the administration) using the medication chart (94.6%) or a list copied from the 
medication chart (5.4%). The medication was prepared for 1 day (71.4%), half a week 
(12.5%) or 1 week (16.1%) by nurses (99.1%) and / or care aids (11.6%). Belgian law 
states that medication should be prepared maximum 24 hours before administration 
and that this preparation should always be performed or supervised by nurses. 
Preparation could happen at night (41.1%), during the day (46.4%) or both (12.5%). In 
92.9% of the cases, the person who prepared the medications was recorded. In 13.4%, 
the person preparing medication also checked if the drugs were prepared correctly and 
in 48.2%, this control was performed by a colleague (see figure 3.9).  
At the moment of preparation, tablets and capsules were already removed from their 
blister in 77.7% of the wards. However, some other galenic forms were prepared 
immediately before administration. This was the fact for solutions (84.8%), effervescent 
tablets (78.6%), powder bags (95.5%), and medication that requires cool storage 
(93.8%). This medication was checked on correctness by the same person (36.9%) or by 
a colleague (22.5%).  
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Figure 3.9: Medication preparation 
 
3.4.4.6 Information about medication 
To ensure correct medication use, nurses need to search information about a specific 
drug (administration route, crushability, …). As drug information sources, 5.4% had the 
“gecommentarieerd geneesmiddelenrepertorium” (commented medication repertory) 
at their disposal, 20.5% had the “compendium of the pharmaceutical industry” (which is 
a compilation of scientific medicines packages inserts) and 71.4% had both. Internet was 
available in only 17% of the wards. 
Other important sources of professional information were the caregivers regularly 
involved with the nursing home. Information could be asked at the pharmacist (85.7%) 
or at the GP or medical coordinator (“CRA”) (96.4%). 18.8% of the nurses kept the 
patient package inserts of medicines but did rarely use them. 8% kept the patient 
package inserts and used them on a regular basis.  
Nurses did sometimes give information to mentally intact residents about their 
medication. On 48.5% of the wards, information about the indication and the intake was 
provided systematically to the residents. But the information about side effects was 
restricted to certain drugs (48.5%).  
On almost every ward (99.1%), medication was crushed (mainly to facilitate the 
swallowing). Crushing of dosage forms can seriously alter the release pattern of the 
drug. For example, crushed enteric coated formulations release their drug in the 
stomach, while crushed sustained release formulations release all their drug at once 
(‘dose dumping’). However, nurses consulted information before crushing in only 21.4% 
of the cases. When the nurses did consult some information source, they consulted the 
medical coordinator (‘CRA’) (64.3%), the pharmacist (33%) or the package inserts of 
medicines (29.5%).  
3.4.4.7 Administration of medication  
Only nurses are legally allowed to administer drugs to the nursing home residents. On 
all of the wards, nurses were indeed involved with the administration of medications. 
However, the interviewed head nurses proclaimed that the medications were also 
administered to the residents by care aids (67%) or nursing students (12.5%). This 
administration was recorded in 80.2% of the wards.  
KCE reports 47 Medication use in Nursing Homes 67 
For mentally intact elderly, the intake was visually controlled afterwards (i.e. control if 
the drugs had “disappeared”) for 74.7% and by swallowing (the nurse waited at the 
bedside of the resident until the medication had been swallowed) in 19.2%. For mentally 
impaired residents, these percentages were 0.9% and 99.1% respectively (see 
figure 3.10). The medication intake was most frequently recorded only in the case when 
the resident did not take the medications (83.9% for mentally intact and 82.1% for 
mentally impaired residents).  
Figure 3.10: Medication administration 
 
3.4.4.8 Evaluation of Pharmacotherapy 
From time to time, nurses evaluated the medication chart in consultation with the GP. 
They assessed together if the medication was still indicated and appropriate, if the dose 
or galenic form needed to be adapted and if other drugs needed to be added. This 
happened sporadically (whenever therapy problems occurred) in 33.9% and systematically 
in 66.1% of the wards.  
3.4.4.9 Resident autonomy in medication management 
On average, 2.6% of the patients on the investigated wards (range: 0 to 17%) were 
completely autonomous regarding their medication: 14.6% of them (range: 0 to 98.5%) 
took their drugs without control on the intake and 83.2% (range: 0 to 100%) with control 
on the intake.  
When there were autonomous people on the ward, 80% of them got a medication 
chart like all the other residents. The nurses also controlled the amount of available 
stock in the room of autonomous residents in 22% of the wards and the expiration date 
of the drugs in 24%.  
3.4.4.10 Hospital 
When a resident needed to be admitted to the hospital, the nursing home always 
(100%) provided an overview of the currently taken medication of that resident.  
0 20 40 60 80 100 120
by care aids
by nursing students
record of administration
mentally intact residents:
 control on intake
mentally impaired residents: 
control on intake
% of wards
visually
swallowing
68  Medication use in Nursing Homes KCE reports 47 
 
Keypoints 
x A drug formulary was present in 91% of wards in the nursing homes but 
only 2 out of 3 wards were using the formulary effectively. 
x In 79% of the wards the medication chart was electronically produced. 
Chronic medication was often ordered without a prescription of the GP 
which makes critical appraisal of polypharmacy and alterations unlikely. In 
2/3 of wards, the appropriateness of medication was systematically assessed 
from time to time by nurse and GP. 
x The correctness of medication delivery was checked in over 8/10 of nursing 
homes. 
x On several points in the preparation and administration of medication, legal 
standards were not always followed. In the majority of nursing homes 
medication was also administered by other personnel than qualified nurses. 
About two third of wards met the legal obligations for medication 
management.   
 
3.4.5 Assessment of the quality of the medication management system 
3.4.5.1 At the level of the institution 
The mean total score for the nursing home management was +0.05, with 39.5% of the 
nursing home management not meeting the legal obligations concerning the medication 
process, and half of them (51.3%) scoring positively. Best domain scores were obtained 
for the medication management (56.6% > 0), and worst scores for the pharmacy (36.8% 
< 0). The scores for the nursing home management ranged between -12 and +7. For 
further details, see table 3.7 below. The scores are also displayed as box plot in 
figure 3.11.  Correlations between the different domains were also assessed.  
Table 3.7: Domain and total scores for the nursing home management  
 
Note: %<0 indicates the frequency of institutions with less than legally obliged activities; %>0 
indicates the frequency of institutions with more than legally obliged activities; all remaining 
institutions had a score of zero. 
domain mean % <0 % >0
min max
medication management 0,5921 -1.75 4 -8 6 32,9 56,6
formulary -0,3947 -3 0 -6 4 26,3 15,8
pharmacy -0,1447 -1 0.75 -3 2 36,8 25
TOTAL 0,0526 -3 4 -12 7 39,5 51,3
range25th 
percentile
75th 
percentile
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Figure 3.11: Box plots of the domain and total scores for the nursing home 
management 
3.4.5.2 At the level of the wards 
The mean total score for the wards was +2.81, with 32.1% not meeting the legal 
obligations. The most common shortages were situated at the domains “medication 
storage” and “medication preparation”, and “formulary”. 64.3% of the wards had a 
positive total score. The best scores were obtained in the domains of communication 
and information. The total scores ranged between -20 and +23. These results are 
detailed in table 3.8 and shown as box plot in figure 3.12 below.  
Statistically significant correlations were found between work procedures and formulary 
(p=0.000), preparation of medication and formulary (p=0.003) and administration of 
medication and information about medication (p=0.008). Unfortunately, these 
correlations have no logical or factor-related meaning.  
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Table 3.8: Domain and total scores for the wards 
Note: %<0 indicates the frequency of institutions with less than legally obliged activities; %>0 
indicates the frequency of institutions with more than legally obliged activities; all remaining 
institutions had a score of zero. 
Figure 3.12: Box plots of the domain and total scores for the wards 
3.4.6 Description of selected residents 
At residents’ level, 2,510 subjects with administrative data and a medication chart 
available were included for analysis. 
3.4.6.1 Age and gender  
Mean age of residents was 84.8 years (range 36-104) with 77.4% women. In figure 3.13 
we present a histogram of the age distribution of residents with a bimodal curve, 
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domain mean % <0 % >0
min max
Work procedures 0,0893 0 1 -1 1 24,1 33
formulary -1,375 -3 1 -7 6 59,8 29,5
communication 1,9821 0 3 0 3 / 66,1
medication  record 0,3125 -1 3 -8 6 36,6 44,6
storage -2,125 -4 0 -8 1 60,7 17
resident autonomy 0,5625 0 1 0 3 / 36,6
preparation -1,9107 -4 0 -9 4 66,1 23,3
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information 5,6339 5 7 -2 8 1,8 97,3
TOTAL 2,8125 2 9 -20 23 32,1 64,3
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presenting a dip in the distribution in the age group 90 to 93 years old, due to the dip in 
nativity during World War I. 
Figure 3.13:  Age distribution of included residents (N=2510) 
In figure 3.14 the increasing percentage of female residents with increasing age is 
presented. Among sexagenarians, 50% of the residents are female, while this percentage 
rises to 82% women in the residents of 90 to 99 years old. 
Figure 3.14:  Percentage of female residents according to age 
The median number of clinical problems was 2 in all age groups, with little difference 
between age groups in the distribution of the extent of pathology (see figure 3.15) 
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Figure 3.15: Number of clinical problems according to age 
By contrast, there was a net increase of the number of care problems with age, with the 
median number of care problems progressing from 2 to 4 (see figure 3.16) 
Figure 3.16: Care problems according to age 
3.4.6.2 Administrative characteristics 
Residents had a privileged reimbursement system for medication (WIGW/VIPO status 
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Welfare support (OCMW/CPAS) with out-of-pocket expenditures for medication paid 
by the local social security system.   
3.4.6.3  Case mix 
In Belgian nursing homes, a crude system for allocating case-mix categories to residents 
is used. This system is the basis for the determination of the per diem funding of nursing 
homes. It is based on a mixture of a four grade dependency scale and the presence or 
absence of dementia.  
In table 3.9 the distribution of residents over these case-mix categories and their 
description is given.  
Table 3.9: Distribution of residents over the Belgian dependency categories 
according to the Katz scale (N=2,520) 
 
Poly-pathology was observed in most residents with clinical problems diagnosed by the 
GP ranging from 0 (9%) to 12 with a mean of 2.6 problems. Cardio-vascular pathology 
was most frequently observed (see figure 3.17). Additionally, residents had between 0 
(11%) and 15 care problems with a mean of 2.7 care problems. The highest frequency 
was observed for fall risk, insomnia and constipation (see figure 3.18).  
Belgian Case-
Mix Class
Description Percentage of residents
Katz O Cognitive fit and physically independent 6.1%
Katz A Minor physical dependencya, not dement OR 
dement and physically independent
15.0%
Katz B Major physical dependencyb, not dement OR 
dement and minor physical dependency
18.5%
Katz C Full physical dependencyc, not dement 12.0%
Katz Cd Full dependency and dement 48.4%
Total 100.0%
aMinor physical dependency: dependent for washing and clothing
bMajor physical dependency: a + dependency for mobility and bathroom
cFull physical dependency: a + b + dependency for incontinence and/or feeding
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Figure 3.17: Frequency of pathological problems 
 
Figure 3.18: Frequency of care problems  
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The treating physician categorized 46% of the residents as demented, and 35% as 
depressed. The overlap between the two diseases is shown in figure 3.19. Only 35% of 
the residents were free of either dementia or depression, 16% suffered from both 
affections, 30% was demented without depression and 19% depressed without 
dementia.  
Figure 3.19:  Venn-diagram of dementia and depression as assessed by the 
treating physician (N=1730) 
14% had a fatal diagnosis with palliative care installed in 9% of residents, of which 3% 
were in terminal phase (see figure 3.20). 
 
Figure 3.20:  Distribution of palliative and terminal care patients (N=1730) 
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Keypoints 
x The majority of the residents were females (77.4%) and had a mean of 2.6 
clinical problems that was constant over all age categories.  In contrast, the 
number of care problems increased from 2 to 4 depending on age. 
x 6 out of 10 residents were eligible for lower co-payments (preferential 
treatment) and in 14% of residents out-of-pocket payments were dealt with 
by the OCMW/CPAS. 
x According to the treating physicians, nearly half of residents had dementia 
and over 1/3 was depressed. 1 out of 10 was receiving palliative care. 
3.4.7 Description of the medication used  
We collected the medication charts of 2,510 residents with an average of 8.1 entries 
per medication chart, resulting in a total of 20,275 recorded entry lines (no entrys lines 
for patients with no medication). 
3.4.7.1  Crude consumption 
Of the 20,275 entry lines on the medication charts, 88% were for chronic medication, 
3% for acute medication, and 9% on an ”as needed” basis. 94% of the entry lines were 
for officially registered medications. Of the 6% entry lines which were not officially 
registered medications, 3% were for magistral preparations, copying officially registered 
medications; 1.4% were for other magistral preparations; 1.4% for topical preparations 
not registered as medication; 0.1% for complementary medicines and 0.1% for 
parapharmacy. 
Entry lines for oral medication accounted for 88% of the entries, entry lines for other 
systemic medication for 7%, and entry lines for topical or instillation medication for 5%. 
A prescription from the physician was needed for 71% of the entry lines, and 57% of the 
entry lines were for reimbursable medication. Of these entry lines for reimbursed 
medication (N=11,546), 19% were for brand drugs without generic alternative, 53% 
were for brand drugs with a generic alternative available, but priced above the reference 
price, and 28% for generics or brands below the reference price. 
3.4.7.2  Medication usage per resident 
Volume 
Very few (0.9%) residents had no medication; 16.6% had 1 to 4 entry lines on the 
medication chart; 49.5% had 5 to 9 entry lines; 27.6% had 10 to 14 entry lines, and 5,5% 
had more than 14 entry lines  (up to a maximum of 22).  
When the analysis was limited to chronic medication, these frequencies slightly changed: 
1.1% residents had no medication; 22.7% had 1 to 4 chronic medications; 53.1% had 
5 to 9 chronic medications; 20.8% had 10 to 14 chronic medications, and 2.1% had 
more than 14 chronic medications (up to a maximum of 22). 
Only 15.1% of the residents were on a course of acute treatment at the moment of 
observation (10.2% on one acute medication, 4.8% on more than one acute medication, 
with a maximum of 6). 
With regard to medication on an “as needed” basis, 44.7% of the residents had at least 
one such entry line on the medication chart (25.9% one medication, 19.9% on more 
then one acute medication, with a maximum of 7). 
In figure 3.21, an overview in boxplots is given of these data on chronic, acute and “as 
needed” medication.    
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Figure 3.21:  Number of medications per patient for chronic, acute, and “as 
needed” medication (N=2510) 
 
The median (P25-P75) number of entry lines on the medication chart was 8(5-10), of 
chronic medications 7(5-10), of oral and systemic medications (e.g. parenteral or 
transdermal) 7(5-9), of only oral medications 7(4-9), of only medications which need a 
prescription 6(4-8), of reimbursed medication 4(3-6). We calculated the prevalence of 
the usage of major therapeutic groups among residents of nursing homes in Belgium in 
figure 3.22. 
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Figure 3.22: Prevalence of medication usage per therapeutic group in 
Belgian nursing homes (N=2,510) 
The variation in the consumption of chronic medicines among institutions was 
considerable. In figure 3.23, we present the results from one province (Antwerpen) to 
illustrate this wide variation with the median of the number of drugs per resident within 
each institution ranging from 5 to 13. The range of the percentages of residents treated 
with a specific therapeutic class was substantial for a number of classes, such as 
antidepressants (19% to 48%), NSAIDs (0% to 26%), Vasodilators (0% to 40%). 
0 10 20 30 40 50 60 70 80
N05: psycholeptica 
A06: laxativa
N06: antidepressants
N02: analgisics
C03: diuretics
B01AC: aspirine
A02: anti-ulcer
C09: ace-inhibitors
C07: betablockers
A11: vitamines
C01D: vasodilators
C08: calciumantagonists
A10: diabetica
N04: parkinson
C10: statines
M01: nsaids
Percentage of residents using the class of medication
One medication more than one
KCE reports 47 Medication use in Nursing Homes 79 
Figure 3.23: Consumption of chronic medicines per nursing home – 
Antwerpen 
 
The number of chronic medication per resident was of course strongly correlated with 
the number of diseases listed for each resident, as there were more medications with 
increasing polypathology (Pearson Correlation Coefficient .534,  p= .001). 
Expenditures 
The total mean expenditure per month and per resident for chronic medication was 
estimated at 140 (SD 125) € (see figure 3.24). Of this total, mean public expenditure for 
chronic reimbursed medication was 90 (SD 115) €, mean co-payment for chronic 
reimbursed medication was 23 (SD 17) € and mean out-of-pocket payment for non-
reimbursed chronic medication was 27 (SD 30) € (see figure 3.25).  In figure 3.26, an 
overview is given of the variation and extent of the 3 types of expenditures for chronic 
medication: public expenditures by the health insurer, co-payment for reimbursed 
medication by the patient, and out-of-pocket expenditures for non-reimbursed 
medication. 29% was cheap medication. Additionally, total mean expenditure for acute 
medication was 17 (SD 24) €. 
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Figure 3.24:  Total expenditure for chronic medication per resident 
 
Figure 3.25 : Mean expenditures for chronic medication 
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Figure 3.26:  Expenditures for chronic medication per resident 
 
Keypoints 
x On average, a resident used 8 medications, ranging from no medication 
(less than 1% of residents) to 22 medications.  Most medication (88%) was for 
chronic use.   Most frequently used were psycholeptic and/or antidepressant 
agents (in 68% of residents), laxatives (50%) and cardiovascular drugs (47%). 
x Expenditures per resident for chronic medication amounted to a mean 
public expenditure of 90 €, co-payment of 23 € and out-of-pocket payment 
for chronic non-reimbursed medication of 27 €. 
3.4.8 Assessment of quality of medication prescribing 
Our aim was to assess several elements of prescribing quality (underprescribing, 
misprescribing, overprescribing) with published sets of prescribing quality indicators, 
using a pragmatic approach. We limited ourselves to items which could be programmed 
on the basis of our clinical questionnaire and on the basis of the description of the 
medication on the medication chart. 
We focused on three published sets (see Appendix 10):  
x ACOVE Criteria of underprescribing 
x BEERS Criteria of inappropriate drugs 
x BEDNURS Criteria for nursing home residents 
In addition, we programmed  
x a list of relevant and prevalent drug-drug interactions, based on recent 
observational study  
x a list of inappropriate medicines as indicated by the Belgian Drug 
Information Center 
x identification of any  chronic use of benzodiazepines and analogues 
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3.4.8.1 ACOVE criteria 
A pragmatic selection of 7 criteria of underutilization was made. Identification of the 
disease (the IF statement) was based on the appreciation of the physician ticking a 
limited list of diseases on the questionnaire.  With the diagnosis of heart failure, no 
information on the ventricular ejection fraction (indicating the pumping capacity of the 
heart) was available.  
Identification of the medicine (the THEN statement) was based on the international 
ATC-classification. No distinction was made between selective and non-selective beta-
blockers. Possible contra-indications for the medicines (the UNLESS statement) were 
disregarded, as the information was not available or too complicated to program. With 
a computer program, all residents were screened for potential cases of underutilization. 
The prevalence of potential problems is given in table 3.10, together with the 
prevalence of the condition in the population.  
Table 3.10 :  Most prevalent prescribing problems according to 7 ACOVE 
Criteria of underprescribing in Belgian nursing homes (N=1,730). 
ACOVE Criteria  % of patients with 
the disease 
(N=1,730) 
% of patients 
with underuse 
(N=1,730) 
Heart Failure and no beta-blocker 32 23 
Heart Failure and no ACE-Inhibitor 32 20 
Myocardial infarction and no betablocker 27 18 
Osteoporosis and no bisfosfanates/VitD/Calcium 26 15 
Myocardial infarction and no aspirine 27 11 
Diabetes and no aspirine 17 9 
Osteoporosis with bifosphanates or VitD but no calcium 26 8 
Substantial underutilization was observed with regard to cardiovascular risk in heart 
failure, myocardial infarction and diabetes. In a substantial number of residents with 
osteoporosis a potential for more aggressive treatment might be present. 
3.4.8.2 Beers criteria 
The BEERS List consists in fact of a list of inappropriate drugs for the elderly, a list of 
inappropriate drugs when dosed too high, and a list of disease-drug interactions (or 
drugs used in contra-indicated conditions). For this project, only the inappropriate 
drugs were identified (regardless of their doses).  
The programming of the disease-drug interactions was attempted but proved to be 
cumbersome, because the delineation of some classes (e.g. anticholinergic 
antihistamincs) was unclear, because information was lacking on details of Belgian 
products (e.g. medicines with high salt content), or because our questionnaire provided 
not enough detail (e.g. incontinence in stead of a split in bladder output dysfunction and 
stress incontinence).  
In figure 3.27, the prevalence of the use of potentially inappropriate drugs among 
nursing home residents is given. During the interpretation of this list, limitations should 
be considered. 
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Figure 3.27:  Prevalence among Belgian nursing home residents of the use of 
potentially inappropriate drugs in 2005 
Limitations:  Digoxin was scored even when the dose was reduced to .125 mg and 
when there was atrial arrhythmia / Oxibutyn and nifedipine were not restricted to short 
acting formulations. Short acting dipiridamole was removed from the 2002 criteria.   
In Belgian nursing homes the prevalence of the use of potentially inappropriate drugs on 
the Beers list is rather low. Respecting the nuances in the Beers Criteria for potentially 
inappropriate drugs would further reduce these low prevalences.   
3.4.8.3 BEDNURS criteria  
Although intended for clinical review of individual residents by clinical pharmacists with 
full access to the medical record, these criteria proved to be relatively straightforward 
and simple to program. In this set of criteria, attention is given to the use of 
psychotropic medication, to NSAIDs, to drug-drug interactions, and to disease-drug 
interactions. Combinations of antidepressants with antipsychotics or benzodiazepines 
were observed in 25% of the residents, and the use of multiple antidepressants in 4%. 
12% of the residents used antipsychotics. Combinations of medicines with a risk of 
hyperkalemia were the third most prevalent problem. Inappropriate combinations of 
NSAIDs with a number of other medicines were observed, as well as a high overall use 
of chronic NSAID.  Five different long-acting benzodiazepines with a prevalence of more 
than 2% were detected (see figure 3.28). 
Beers Criteria : % of residents scoring on individual items 
(N=1,730)
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Figure 3.28: Most prevalent prescribing problems according to the 
BEDNURS criteria in Belgian nursing homes in 2005 
Limitations: Antipsychotic use was scored without excluding chronically psychotic 
patients / monotherapy of heart failure with diuretics was disregarded because of 
programming error. 
3.4.8.4 Other criteria to assess prescribing quality  
Our attempt to address problems of drug-drug interactions by programming a list of 
relevant and prevalent interactions based on a European observational study yielded 
little additional information for the detection of potential problems The same held true 
for the programming of a Belgian list of non-recommended medicines. Finally, we flagged 
the chronic use of any benzodiazepine or analogue, whether it was used as a hypnotic 
or an anxiolytic, or as an antiepileptic.  
3.4.8.5 The prescribing quality problem score used in this study  
For each resident, we run computer programs to flag potential problems according to 
the three published sets of quality indicators and the three other approaches described 
above. All flags for one resident were added to a sum-score. The purpose of this sum-
score was its use in an explorative analysis of the explanatory power of institutional 
characteristics with regard to the variability in the quality of prescribing within 
institutions. The purpose of this sum-score is not to make a reliable estimation of the 
individual level of quality of prescribing in the different institutions. 
We made this sum-score because each set of quality criteria measured different aspects 
of prescribing quality ranging from under- and overprescribing to misprescribing. There 
was however some degree of overlap in the items of the different sets of prescribing 
quality indicators with regard to psychotropic drug use, some drug-drug interactions 
and some disease-drug interactions. The overall relationship between each set of quality 
criteria was limited and showed the highest correlation between the score for drug-
drug interactions and BEERS criteria (rs=.334) and between the chronic use of 
benzodiazepine and BEDNURS (rs=.304). All other correlation coefficients were low 
(rs<.200).  No attempt was made to correct for this overlap. 
In figure 3.29 the contribution of the different sets to the overall sum-score is 
described. Few residents scored on the drug-drug interaction set (5%) and on the set 
Bednurse Criteria: Prevalence of patients scoring on indivual items (N=1730)
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for obsolete drugs (8%). 27% of the residents had a flag on the set of BEERS criteria; 
65% on the BEDNURS criteria and 58% on the ACOVE criteria. 
Figure 3.29 Number of flags per resident on the different sets of prescribing 
quality indicators 
In figure 3.30 the result of summing up all flags per resident is shown. The median (P25-
P75) is 2 (1-4) with a range from 0 to 13. 
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Fig 3.30:  Number of flags per resident on the overall Prescribing Quality 
Problem Score 
There was considerable variation within institutions of this sum-score where the median 
number of flags per resident per institution ranged from a median of 1 to a median of 
5 flags per resident between institutions. The Spearman rank correlation between this 
prescribing quality problem score and the number of diseases per resident ticked by the 
physician on the clinical questionnaire was .429 (p < .01). 
Finally, we examined the prevalence of use of a number of active substances which were 
discussed in the study of the national aggregated data. The prevalence of usage of 
molsidomine was 10%, acetylcysteine 8%, anti-cholinergic anti-Alzheimer medications 
5%, clopidogrel 5%, cetirizine 4%, anticholinergic spasmolytica 4%, betahistine  (a 
medication marketed for vertigo) 3%, other anti-Alzheimer medications 0.2%, and 
piroxicam (a long-acting NSAID) 0.1%. 
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Keypoints 
x Under-utilization was mainly observed for medication that reduces 
cardiovascular risk.   
x Antidepressants were combined with benzodiazepines or antipsychotics in 
1/4 of cases.  Some combinations with a high risk for hyperkalemia and 
several inappropriate combinations with NSAIDs were prescribed.   
x Only few residents received a combination that could lead to dangerous 
drug-drug interactions. 
x The median number of quality problems was 2 per resident, ranging from 0 
to 13.  There was a considerable variation between institutions with a 
median ranging from 1 to 5. 
3.4.9 Relationship between residents’ characteristics and parameters of 
prescribing quality 
3.4.9.1 Age and gender 
There was no linear relation between age and medication use (r=-.037, p=.062).  As 
shown in figure 3.31, the number of chronic medication increased to a mean of 8.4 in 
the age category 70-79 and decreased to a mean of 6.6 in the age category of 100 plus. 
No difference could be observed in the number of chronic medication and the total 
expenditure for chronic medication between males and females. However, the total 
quality problem score differed according to gender with a higher mean score for 
females compared to males of 3.1 (SD 3.3) and 2.7 (SD 3.0), respectively (p<.001).   
Figure 3.31: Consumption of chronic medication according to age 
3.4.9.2 Katz Scale 
The number of medications used varied considerably according to the Katz score 
(p<.001) with the highest consumption observed in the Katz C group with a mean of 8.6 
(SD 3.5) (figure 3.32). Total expenditures for chronic medication and the total quality 
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problem score followed the same trend. A linear decrease in chronic medication use 
was observed with increasing degree of dementia (p<.001) (see figure 3.33).  
Figure 3.32: Consumption of chronic medication according to Katz scale 
 
Figure 3.33: Consumption of chronic medication according to mental 
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3.4.9.3  Clinical problems 
A high positive linear correlation could be observed between the number of 
pathological problems and the number of chronic medications used (r=.535, p < .001) 
(figure 3.34), total expenditures (r=.313) and the total quality problem score (r=.409).  
Albeit less pronounced, the same significant positive correlations could be observed 
between on the one hand the number of care problems and on the other hand chronic 
medication (r=.326), total expenditures for chronic medication (r=.176) and the total 
quality problem score (r =.331) (all p < .001). 
Figure 3.34: Relationship between polypathology and chronic medication 
The clinical diagnosis of depression resulted in an increase in the consumption of 
chronic medication from a mean of 6.3 (SD 3.2) to a mean of 8.6 (SD 3.3) (p<.001) and 
an associated increase in total expenditures and total quality problem score (all p<.001).  
In contrast, the clinical diagnosis of dementia lowered the medication use, total 
expenditures and total quality problem score (p<.001, p=.028 and p<.001 respectively). 
The evolution in the amount of chronic medication used in different stages of palliative 
care is shown in figure 3.35 with highest consumption in residents with a fatal diagnosis 
but not in palliative care as yet.  Although medication use decreased in the palliative 
care phase, total expenditures for chronic medication did not.   
Figure 3.35: Consumption of chronic medication according to degree of 
palliative care 
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3.4.9.4 Administrative characteristics of residents  
The WIGW/VIPO statute of a resident did not influence the amount of chronic 
medication used, the total expenditure or the total quality problem score.  Only the co-
payment for chronic medication decreased with one third in residents with a 
WIGW/VIPO statute. At residents’ level, also OCMW/CPAS dependency had no 
influence on consumption, expenditure or quality. 
3.4.10 Univariate relationship between institutional characteristics and 
parameters of prescribing quality at resident level 
3.4.10.1 Type of nursing home 
Large OCMW/CPAS nursing homes showed a significant lower consumption of chronic 
medication with a lower co-payment for this medication and a higher amount of cheap 
drugs (table 3.11 and figure 3.36). 
Table 3.11: Parameters of prescribing quality according to type of nursing 
home 
 
In large public nursing homes less prescribing quality problems were noted (ANOVA 
p=0.001).  
Figure 3.36 : Quality problem score according to type of nursing home 
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P=0.001
OCMW small OCMW large Private small Private large
n = 548 n = 562 n = 638 n = 762
mean (SD) mean (SD) mean (SD) mean (SD)
number of drugs 8,6 (3,9) 7,8 (3,9) 7,9 (3,7) 8,1 (3,7) 0,002
number of chronic systemic drugs 7,4 (3,5) 6,8 (3,4) 7,1 (3,5) 7,2 (3,3) 0,059
public expenditure for chronic reimbursed drugs 97 (128) 86 (102) 90 (114) 93 (121) 0,0780
co-payment for chronic reimbursed drugs 24 (17) 21 (16) 24 (17) 24 (17) 0,004
out of pocket exp. chronic non-reimbursed drugs 26 (25) 30 (41) 26 (27) 28 (29) 0,172
percentage of cheap drugs 28% 32% 30% 26% 0,036
n = 401 n = 379 n = 463 n = 487
quality problem score 3,6 (2,4) 3,3 (2,3) 3,3 (2,3) 3,4 (2,3) 0,354
p-value  of 
difference
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3.4.10.2 Province 
A comparison of the parameters of prescribing quality between the 3 provinces 
included in the PHEBE project, revealed a significantly higher co-payment and a higher 
out-of-pocket expenditure in the province of Hainaut while the percentage of cheap 
medication was lower (table 3.12 and figure 3.37). 
Table 3.12: Parameters of prescribing quality according to province 
 
Figure 3.37: Expenditures for chronic medication per province 
3.4.11 Univariate analysis at institutional level 
3.4.11.1 Institutional characteristics 
Large differences in institutional characteristics could be observed between different 
types of nursing homes.  Mainly large OCMW/CPAS nursing homes had an important 
percentage of their patients treated by the CRA (mean 36% versus about 20% for the 
other types). In contrast, particularly the large private homes had to work with a large 
number of family doctors (mean 44). Nursing staff ratios varied considerably between a 
mean of one nursing staff member (including bachelors + graduates) per 7.7 residents in 
small OCMW/CPAS homes to one per 10.2 residents in large private homes (p<.018).  
Differences in staff ratios disappeared if also nurse assistants were taken into account. 
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number of drugs 8.1 (3.8 ) 8,1 (3.9) 8.1 (3.7) 8.1 (3.8) 0,804
number of chronic systemic drugs 7.1 (3.4) 7.2 (3.6) 7,0 (3.2) 7.1 (3.3) 0,760
public expenditure for chronic reimbursed drugs 90 (115) 91 (119) 90 (117) 87 (107) 0,777
co-payment for chronic reimbursed drugs 23 (17) 23 (17) 22 (16) 25 (17) 0,005
out of pocket exp. chronic non-reimbursed drugs 27 (30) 27 (29) 25 (32) 31 (31) <0,001
percentage of cheap drugs 29% 31% 28% 27% 0,001
n = 1730 n = 654 n = 572 n = 504
quality problem score 3.4 (2.3) 3,2 (2.3) 3,6 (2.4) 3,4 (2.3) 0,001
p-value  of 
difference
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The percentage of nurses with a bachelor degree (in FTE) did not differ significantly 
between strata. The delivery of medication by a hospital pharmacist could only be 
observed in OCMW/CPAS nursing homes.   
Price competition for medication delivery differed considerably between different types 
of nursing homes ranging from 100% of large OCMW/CPAS homes to only 37% of small 
private homes having competition (figure 3.38).  In all private homes, residents received 
a separate bill for their medication. In OCMW/CPAS homes, this was the practice in 
65% in the large and 80% of the small homes. 
Figure 3.38:  Price competition for the delivery of medication 
 
The practice of having a large amount of patients treated by the CRA differed between 
provinces with a mean of 40% of patients treated by the CRA in Antwerpen, 18% in 
Hainaut and 11% in Oost-Vlaanderen.  Nursing staff ratios were comparable in both 
Flemish provinces with on the average one staff member per 8.1 residents.  In Hainaut, 
one staff member had to take care about a mean of 10.9 residents. 
Hospital pharmacists were only active in the nursing homes of Antwerpen. Price 
competition was used in 85% of the homes in Antwerpen compared to half of the 
homes in Oost-Vlaanderen and Hainaut. 
3.4.11.2 Case mix as part of the institutional characteristics 
To determine the case-mix of the residents, residents’ characteristics (age, gender, 
OCMW/CPAS dependency) as well as clinical parameters (pathology problems, care 
problems and dementia) were taken into account. 
Case-mix of residents did not significantly differ between the different types of nursing 
homes.  According to province of localization, significant differences in case-mix could 
be observed for mean age of residents (older in Hainaut), mean percentage of 
OCMW/CPAS dependency (higher in Antwerpen), mean percentage dementia (highest 
in Antwerpen) and mean number of care problems (highest in Hainaut). 
3.4.11.3 Relationship between institutional characteristics and the quality of the medication 
management system 
Some of the structural aspects of the nursing homes had a substantial influence on the 
quality of the medication management system. A positive relationship could be observed 
OCMW
large
OCMW
small
Private
large
Private
small
0
10
20
30
40
50
60
70
80
90
100
%
 o
f i
ns
tit
ut
io
ns
 w
ith
 p
ric
e 
co
m
pe
tit
io
n 
%
 o
f i
ns
tit
ut
io
ns
 w
ith
 p
ric
e 
co
m
pe
tit
io
n 
KCE reports 47 Medication use in Nursing Homes 93 
with the presence of a hospital pharmacist and a better nursing staffing (less residents 
per staff member, more bachelors). A negative relationship was observed with the 
location in the province of Hainaut and with the practice of offering a separate bill for 
medication. Only the quality score for self medication forms an exception to these 
general trends. Here we noticed a positive relationship with location in Hainaut, a high 
number of residents and a high number of residents treated by one nursing staff 
member.   
Clinical aspects of the case-mix did not show any significant relationship with the quality 
of the medication management system in the nursing homes. In contrast, higher 
percentage of females, older mean age and higher percentage of OCMW/CPAS 
dependent residents had a positive influence on the total quality score as well as some 
of the partial scores (table 3.13) 
Table 3.13: Relationship between institutional characteristics and the quality 
of the medication management system 
Total quality score
Procedures Formulary Preparation Self medication
Institutional characteristics rs rs rs rs rs
Structural
OCMW nursing home
Location in Hainaut -0,243 -0,393 -0,195 -0,198 0,284
Total number of beds -0,236
Number of residentsat the ward 0,313
Percentage treated by CRA
Hospital pharmacist 0,291 0,366 -0,192
Price concurrence
Separate bill for medication -0,241 -0,319
Ratio residents per nurse -0,262 -0,229 -0,323 0,205
Percentage Bachelors 0,242 -0,230
Case Mix
Mean birth year -0,251
Percentage female 0,299 0,255 0,190
Percentage OCMW dependent 0,237 0,223 0,251
Mean number of pathological problems
Mean number of care problems
Percentage dementia
Partial scores
 
3.4.11.4 Relationship between institutional characteristics and the parameters of 
prescribing quality 
As shown in table 3.14 structural parameters as well as case-mix were clearly related to 
the different aspects of prescribing quality. The presence of a hospital pharmacist and 
price competition had a positive influence on expenditure for medication. Quality 
problems decreased with high activity of the CRA and the presence of a hospital 
pharmacist, with higher percentage of OCMW/CPAS dependent residents and 
dementia. Quality problems increased with higher percentage of females and higher 
mean number of pathological and care problems.   
Type and size of nursing home and ward, staff ratio and mean age of residents did not 
show any relationship with the parameters of prescribing quality. 
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Table 3.14: Relationship between institutional characteristics and the 
parameters of prescribing quality 
n of chronic 
medication
public exp 
reimbursed
co-payment 
reimbursed
percentage 
cheap
quality 
problems
Institutional characteristics rs rs rs rs rs
Structural
OCMW nursing home
Location in Antwerpen  0,317 -0,384
Location in Hainaut 0,267 -0,299
Total number of beds
Number of residentsat the ward
Percentage treated by CRA 0,211 -0,265
Hospital pharmacist -0,244 0,372 -0,213
Price concurrence  -0,218 -0,290 0,267
Separate bill for medication  -0,410 -0,288
Ratio residents per nurse
Percentage Bachelors
Case Mix
Mean birth year
Percentage female 0,195
Percentage OCMW dependent -0,197 0,285 -0,239
Mean number of pathological problems 0,509 0,356 0,428 -0,192 0,560
Mean number of care problems 0,250 0,210 -0,355 0,416
Percentage dementia -0,385  
3.4.11.5 Relationship between the quality scores of the medication management system 
and the parameters of prescribing quality   
Univariate analysis of the relationship between the quality of medication management 
systems in the nursing homes and prescribing quality only delivered a limited number of 
significant results.  A better score on the use of a formulary resulted in an increase in 
the percentage of cheap medication (table 3.15).  
Table 3.15: Relationship between the quality of the medication management 
system and parameters of prescribing quality 
 
n of chronic 
medication
public exp 
reimbursed
co-payment 
reimbursed
percentage 
cheap
quality 
problems
rs rs rs rs rs
Level of the ward
Work procedures
Formulary 0,392
Communication
Medication record -0,207
Storage of medication
Self medication
Preparation
Administration
Information
Total score at ward level 0,225
Level of the institution
Medication management
Formulary 0,358
Activities of pharmacist -0,309
Total score at institutional level -0,217
Quality scores of medication 
management system
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3.4.12 Multivariate analysis  
This analysis was performed at the level of the institution and compared institutional 
characteristics (see method for the full list of the variables) and the exogenous variables 
of appropriateness of prescribing (see methods for operationalization).  
The iterative omission of insignificant variables procedure (cfr. supra for a description) 
resulted in a “Final model”.  Detailed regression results of the final models included 
estimated coefficients, their standard errors, t-statistics and p-values.  Highly significant 
variables (p-values < 0.05) are printed in bold (see Appendix 11 and 12). All models 
explain between 53% and 78% of the variation of the outcome variables.   
The average number of medication was mainly influenced by the degree of poly-
pathology and the number of care problems of the residents.  The average number of 
medication decreased with a more favorable resident/nursing staff ratio.  Focusing on 
the average number of chronic systemic medication per resident, the same problem 
scores and staffing variables showed to have a significant effect. For chronic systemic 
medication, also the percentage of RVT beds in the nursing home was positively related 
to the number of chronic systemic medication. 
The variation in public expenditures for chronic medication was mainly influenced by 
the number of care problems, the percentage of residents with OCMW/CPAS 
dependency, the resident/nursing staff ratio, the size of the institution and the number 
of residents treated by the CRA. The average amount of co-payment was mainly 
influenced by the percentage of women, the percentage of OCMW/CPAS dependency, 
the poly-pathology of the residents and the size of the nursing home.  The percentage 
of cheap medication prescribed was negatively influenced by the monopoly position of 
the pharmacist. In contrast, price competition had a positive influence on the amount of 
inexpensive medication used. 
The total score of prescribing quality problems increased with higher poly-pathology 
and in larger institutions. The problem score decreased with a higher number of 
residents treated by the CRA, a larger number of activities performed by the 
pharmacist, a higher mean age of the residents and a higher percentage of dementia. 
Additional multivariate analysis with various aspects of the quality of the medication 
management system as dependent variables revealed that particularly the extent and the 
qualification of the staff played a role in explaining the variation among nursing homes 
(see Appendix 12). 
In summary, focusing on institutional characteristics (and after correcting for case-mix) 
it is clear that resident/nursing staff ratios contribute substantially in explaining 
differences in outcome variables.  
Other institutional characteristics (size, supply of drugs, medication management 
scores) seem to be of relative minor importance in explaining differences in the 
outcome variables: these characteristics were estimated significantly in maximum 2 of 
the 7 models. 
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Keypoints for 3.4.9 to 3.4.12 
x Poly-pathology and a high number of care problems increased the number 
of prescribed medications as well as the number of prescribing quality 
problems. 
x Large OCMW/CPAS nursing homes showed a significant lower 
consumption of chronic medication with a lower co-payment for this 
medication and a higher amount of cheap drugs.  
x A significantly higher co-payment and a higher out-of-pocket expenditure in 
the province of Hainaut were observed while the percentage of cheap 
medication was lower. 
x The presence of a hospital pharmacist and price competition showed a 
positive relation with expenditure for medication.  
x Quality problems decreased with high activity of the CRA and the presence 
of a hospital pharmacist, with higher percentage of OCMW/CPAS 
dependent residents and dementia.  Quality problems increased with higher 
percentage of females and higher mean number of pathological and care 
problems.   Staffing played a role in  the variation among nursing homes. 
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4 DISCUSSION AND GENERAL 
CONCLUSIONS 
Authors: Robert Vander Stichele, Dirk Ramaekers, Carine Van de Voorde, 
Monique Elseviers, Mirko Petrovic  
4.1 STRENGHTS OF THE STUDY 
In this report, for the first time, national aggregated data on medication use and 
expenditures of reimbursed medicines in rest- and nursing homes in Belgium are 
described, making it possible to assess the impact of this segment on the total health 
care budget. In the field study, a large representative sample of Belgian residents, 
stemming from a considerable number of institutions of 3 of the 10 provinces of the 
country, is investigated. Detailed information on the clinical and functional status of the 
residents was collected and a thorough analysis of prescribing quality was performed, 
using a range of internationally accepted sets of prescribing quality indicators, suitable 
for electronic evaluation. The close collaboration with the management of the nursing 
homes and with the coordination physicians guaranteed the high response rate of the 
treating physicians, resulting in high quality and high clinical content of the data. 
In the collaborating institutions the medication management system was evaluated in 
detail with an extensive questionnaire and a newly developed scoring system. Because 
we combined an extensive data collection of institutional characteristics with a 
thorough assessment of prescribing quality, we were able to study the relationship 
between both in univariate and multivariate analysis, at the level of the residents and at 
the level of the institutions. 
4.2 LIMITATIONS OF THE STUDY  
Drug utilization data based on aggregated national data are only crude consumption 
measures, sometimes difficult to interpret without clinical information. There is some 
imprecision in the consumption data from the nursing homes served by hospital 
pharmacists, because of practical problems with invoice data. Prudent interpretation of 
geographical variation of these aggregated data is warranted, because of the problem of 
ecological fallacy.  
Data collection of medication usage in the field study was based on the medication 
charts as recorded in the nursing record. Detection bias is possible and more likely for 
“if needed” or acute medication. We did not attempt to collect expenditure data on the 
“if needed” medication because it was not possible to record their actual consumption 
in a cross-sectional study.  The calculations of expenditures for acute medications were 
based on a crude estimation of duration of therapy. Volume was calculated with the 
Defined Daily Dose, which is based on the standard dose for the main indication of the 
drug in adults. Recommendations for dose reductions in frail elderly were not taken 
into account in these calculations and must be considered in the evaluation of the 
consumption of individual drugs. 
For the construction of disease-oriented quality indicators, data were collected on the 
clinical diagnoses and care problems of the residents, based on the assessment of the 
treating physician, responding to a non-validated questionnaire. This is but an 
approximation of the full risk profile and co-morbidity of the residents.   
We applied automated scoring algorithms for flagging potential prescribing quality 
problems, based on sets of prescribing quality indicators, originally designed for labour-
intensive, individual assessment of residents by clinical pharmacists, having access to the 
full medical record. Individual chart review by clinical pharmacists allows for more 
accurate establishment of diagnoses, and specification of clinically acceptable exceptions 
to general rules of prescribing. These limitations may lead to a limited degree of false 
positive detections of quality problems. On the other hand, it was not possible to 
program all elements of the Beers Criteria, leading to underdetection of problems. This 
hampers the use of these data for international comparisons.  We made a crude sum-
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score of the flags detected by the different sets of quality indicators, because each set of 
quality criteria measures different aspects (misprescribing, underprescribing, 
overprescribing). However, there is a limited overlap between the different sets, and no 
attempt to correct for this overlap was made.  
Our analysis of the complex relation of institutional characteristics with prescribing 
quality was hampered by the lack of information on an obvious determinant, namely the 
prescribing physician, and by the lack of information on true outcome variables such as 
mortality, hospitalization admission rates and quality of life. This was a cross-sectional 
study, with a single observation in time. Longitudinal research would give more insight 
in the dynamics of the functional status, medical condition and medication usage of 
nursing home residents. 
We were able to conduct a multivariate analysis of the relationship between 
institutional characteristics and prescribing quality. However, studying multiple models 
for several dependent variables may increase the chance of erroneously finding 
significant results. In addition, considerable collinearity between the independent 
variables increases the difficulty of a correct interpretation of the results.  The weight of 
dummy variables (e.g. private institution or not) may distort results, especially when the 
difference between for profit and non-for profit private institution is ignored or biased. 
Therefore, we performed a full and systematic univariate analysis first and made prudent 
conclusions on possible relationships, only based on correlations confirmed in both 
univariate and multivariate analysis. Because we were not able to aggregate the 
residents’ data to the level of the ward, it was not possible to perform a multi-level, 
multivariate analysis.   
4.3 MEDICAL DISCUSSION OF THE DETECTED PRESCRIBING 
QUALITY PROBLEMS  
In both the study of the aggregated national drug utilization data and in the results of 
the field study a number of prevalent prescribing quality problems were identified. In the 
following sections we will discuss the clinical relevance of these problems, in the light of 
the available evidence in the medical literature.  
4.3.1 Discussion on the national drug utilization data in rest and nursing homes 
The scope of this research project did not permit us to perform a full systematic review 
or health technology assessment including a cost-effectiveness analysis for every single 
drug. However, a rapid literature search on several of the drugs frequently used in 
Belgian rest and nursing homes leads to numerous recent systematic reviews and some 
recent good quality clinical trials. The utility of certain frequently used drugs and the 
appropriateness of some prescription patterns can be questioned.  Since we did not 
dispose of other variables like clinical patient characteristics per medication group it is 
in general not warranted to interpret the national data towards an under- or overuse 
and hence to appraise the drug utilization quality. However, certain prescription 
patterns can be discussed for those drugs that are linked to one or a limited number of 
indications and were the evidence clearly points towards possible quality problems 
related to effectiveness, appropriateness and safety.   
Molsidomine, a so called nitric oxide donor and the number one in the group of 
cardiovascular drugs used in Belgian rest and nursing homes, is used for the treatment 
of patients with stable angina pectoris. It is commercialized in several European 
countries among which Belgium. Molsidomine features a similar pharmacological profile 
as the organic nitrates. With regard to pharmakinetic effects, organic nitrates and 
molsidomine are similar.161 As the onset of action of molsidomine is comparatively slow, 
it is not used to treat acute cases of angina. Furthermore, due to its carcinogenic effect, 
molsidomine should only be considered when the treatment with organic nitrates is not 
sufficient, for example in the ‘nitrate-free’ interval. Pharmacokinetics and metabolism of 
molsidomine are impaired in elderly subjects. In patients with liver disease and 
congestive heart failure similar changes were observed. Clearance is also impaired in 
patients with liver disease, but the pharmacokinetics of molsidomine was not markedly 
altered by impaired renal function.162 The acute toxicity of molsidomine as well as the 
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organic nitrates are directly related to their therapeutic vasodilatation of orthostatic 
hypotension, tachycardia and throbbing headache.  
The evidence concerning long-term effects of molsidomine is scarce.163 There is no high 
quality evidence that molsidomine compared to placebo reduces the number of angina 
pectoris attacks, nor that it influences long term endpoints such as morbidity and 
mortality. Some studies showed a positive effect on a surrogate endpoint i.e. exercise 
tolerance. There is no evidence for the hypothesis that there is no tolerance 
development with the use of molsidomine.164 In clinical practice guidelines, such as the 
recently updated guideline of the European Society of Cardiology, molsidomine is not 
mentioned in the algorithm for the medical management of stable angina.165 There is 
only one reference to a study that studied the noninferiority of molsidomine 16 mg 
compared with 8 mg in institutions in Hongary, Poland and Belgium and that was 
written by employees of Therabel Pharma.166 
Since no detailed clinical data were available, it is impossible to appraise the 
antihypertensives prescription behavior. Geographical variations in antihypertensives 
show clear preferences towards either more diuretics (including thiazides) or towards 
more second line treatments such as amlodipine, ACE inhibitors and angiotensin II 
antagonists (sartans).167 The recommendations of the NRKP/CNPQ favor diuretics over 
the other abovementioned classes as first line treatment. However, to interpret the 
differences in prescription behavior more epidemiological data and more longitudinal 
analyses of the sequence on prescribed antihypertensive agents based on e.g. the data of 
the sickness funds are needed.   
In old age, depressive syndromes often affect people with chronic medical illnesses, 
cognitive impairment or disability. The number of prescriptions of antidepressants is 
huge in this elderly population in Belgium. Without detailed clinical data on the 
depressive disorders and the diagnostic process followed, it is impossible to suggest an 
underuse or overuse of antidepressants. The use of atypical antipsychotics is very 
popular in Belgian rest- and nursing homes. It is unlikely that they are often used for 
schizophrenia in this population, so that the most frequent indications are most likely 
behavioral and psychological symptoms of dementia (BPSD). The atypical antipsychotic 
drugs are being used with increasing frequency without clear evidence of the nature and 
extent of the clinical value of antipsychotic medications. Few high quality randomised 
trials have evaluated their use for BPSD and there have been concerns about adverse 
effects, significant risk for cerebrovascular events especially with risperidone, and 
increased mortality overall. Several of these newer atypical drugs are more expensive 
than the older ‘typical’ antipsychotics. Limited evidence supports the perception of 
improved efficacy and adverse event profiles compared with typical antipsychotic 
drugs.168, 169 Recently, in a government sponsored effectiveness trial170, it was shown that 
atypical antipsychotic drugs were somewhat more effective but also more toxic than 
placebo in Alzheimer patients. There was no difference for the clinically highly relevant 
primary endpoint (drug discontinuation for any reason) as an indicator of the overall 
success of drug therapy. Although these findings do not invalidate therapeutic trials of 
these drugs in appropriately selected patients with Alzheimer disease, taken into 
account the volume and the large variations in the use of these drugs, they do suggest 
that their appropriate use urgently needs further investigation. 
The use of acetylcholinesterase inhibitors for dementia, the so called anti-Alzheimer 
drugs, has been largely debated in the medical literature.171 A Cochrane reviewer of 
cholinesterase inhibitor trials explored the potential effects of several limitations and 
methodological flaws and concluded that the likely magnitude of the bias does not 
invalidate the beneficial findings of the studies.172 Donepezil is the most frequently used 
drug in this class in Belgium. People with mild, moderate or severe dementia due to 
Alzheimer's disease experience benefits in cognitive function, activities of daily living and 
behavior. The debate on whether donepezil is effective continues despite the evidence 
of efficacy from the clinical studies because the treatment effects are small and are not 
always apparent in practice.173 There is no evidence to support the use of donepezil for 
patients with mild cognitive impairment. The putative benefits are minor, short lived and 
associated with significant side effects.174 The cost-effectiveness of these expensive drugs 
is unclear and highly dependent on assumptions surrounding clinical effect and local cost 
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data.175 Extracts of the leaves of the maidenhair tree, gingko biloba, have been used in 
traditional Chinese medicine for thousands of years for several purposes. Clinical trials 
of the effects on dementia show inconsistent results.176 Several case reports describe 
bleeding complications with Ginkgo biloba, with or without concomitant drug 
therapy.177 
Mucolytics are the drugs most prescribed for respiratory disease in rest- and nursing 
homes. The most dominant drug in this class, N-acetylcysteine, was promoted to 
reduce the number of acute COPD exacerbations, supported by some systematic 
reviews.178 However, there is insufficient evidence for the systematic use of 
acetylcysteine179 and a recent large prospective multi-centre study (BRONCUS), 
reported that acetylcysteine in the regular dose of 600 mg daily is ineffective at 
prevention of deterioration in lung function and prevention of exacerbations in patients 
with COPD.180 
The more recently commercialized anti-allergic agent levocetirizine is an enantiomer of 
cetirizine, and is thus as such not a new compound, but part of an already known and 
cheaper preparation. Levocetirizine has not been shown to have any advantage over 
cetirizine with respect to clinical efficacy, adverse drug reactions or cost. 
Clopidogrel, related to the older ticlopidine, and much more expensive than aspirin, is 
widely prescribed in Belgian rest and nursing homes for chronic treatment. In general, 
the use of antithrombotic agents has risen dramatically over the last years. In theory, it 
has however only limited indications, especially in those circumstances where aspirin is 
contraindicated or not tolerated and in a limited time interval following coronary stent 
implantation (e.g. 1 month following bare metal stents and 3 to 6 months following drug 
eluting stents). It can also be considered during the first few months following an acute 
coronary syndrome. There is evidence that long-term chronic treatment with 
clopidogrel plus aspirin is not more effective than aspirin alone for reducing 
cardiovascular (CV) events.181 On the other hand, it has been shown that bleeding risks 
with this combination antiplatelet therapy, which is a matter of concern in the elderly, is 
remarkably high.182 Since there is only a marginal benefit of clopidogrel over aspirin in 
cardiovascular high risk patients while the price is much higher, the cost-effectiveness of 
this approach for patients where low dose aspirin is not contraindicated should be 
questioned. 
Statins are widely viewed as very effective and safe. Their benefits to coronary artery 
disease have been copiously documented and are incontrovertible. In addition, statins 
have been shown to benefit survival in a large study of middle-aged men with, or at high 
risk for, heart disease.183 Nonetheless, all drugs have potential adverse reactions despite 
their potential benefits. Understanding these risks is vitally important, particularly in frail 
elderly patients in whom both risks and benefits differ relative to younger patients. 
Evidence suggests the balance of benefits to risks may be less favourable in frail elderly. 
Cholesterol becomes a less potent predictor of cardiovascular problems, and adverse 
reactions from drugs, including statins, may become more prominent. While patients at 
high risk for cardiovascular disease receive mortality benefit from statins in studies 
predominating in middle-aged men183 no trend toward survival benefit is seen in elderly 
patients at high risk for cardiovascular disease.184 A less favourable risk-benefit profile 
may particularly hold for patients older than 85, in whom benefits may be more 
attenuated and risks more amplified.185 In fact, in this older group, higher cholesterol has 
been linked observationally to improved survival.183 
The rationale for venous thromboembolism prophylaxis is based on the clinically silent 
nature of the disease. In fact, most events cause few specific symptoms, and the clinical 
diagnosis is notoriously unreliable. Beyond the immediate complications of pulmonary 
embolism, which can lead to death, unrecognized and untreated DVT can cause long-
term morbidity from chronic venous stasis (postphlebitic syndrome) and predispose 
patients to recurrent venous thromboembolism. Each institution should have guidelines 
for identifying patients at risk, as well as a policy for providing prophylactic therapy.  
Non-pharmacologic prophylactic measures include compression stockings, leg elevation, 
and early mobilization. Aspirin may be appropriate for prophylaxis of arterial 
thrombosis, but is not adequate for prevention of venous thrombosis. Low-molecular-
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weight heparins (LMWHs) are used for DVT prophylaxis and in the treatment of DVT. 
LMWH are mostly given subcutaneously. The bleeding risk associated with LMWH 
administration is similar to or slightly lower than the risk observed with unfractionated 
heparin and is related to dose and molecular weight. 
Elderly patients who are candidates for prophylaxis include those with limited mobility, 
those with chronic conditions such as paraplegia, and those requiring permanent 
respiratory assistance. However, the true long-term risk of VTE in these patients is not 
well known; no studies have been performed that evaluate the benefit of prophylaxis 
with an appropriate duration of treatment in this population.  
Most long-term care residents with atrial fibrillation would be at high risk for embolic 
stroke, a disastrous complication. Additionally, they are theoretically good candidates 
for adjusted-dose warfarin treatment for atrial fibrillation.186 They should be accessible 
for monitoring and should have less dietary variability, a controlled medication list, and 
supervised medication administration. Balancing these features is at least a moderate 
risk of severe bleeding from anticoagulation based on age, co-morbidities, and 
polypharmacy. The decision to start warfarin will therefore be based on the individual's 
risks and potential benefits. The optimal intensity of anticoagulation is unknown for 
subgroups of patients with atrial fibrillation who have at least an intermediate risk of 
bleeding (e.g., adults older than 75 or 80 years), but there is no evidence that an INR 
lower than 2-2.5 is efficacious. Another option is to use aspirin instead of warfarin for 
patients at high risk of bleeding.187-189 
4.3.2 Discussion of the prescribing quality problems detected in the field study 
The quality of drug utilisation will be discussed starting from the different criteria and 
quality systems that were applied to the data generated by the field study. 
PROBLEMS IDENTIFIED WITH THE ACOVE CRITERIA OF UNDERPRESCRIBING  
Heart failure and no beta-blocker 
Beta blockers should be considered standard therapy in patients with New York Heart 
Association class II or class III heart failure who are hemodynamically stable, who do not 
have dyspnea at rest and who have no other contraindications to the use of these 
agents.190 
Heart failure and no ACE-inhibitor191, 192      
Overwhelming evidence accumulated during almost 20 years of clinical experience has 
established the benefits of this drug, which blocks the harmful effects of angiotensin, a 
substance that causes blood vessels to narrow, said the study authors. Current 
guidelines recommend that all patients with systolic dysfunction should be getting ACE 
inhibitors, unless they have a contraindication to the use of these drugs. Physicians 
might be reluctant to prescribe ACE inhibitors in certain high-risk patients, such as 
those with kidney disease. Some health care delivery systems might lack the necessary 
structure, controls or resources to ensure that heart failure patients receive the best 
care possible. Or, some physicians possibly lack awareness about the potential benefits 
of treatment with ACE inhibitors.  
Myocardial infarction and no beta-blocker193  
Although beta-adrenergic antagonists can significantly reduce mortality after a 
myocardial infarction, these agents are prescribed to only a small number of patients. 
Underutilization of beta blockers may be attributed, in part, to fear of adverse effects, 
especially in the elderly and in patients with concomitant disorders such as diabetes or 
heart failure. However, studies have shown that such patients are precisely the ones 
who derive the greatest benefit from beta blockade. Advancing age or the presence of 
potentially complicating disease states is usually not a justification for withholding beta-
blocker therapy. With use of cardioselective agents and through careful dosing and 
monitoring, the benefits of beta blockers after myocardial infarction far outweigh the 
potential risks in most patients.  
Osteoporosis and no VitD/Calcium/ bisfosfonates194  
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Osteoporosis is caused by the cumulative effect of bone resorption in excess of bone 
formation. Multiple treatments are available and more are being developed. 
Calcium and Vitamin D: less than one third of elderly residents take in the recommended 
amounts of calcium and vitamin D. Patients with malabsorptive problems, renal disease 
or liver disease may have further problems. Calcium and Vitamin D supplementation 
have been shown to reduce the risk of hip fracture in older adults. Calcium should be 
given with meals for optimal absorption and adults should take in at least 1000 mg/day 
(ideally 1500 mg/day in postmenopausal women or those with osteoporosis). Vitamin D 
(25 and 1.25 D3) can be checked, but if the serum calcium level is normal most would 
recommend empiric treatment with additional vitamin D of at least 400 IU. In frail older 
patients with limited diets and sun exposure, the required amounts are most likely 
much higher, at least 600-800 IU daily.  
Bisphosphonates: these drugs act to decrease bone resorption. Multiple studies have 
demonstrated a significant benefit in the reduction of hip and vertebral fractures. It is 
important to remember that those at highest risk for fracture (the older patients and 
those with existing vertebral fractures) were the patients who derived the most benefit 
from treatment. Contraindications include renal failure and significant oesophageal 
erosions/disease. 
Diabetes and no aspirin195  
Patients with type 2 diabetes mellitus have a markedly increased risk of cardiovascular 
morbidity and mortality. Guidelines of both the American and Canadian Diabetes 
Associations recommend the use of aspirin as antiplatelet therapy for all adults with 
type 2 diabetes. Aspirin is a safe, inexpensive, and readily available therapy that is 
effective for preventing cardiovascular disease, and patients with type 2 diabetes are 
particularly likely to benefit from such preventive therapy. 
However, we found significant underuse of aspirin therapy among our study population. 
Low dose aspirin should be included and better promoted as a factor in high-quality, 
evidence-based diabetes management.  
PROBLEMS IDENTIFIED WITH THE BEERS CRITERIA OF POTENTIALLY 
INAPPROPRIATE MEDICATION  
Digoxin196  
The incidence of digoxin toxicity increases with age, largely because the two most 
common conditions that benefit from use of digoxin, congestive heart failure and atrial 
fibrillation, are markedly more prevalent in old age. Current reviews conclude that the 
drug still has beneficial effects in patients who remain symptomatic with appropriate 
treatment with diuretics and angiotensin-converting enzyme inhibitors.197 Whether the 
elderly are more sensitive to the effects of digoxin because of age per se is unclear. 
However, several other factors render the elderly more susceptible to digoxin toxicity. 
These include an age-related decline in renal function and a decrease in volume of 
digoxin distribution. There is also an increase in the number of comorbid conditions, 
including cardiovascular and chronic obstructive pulmonary disease, which heightens 
susceptibility to digoxin toxicity. Moreover, treatment of these diseases with such 
interactive medications as quinidine and calcium channel blockers may increase the 
serum level of digoxin. Similarly, such electrolyte imbalances as hypokalemia and 
hypomagnesemia occur more frequently in the elderly as a result of diuretic therapy. 
Oxybutinin198 
Oxybutynin is a tertiary amine with anticholinergic and spasmolytic effects on the 
bladder smooth muscle. It was developed specifically for overactive bladder and to 
suppress involuntary bladder contractions. Oxybutynin works by a direct antispasmodic 
action on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth 
muscle. It is selective for muscarinic receptors on the detrusor and is more potent and 
more direct than atropine. Despite an improved anticholinergic side effect profile, side 
effects are still frequently dose limiting, or cannot be tolerated in the elderly. 
Anticholinergic effects are important causes of acute and chronic confusional states. 
Nevertheless, polypharmacy with anticholinergic compounds is common, especially in 
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nursing home residents. Recent studies have suggested that the total burden of 
anticholinergic drugs may determine development of delirium rather than any single 
agent.  
Amiodarone199  
Beers criteria for safe medication use in older adults include also amiodarone. 
Amiodarone is considered a "broad spectrum" antiarrhythmic medication, that is, it has 
multiple and complex effects on the electrical activity of the heart which is responsible 
for the heart's rhythm. Amiodarone is used for many serious arrhythmias of the heart 
including ventricular fibrillation, ventricular tachycardia, atrial fibrillation, and atrial 
flutter. Although amiodarone has many side effects, some of which are severe and 
potentially fatal, it has been successful in treating many arrhythmias where other 
antiarrhythmics fail. In addition to being an antiarrhythmic medication, amiodarone also 
causes blood vessels to dilate. This effect can result in a drop in blood pressure. 
Amiodarone may interact with beta- blockers, or certain calcium-channel blockers, such 
as verapamil or diltiazem, resulting in an excessively slow heart rate or a block in the 
conduction of the electrical impulse through the heart. It is recommended that the dose 
of digoxin is cut by 50% when amiodarone therapy is started. Amiodarone can result in 
phenytoin toxicity because it causes a two- or three-fold increase in blood 
concentrations of phenytoin. Symptoms of phenytoin toxicity include unsteady eye 
movement (temporary and reversible), tiredness and unsteady gait. Amiodarone also 
can interact with tricyclic antidepressants (e.g. amitriptyline), or phenothiazines and 
potentially cause serious arrhythmias. Amiodarone interacts with warfarin and increases 
the risk of bleeding. The bleeding can be serious or even fatal. This effect can occur as 
early as 4-6 days after the start of the combination of drugs or can be delayed by a few 
weeks.  
Nifedipine200  
Calcium antagonists have long been used as first-line drugs for hypertension and angina. 
However, deleterious effects have also been reported in patients treated with calcium 
antagonists. A fall in diastolic BP and a rapid increase in heart rate can be associated 
with ischemic episodes without with nifedipine. Slow-release nifedipine may induce 
myocardial ischemia through a heart-rate increase and a decrease in coronary blood 
flow due to lower diastolic BP in patients with severe coronary artery disease.  
Gastric ulcer and NSAID201  
Non-steroidal anti-inflammatory drugs including aspirin use is the second most common 
aetiologic factor for peptic ulcer disease and a major factor for peptic ulcer 
complications. The use of non-steroidal anti-inflammatory drugs, including cyclo-
oxygenase-2 inhibitors, may increase the short-term risk of complications and death in 
patients with bleeding peptic ulcers.  
Fall risk and benzodiazepines  
In our study, more than half of the nursing home residents with fall risk took 
benzodiazepines. Benzodiazepines have been recognized as an independent risk factor 
(IRF) for falls among the elderly. Benzodiazepines may produce inappropriate sedation 
and psychomotor impairment and are associated with an increased risk of falls and hip 
fractures.202 A recent prospective, multi-centre study of approximately 8,000 
hospitalized patients showed that benzodiazepines with very short and short half-lives 
were positively associated with falls during a hospital stay and that their use is an IRF for 
falls.203 The study also showed that patients were at a greater risk of falls if they were 
receiving other psychotropic agents or diabetic agents, if they had cognitive impairment, 
a high level of comorbidity, advanced age (>80 years), or if they stayed in the hospital 
for 17 days or more. Long-acting benzodiazepines have been shown to markedly 
increase the risk of falls and hip fracture.203 Up to 20% of older adults take 
benzodiazepines; benzodiazepine use is more common among women, whereas alcohol 
use and abuse is more common among men.204 Prescriptions for these agents should be 
carefully evaluated in institutionalized elderly patients. 
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PROBLEMS IDENTIFIED WITH THE BEDNURS CRITERIA    
Combination of psychotropics205, 206 
Use of psychotropic medication is very common in nursing home residents. The 
prevalence of committant prescribing of psychotropic drugs in our study is substantial. 
This may be a potentially important and avoidable risk factor for drug-related illness in 
elderly people. It has been shown in the literature that abundant sedative drug use has 
been associated with high age, female gender, poor basic education, poor health habits 
(e.g., smoking), depression, dementia, or impaired mobility. Users also have poor self-
perceived health. More studies are needed in this field. Physicians caring for nursing 
home residents require further education on the benefits and adverse effects of 
psychotropic drugs in frail elderly people. 
Chronic use of antipsychotics207 
Continuous use of antipsychotics in our study exceeds 10%. It has been shown in the 
literature that chronic use of antipsychotic has been related to both depressive 
symptomatology and sleep problems. If a patient initially has responded well, the 
following duration of treatment before attempting to taper and discontinue the 
antipsychotic has been recommended: delirium, 1 week; agitated dementia, taper within 
3-6 months. Combinations with carbamazepine, tricyclic antidepressant and fluoxetine 
have been considered as contraindicated. Extra monitoring has been recommended 
when combining any antipsychotic with lithium, lamotrigine, or valproate or with 
codeine, phenytoin, or tramadol.  
Combination of ACE-inhibitors and potassium or potassium-saving diuretics208, 209 
Combination of ACE-inhibitors and potassium or potassium-saving diuretics was found 
in more than 10% of the participants in our study. A potentially serious side effect of 
taking ACE inhibitors is increased blood potassium levels. Taking potassium 
supplements, potassium-containing salt substitutes or large amounts of high-potassium 
foods at the same time as ACE inhibitors is not recommended. Potassium sparing 
diuretics have generally been avoided in patients receiving ACE inhibitors, owing to the 
potential risk of hyperkalaemia. Nevertheless, a recent randomised placebo controlled 
study, the randomised aldactone evaluation study (RALES), reported that hyperkalaemia 
is uncommon when low dose spironolactone (25 mg daily) is combined with an ACE 
inhibitor. Risk factors for developing hyperkalaemia include spironolactone dose >50 
mg/day, high doses of ACE inhibitor, or evidence of renal impairment. It is 
recommended that measurement of the serum creatinine and potassium concentrations 
is performed within 5-7 days of the addition of a potassium sparing diuretic to an ACE 
inhibitor until the levels are stable, and then every one to three months. 
Longacting benzodiazepines210 
Benzodiazepines with oxidative pathways and longer half-lives, such as chlordiazepoxide, 
diazepam, and flurazepam, are more likely to accumulate in the body and cause 
prolonged sedation. Long-acting benzodiazepines are not recommended for elderly 
patients because they increase the risk of impaired cognitive function, falls, and hip 
fractures. The prevalence of long-term benzodiazepine use among nursing home 
residents in our study does not exceed 5%. Nevertheless, this topic merits attention 
given that this segment of the population could be expected to grow and given that 
elderly persons are particularly prone to adverse reactions to benzodiazepines.  
Neuropsychiatric symptoms of dementia are common and associated with poor 
outcomes for patients and caregivers. Although non-pharmacological interventions 
should be the first line of treatment, a wide variety of pharmacological agents are used 
in the management of neuropsychiatric symptoms; therefore, concise, current, 
evidence-based recommendations are needed. Recently a systematic review on this 
subject was conducted by Sink et al.211 They concluded that pharmacological therapies 
are not particularly effective for management of neuropsychiatric symptoms of 
dementia. 
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PROBLEMS WITH MEDICATIONS WITH LIMITED EVIDENCE BASE FOR EFFICACY 
Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID). Used for the management 
of several different symptoms and numerous conditions, NSAIDs as a group continue to 
be among the most frequently prescribed medications. Nevertheless, physicians 
generally recognize that the prudent use of NSAIDs requires cognizance of potential 
side effects. Clinical experience suggests that, although complications can occur early in 
the course of treatment, they are more likely to occur with chronic use. According to 
the revised Beers criteria piroxicam belongs to potentially inappropriate medications for 
the elderly.  
Gastrointestinal toxicity is the most frequently encountered side effect associated with 
piroxicam and other NSAIDs and presents considerable concern. Approximately one 
half of all hospital admissions for a bleeding ulcer are attributed to the use of NSAIDs, 
aspirin, or the two taken in combination during the week prior to admission.212 The 
relative risk of gastric ulcer (4.7), duodenal ulcer (1.1 to 1.6), bleeding (3.8), perforation, 
and death are all increased by NSAID use when such patients are compared to those 
who do not take these products. Patients at increased risk of developing GI 
complications include those with a prior history of peptic ulcer and especially those 
with prior upper GI bleeding, regardless of the source. These patients had a relative risk 
of 13.5 for a recurrent complication.213 
Renal complications are the second greatest concern associated with piroxicam use. 
Renal side effects include fluid and electrolyte disturbances such as sodium and water 
retention and/or hyperkalemia. Acute renal failure, nephrotic syndrome with acute 
interstitial nephritis, and papillary necrosis may also occur.214 Although renal events are 
uncommon, they can have profound consequences if the drug use is not stopped and 
appropriate care is not initiated. 
The effect of piroxicam on the function of antihypertensive medications is another area 
of concern. Concomitant use of NSAIDs plus antihypertensive medication increases 
with age to greater than 50% among the elderly.215 A large, case-controlled study of 
patients more than 65 years of age demonstrated that recent users of NSAIDs had a 
1.7-fold increase in risk of initiating antihypertensive therapy when compared with non-
NSAID users.216 It appears that NSAID use reduces the antihypertensive effects of 
angiotensin-converting enzyme (ACE) inhibitors to the greatest degree while having 
lesser effects on beta blockers, diuretics, vasodilators, and calcium channel blockers.217, 
215 
Allergy to piroxicam and other NSAIDs occurs in approximately 0.3% of the population. 
A not uncommon side effect associated with piroxicam is interference with hemostatic 
disorders. Aspirin irreversibly acetylates cyclooxygenase and thereby inhibits synthesis 
of both TXA2 and PGI2. In contrast, NSAIDs reversibly inhibit cyclooxygenase. There is 
conflicting evidence as to whether aspirin and other NSAIDs are associated with 
increased bleeding from surgery.218 However, where an association is suspected, the 
following factors may portend a high risk for bleeding complications: age older than 60 
years, bleeding disorders, liver dysfunction, thrombocytopenia, and other risk factors 
such as alcohol use and use of oral anticoagulants. 
Betahistine is advocated as a vestibular suppressant mainly for Meniere's disease. 
Betahistine was approved by the US FDA about 30 years ago for roughly 5 years, but 
later approval was withdrawn because lack of evidence for efficacy and because the 
major report of effectiveness contained deficiencies and misrepresentations.219 
Subsequently, four double-blind studies have been done reporting reduction of vertigo 
attacks with betahistine.220-223 Nevertheless, these studies may have been flawed and a 
recent review suggested that it is presently still unclear if betahistine has any effect in 
Meniere's disease.224 Betahistine was again reviewed by the FDA in June of 1999. 
Essentially, the conclusion seems to be that there is no evidence that it is harmful, but 
also little evidence that it has any therapeutic effect. It thus is similar in official status to 
an inert substance.  
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4.4 GENERAL CONCLUSIONS 
4.4.1 The magnitude of medication use and costs for long-term residential 
elderly in Belgium 
The national aggregated data on drug utilization in Belgian rest- and nursing homes 
clearly illustrate certain prescription patterns, habits and often large geographical 
differences for those drugs that are linked to one or a limited number of indications. 
The field study (PHEBE project) showed the high number of 8 chronic medications per 
resident among residents in nursing homes, highly related to the polypathology of the 
residents.  
Albeit only 1.4% of the Belgian population lives in nursing homes, the data from this 
study and data from national claims databases mm  indicate that 5.6% of the public 
expenditures on medication (pharmaceutical specialties) may be generated by nursing 
home residents (123 million € in 2004 in Belgium). Residents of nursing homes generate 
considerable public expenditures for pharmaceutical care (90 € per month), but also pay 
hefty amounts of personal money out-of-pocket for co-payment of chronic reimbursed 
medicines (23 € per month) as well as for payments to the pharmacy for non-
reimbursed medication (27 € per month).  
4.4.2 The medical needs of residents in nursing homes  
We detected an average of 5 medical problems per resident (2.7 clinical problems and 
2.6 care problems). The treating physician categorized 46% of the residents as 
demented, and 35% as depressed, with an overlap between the two diseases of 16%. At 
the moment of the survey, 9% of the residents were in palliative care, of which one in 
three was in terminal care.  
The number of medical diagnoses does not increase with increasing age, in contrast to 
the number of care problems by resident, showing a significant increase in the very old. 
4.4.3 Measurement of the quality of prescribing  
The average number of potential prescribing quality problems per resident was high. A 
number of clinically relevant problems with a substantial prevalence could be identified 
as a possible target for prescribing quality improvement programs. 
None of the existing sets of prescribing quality indicators provides a comprehensive 
view of the different aspects of evidence-based clinical practice, and all require further 
adaptation to local medical practices. The implementation of accepted sets of 
prescribing quality indicators requires more explicit specifications for the definition of 
drug classes in terms of the Anatomic Therapeutic Chemical Classification (ATC) of the 
World Health Organization. In addition, further validation of physician assessed lists of 
medical diagnoses and care problems is needed.  Finally, validation is needed of the 
application of these sets of quality indicators in the context of automated analysis of 
medication charts.    
4.4.4 The general characteristics of Belgian nursing homes and their medication 
management systems 
Belgium has a well-established network of rest and nursing homes within its cities and 
villages, mainly run by community social services, by religious charities or by private for-
profit corporations. Belgian residential homes for the elderly have a mix of residents 
where slightly and highly dependent patients and demented and non-demented patients 
live together in one institution. Many residents are still supervised by their former 
general practitioner, but in some nursing homes the coordinating physician is 
responsible for more than half of the residents of the home. The large majority of 
                                                     
mm Public expenditures on pharmaceutical specialties amounted to 2,213 million € in 2004 (personal 
communication M De Falleur – RIZIV/INAMI). 
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nursing homes are served by community pharmacists, with little engagement in clinical 
pharmacy activities. About one in ten nursing homes is served by a hospital pharmacist.  
The medication management systems in the nursing homes are poorly developed and 
focus mainly on the distribution process inside the institution, and less on the 
appropriateness of prescribing. Few residents manage to keep some form of autonomy 
with regard to medication, except in institutions with limited staff and poor distribution 
management.    
Although a drug formulary is formally available in most institutions, the implementation 
of this formulary and its impact on the drug choice process of the visiting physicians 
seems to be limited. Nursing homes run by the local community social service 
(OCMW/CPAS) more often have a hospital pharmacist running the medication supply 
to the institution, more often have coordinating physician treating a high number of 
residents within the institution, and more often have more intense medication 
management systems.   
4.4.5 Institutional characteristics associated with the quality of prescribing   
In the field study, lower quality of prescribing was associated with the location of the 
nursing home in Hainaut, and with a lower number of residents per attending physician. 
Higher quality of prescribing was associated with higher activity of the coordinating 
physician, better implementation of the formulary, and greater activity of the delivering 
pharmacist. Higher expenditures were associated with the province of Hainaut and with 
the absence of price competition.   
With regard to the impact of case-mix, we observed that the volume of medication 
usage did not increase in the very old. Dementia and end-of-life care seems to be 
associated with a decrease in the volume of medication usage. 
4.4.6 Implications for research and practice 
There is a need for reliable and feasible scales to assess the case-mix of institutions and 
the continuous functional assessment of individual residents. Given the imminent digital 
revolution in health care facilities, the transformation of the pharmaceutical and clinical 
data collection methods in this cross-sectional research to tools for continuous, 
automated data-collection based on computerized nursing records seems feasible. The 
effectiveness of collective feedback on prescribing quality indicators to the community 
of visiting physicians to a nursing home merits further investigation. 
Interventions to enhance the quality and the affordability of medications in nursing 
homes will be more cost-effective when these interventions not only have an impact on 
the drug choice process for residents of nursing homes, but also on the drug choice 
process for all elderly patients on the list of the general practitioners. 
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5 APPENDICES 
APPENDIX 1: ORGANISATIEKENMERKEN VAN 
BELGISCHE RUSTHUIZEN (ROB) EN RUST- EN 
VERZORGINGSTEHUIZEN (RVT)  
Deze appendix bevat een beschrijving van de data over de instellingskenmerken, die 
door het RIZIV/INAMI ter beschikking gesteld zijn. De data werden in functie van de 
studie gereorganiseerd. Het resultaat van deze manipulaties is de finale dataset waarmee 
de analyses in sectie 1.1 uitgevoerd zijn. Op basis van de data die door het RIZIV 
overgemaakt zijn, is een database aangemaakt volgens onderstaand schema. De database 
bestaat uit 4 tabellen. We geven voor elke tabel de variabelen die erin zijn opgenomen, 
een omschrijving van de variabele en het aantal observaties. Een aantal van de variabelen 
zijn door de onderzoeksequipe aangemaakt.  
Tabel 1 : INSTITUTION_CHR 
Variabele Beschrijving 
riziv_nr_an gecodeerde vorm van identificatienummer van de ROB of RVT 
institut_an gecodeerde vorm van identificatienummer van de instelling 
Type type dat overeenkomt met riziv_nr: {ROB, RVT} 
NIS NIS-code van arrondissement instelling 
Nr_beds aantal bedden laatste kwartaal 2004 per riziv_nr 
In de tabel INSTITUTION_CHR zitten volgend aantal observaties: 
Totaal ROB en RVT 3,661 
Totaal instellingen 2,650 
Totaal ROB en RVT  1 bed 2,693 
Totaal instellingen  1 bed 1,720 
We gebruiken de term ‘instelling’ of ‘institution’ voor het gebouw of de gebouwen met 
ofwel uitsluitend ROB-bedden, ofwel uitsluitend RVT-bedden of ROB- én RVT-bedden. 
Het deel van de instelling met ROB-bedden noemen we ‘rest home’, het deel met RVT-
bedden ‘nursing home’.  
Tabel 2 : RIZIV_LAY_DAY 
Variabele Beschrijving 
riziv_nr_an gecodeerde vorm van identificatienummer van de ROB of RVT 
entitled rechthebbend of niet: {yes,no} 
dependency • ROB: {O,A,B,C,Cd} 
• RVT: {B,C,Cd,Cc} 
nr_lay_day aantal gefactureerde ligdagen laatste kwartaal 2004 
fl_maxbeds • 1: record maakt deel uit van instelling die in laatste kwartaal 2004 meer dan 
103% gefactureerde ligdagen had t.o.v. (aantal bedden x 92 dagen) in gegevensbestand 
RIZIV_LAY_DAY  
• 0: records die niet onder 1 vallen 
In de tabel RIZIV_LAY_DAY zitten volgend aantal observaties: 
Verwijderd want niet RVT/ROB (bv. centra voor 
dagverzorging)  
298 
Totaal na verwijdering 24,198 
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Tabel 3 : PERSONNEL_DETAIL 
Variabele Beschrijving 
riziv_nr_an gecodeerde vorm van identificatienummer van de ROB of RVT 
Qualification 1 verpleegkundige A1 
2 verpleegkundige A2 
3 ziekenhuisassistent 
4 verzorgende 
5 kine 
6 ergo 
7 logo 
8 reactiveringspersoneel 
9 ander personeel A1/univ. 
10 ander personeel A2 
11 ander personeel < A2 
fte_amount Full time equivalent voor beroepskwalificatie 
fte_nr Aantal personeelsleden met waarde van fte_amount (vb fte_amount=0.75 en fte_nr=3 
betekent 3 personeelsleden met 0.75 fte) 
In de tabel PERSONNEL_DETAIL zitten volgend aantal observaties: 
Verwijderd want niet RVT/ROB (bv. centra voor 
dagverzorging)  
314 
Totaal na verwijdering 101,733 
Tabel 4 : KATZ_SCORES 
Variabele Beschrijving 
pID uniek identificatienummer patiënt, enkel voor deze studie 
riziv_nr_an gecodeerde vorm van identificatienummer van de ROB of RVT 
birthyear  geboortejaar patient 
gender  geslacht van de patiënt: {M,V} 
depend_cat  Afhankelijkheidscategorie op basis van de Katz-scores: {O,A,B,C} 
katz_wash  evaluatie hulpbehoevendheid m.b.t. zich wassen {1,2,3,4} 
katz_dress  evaluatie hulpbehoevendheid m.b.t. zich aankleden {1,2,3,4} 
katz_transfer  evaluatie hulpbehoevendheid m.b.t. zich kunnen verplaatsen {1,2,3,4} 
katz_wc  evaluatie hulpbehoevendheid m.b.t. toiletbezoek {1,2,3,4} 
katz_contin  evaluatie hulpbehoevendheid m.b.t. urine en faeces continentie {1,2,3,4} 
katz_food  evaluatie hulpbehoevendheid m.b.t. eten en drinken {1,2,3,4} 
katz_time  evaluatie hulpbehoevendheid m.b.t. oriëntatie in de tijd {1,2,3,4,5} 
katz_space  evaluatie hulpbehoevendheid m.b.t. oriëntatie in de ruimte {1,2,3,4,5} 
In de tabel KATZ_SCORES zitten volgend aantal observaties (toestand op 31/12/2004): 
Verwijderd want niet geldige codes 17 
Verwijderd want niet RVT/ROB 564 
Totaal na verwijdering 117,926 
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APPENDIX 2: OVERZICHT WETTELIJKE 
BEVOEGDHEDEN EN BESCHIKBARE 
GEGEVENSBRONNEN M.B.T. RUSTHUIZEN EN 
RUST- EN VERZORGINGSTEHUIZEN  
INLEIDING 
Het doel van dit document is om bestaande (administratieve) gegevensbronnen m.b.t. 
de rusthuissector in kaart te brengen. Deze gegevens kunnen zowel betrekking hebben 
op de instelling als op de bewoners ervan. Daarom werd in eerste instantie nagegaan 
welke gegevens ROB/RVT al dan niet periodiek dienen te rapporteren aan de 
verschillende beleidsinstanties. Het is niet de bedoeling om in dit deel reeds concrete 
gegevens of cijfers te presenteren.  Er wordt echter wel een globaal beeld geschetst 
over welke gegevens de instellingen moeten rapporteren aan de verschillende instanties 
(zowel federale als regionale). Uit de opsommingen blijkt dat de ROB/RVT aan een 
aantal instanties verantwoording verschuldigd zijn en dat er soms een (aanzienlijke) 
overlapping is van data die meegedeeld dienen te worden aan de verschillende 
instanties. Verder dienen nog een groot aantal documenten, vergunningen, 
overeenkomsten en verslagen in de instelling ter beschikking van de inspectie gehouden 
te worden. Behalve deze verplichte rapporteringen betreffende individuele 
rusthuiskenmerken, personeels- en bewonersgegevens op het niveau van het rusthuis 
worden ook gegevens verzameld op het niveau van de bewoners (de 
factureringsgegevens gezondheidszorg betreffende de geneeskundige verstrekkingen en 
de Farmanet-gegevens betreffende geneesmiddelen).   
Verder zijn er in het verleden reeds studies uitgevoerd die (sommige deelaspecten van) 
de rusthuissector en/of hun bewoners beschrijven of onderzoeken (bv. QualidemI en 
QualidemII, grijze literatuur, …). Deze studies geven een dikwijls een algemeen beeld (al 
dan niet aan de hand van steekproeven en veldonderzoek), maar stellen geen gegevens 
of resultaten beschikbaar op individueel rusthuis- of bewonersniveau. In dit deel wordt 
de nadruk gelegd op een inventarisatie van gegevens die in principe voor elk rusthuis en 
voor elke bewoner gekend zijn door diverse administraties en diensten en die dus, mits 
toestemming van de bevoegde diensten, in principe (en eventueel na koppeling) 
beschikbaar en bruikbaar zouden  kunnen zijn voor dit onderzoek. De gerapporteerde 
gegevens zijn echter niet exhaustief : ze zijn gelimiteerd tot die data die relevant zijn 
voor de verdere realisatie van het PHEBE-project. Derhalve zal de nadruk liggen op 
gegevens die betrekking hebben op de organisatiekenmerken van het rusthuis en op de 
geneesmiddelen. 
Wij situeren kort de voornaamste federale en regionale beleidsverantwoordelijken 
m.b.t. de rusthuissector, zowel op politiek als op administratief niveau. Ook wordt een 
opsomming gegeven van de gegevens die ROB/RVT verplicht periodiek dienen te 
rapporteren aan de diverse instanties of ter beschikking te houden van inspecties.  Tot 
slot wordt kort opgesomd welke gegevens op bewonersniveau via de VI gekend zijn 
(koppeling van bewonersgegevens aan factureringsgegevens gezondheidszorg en 
Farmanet). 
SITUERING VAN BELEIDSVERANTWOORDELIJKHEDEN 
De complexe Belgische staatsstructuur heeft ook gevolgen voor de werking van 
ROB/RVT en voor de (verplichte) periodieke en occasionele rapportering van gegevens 
omtrent hun werking.  De gedeelde federale en regionale bevoegdheden betreffende de 
rusthuissector en hun bewoners geeft aanleiding tot zowel een duplicatie als tot een 
versnippering van de gegevens(bronnen). 
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Federale Overheid 
Op het federale niveau vallen de ROB/RVT voornamelijk onder de politieke 
verantwoordelijkheid van de Minister van Sociale Zaken en Volksgezondheid waar 
vooral de cel “Zorginstellingen en farmaceutische specialiteiten” de sector opvolgt. 
Administratief zijn deze bevoegdheden verdeeld over twee Federale OverheidsDiensten 
(FOD), enerzijds de FOD Sociale Zekerheid (en de Openbare Instellingen van Sociale 
Zekerheid) en anderzijds de FOD Volksgezondheid, Veiligheid van de Voedselketen en 
Leefmilieu.  
Binnen de FOD Sociale Zekerheid zijn het Directoraat-Generaal (DG) Sociaal beleid en 
het DG Sociale Inspectie de meest relevante diensten. Ook het RIZIV valt onder de 
bevoegdheid van deze FOD. Sinds 1 januari 2002 heeft het RIZIV een 
bestuursovereenkomst met de Staat en is daardoor een openbare instelling voor sociale 
zekerheid (OISZ) geworden. Een OISZ beheert een sociale zekerheidstak en verstrekt 
in een aantal gevallen sociale prestaties aan degenen die hierop recht hebben.   
Het is echter vooral de FOD Volksgezondheid, Veiligheid van de Voedselketen en 
Leefmilieu en meer specifiek het DG Organisatie van de Gezondheidsvoorzieningen die 
van groot belang is voor de werking van rusthuizen. Binnen dit DG is de Cel “Ouderen- 
en Chronische Zorg” belast met de voorbereiding en ondersteuning van het federale 
beleid inzake ouderen- en chronische zorg.   
Verder zijn er ook nog partiële bevoegdheden (voornamelijk inspecties en controles op 
naleving van de wetgeving) voor : 
x FOD Sociale Zekerheid (Controle op correcte toepassing van de 
sociale zekerheidswetten (R.S.Z-wetgeving, jaarlijkse vakantie, 
arbeidsongevallen, kinderbijslag voor loonarbeiders, … ) en bestrijding 
van sociale fraude)  
x FOD Werkgelegenheid, Arbeid en Sociaal Overleg (Inspectie Welzijn 
op het werk) 
x FOD Economie, KMO, Middenstand en Energie (Inspectie dagprijs, 
boekhouding)  
x FOD Financiën (Administratie van de ondernemings- en 
inkomensfiscaliteit). 
x Federaal Agentschap voor de Veiligheid van de Voedselketen 
Gemeenschappen en Gewesten 
Op het niveau van de Vlaamse Gemeenschap ligt de politieke verantwoordelijkheid over 
de rusthuizen bij de Vlaamse Minister van Welzijn, Volksgezondheid en Gezin. 
Administratief is het Departement Welzijn, Volksgezondheid en Cultuur (WVC) 
bevoegd. Meer specifiek zijn vooral twee administraties binnen dit departement  
betrokken bij het beleid betreffende rusthuizen, met name de Administratie 
Gezondheidszorg en de Administratie Gezin en Maatschappelijk Welzijn. Binnen de 
Administratie Gezondheidszorg is vooral de Afdeling Verzorgingsvoorzieningen van 
belang.   
Onder de Administratie Gezin en Maatschappelijk Welzijn ressorteert de Afdeling 
Inspectie en Toezicht die de welzijnsdiensten inspecteert die door deze administratie 
worden erkend en/of gesubsidieerd (bv. ROB).  Onder deze administratie  bevindt zich 
ook de Afdeling Welzijnszorg. De erkenning (en subsidiëring) behoort niet tot de 
bevoegdheid Inspectie en Toezicht, wel tot de bevoegdheid van de Afdeling 
Welzijnszorg. Deze laatste afdeling omvat o.a. een Team Ouderenvoorzieningen. Dit 
team onderzoekt en doet voorstellen aan de minister inzake programmatie en 
erkenning voor rusthuizen, serviceflatgebouwen en werkingstoelagen aan 
ouderenvoorzieningen. Daarnaast verricht het team beleidsvoorbereidend werk en 
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brengt advies uit aan het Vlaams Infrastructuurfonds voor Persoonsgebonden 
Aangelegenheden (VIPA). Het team kent subsidies voor de animatiewerking toe aan de 
erkende rusthuizen. De ROB/RVT inspecties van de Vlaamse Gemeenschap omvatten 
de Inspectie Welzijn, Inspectie Volksgezondheid en Brandweerinspectie. 
Verder is er nog een “Gezamenlijk loket ROB, RVT en Inspectie en Toezicht” om de 
ROB-inspecties (Administratie Gezin en Maatschappelijk Welzijn) en RVT-inspecties 
(Administratie Gezondheidszorg) zoveel mogelijk te coördineren en om de ROB- en de 
RVT-erkenning op dezelfde dag te inspecteren (weliswaar door twee inspecteurs 
behorend tot verschillende administraties). 
Op het niveau van de Franstalige Gemeenschap ligt de politieke verantwoordelijkheid 
over de rusthuizen bij de Ministre de la Santé, de l’Action sociale et de l’Egalité des 
Chances. 
De administratieve overheidsdienst die betrokken is bij het rusthuisbeleid is de 
“Direction Générale de l’Action sociale et de la Santé” en meer specifiek de “Division 
du Troisième âge et de la Famille”.  Onder deze “Division” ressorteert de “Direction 
du Troisième âge”. 
Het Decreet van 5 juni 1997 en de uitvoeringsbesluiten van 3 december 1998 vormen 
samen met het Koninklijk Besluit van 21 september 2004 (B.S. 28/10/2004) betreffende 
de vaststelling van de normen voor de bijzondere erkenning als rust- en 
verzorgingstehuis of als centrum voor dagverzorging, de voornaamste wettelijke basis 
voor de uitvoering van de competenties van deze diensten. Deze diensten hebben, 
binnen het kader van de programmatie vastgelegd door de Waalse regering, de 
bevoegdheid om ROB/RVT en CDV te erkennen. Verder behoren ook de  normering, 
de inspecties en de behandeling van klachten tot hun takenpakket. Niet naleving van de 
normen kan, na advies van de betrokken administratie, leiden tot de beslissing van de 
bevoegde minister om de erkenning op te schorten, te weigeren of om de erkenning in 
te trekken.  
Ook de Duitstalige Gemeenschap heeft bevoegdheden, met name de Minister für 
Ausbildung un Beschäftigung, Soziales und Turismus als politieke overheid en de 
“Abteilung Familie, Gesundheid und Soziales” van het “Ministerium der DG” als 
administratieve overheid. 
Wat betreft de Nederlandstalige burgers in het Brusselse Gewest is de Vlaamse 
Gemeenschapscommissie bevoegd, de Franstalige burgers in het Brussels Gewest vallen 
onder de bevoegdheid van de Franse Gemeenschapscommissie. 
RAPPORTERING VAN ROB/RVT AAN DIVERSE BELEIDSINSTANTIES 
FOD Volksgezondheid, Veiligheid van de Voedselketen en Leefmilieu  
Wat betreft de jaarlijkse statistische RVT-enquête FOD Volksgezondheid, Veiligheid van 
de Voedselketen en Leefmilieu jaarlijkse dient vermeld te worden dat de cel 
“Chronische en ouderenzorg” een nieuw formulier voor de statistische RVT-enquête 
voorbereidt. Aangezien dit project echter nog niet afgerond is, meldt de FOD 
Volksgezondheid, Veiligheid van de Voedselketen en Leefmilieu in een omzendbrief aan 
de directies van de rust- en verzorgingstehuizen dat de statistische RVT-gegevens 2004 
niet verzameld zullen worden. 
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FOD Sociale Zekerheid (RIZIV, OISZ) 
De ROB en RVT dienen per trimester een aantal gegevens mee te delen aan het RIZIV 
teneinde de Dienst Verzorgingsinstellingen in staat te stellen de tegemoetkoming te 
berekenen voor volgende domeinen :  
x Instellingsforfait ROB-RVT en CDV  
x Financiering maatregelen "eindeloopbaan"  
x Financiering maatregelen loonharmonisering voor bovennormpersoneel 
("derde luik").  
De vereiste gegevens kunnen ingedeeld worden in drie grote categorieën:  
x Inrichting (Informatie over de inrichting/dienst) 
x Personeel (Informatie m.b.t. de contracten van de personeelsleden, en 
het aantal gepresteerde uren/dagen per trimester) 
x Dagen (Aantal gefactureerde dagen voor rechthebbenden en andere 
patiënten) 
Een aantal van deze gegevens (bv. m.b.t. de inrichting) worden reeds vooraf ingevuld 
door het RIZIV en dienen door de instelling slechts gecontroleerd en eventueel 
aangevuld of gecorrigeerd te worden. 
Gegevens met betrekking tot de inrichting/dienst 
x Benaming en Riziv-nummer 
x Gemiddelde wekelijkse arbeidsduur voor voltijdse prestaties (het aantal 
uren per week dat er door een voltijds equivalent moet gepresteerd 
worden in de inrichting) 
x Gemeenschap / Gewest 
x Sector : OCMW, Privaat VZW of Privaat commercieel 
x Coördinerend geneesheer (enkel voor inrichtingen met RVT) : ja/neen 
x Palliatieve functie (enkel voor een aantal ROB en RVT) : ja/neen 
Personeel 
Het gaat hier om de gegevens m.b.t. de rustoordfinanciering, de financiering “derde 
luik” (kostprijs harmonisering loonbarema’s in de ROB-RVT-CDV) en de financiering 
van de eindeloopbaan. Onder personeelsleden wordt bedoeld : al het loontrekkend 
personeel, het statutair personeel in de openbare inrichtingen/diensten, het interim-
personeel, de zelfstandige verantwoordelijke van een inrichting/dienst en de zelfstandige 
verpleegkundigen en/of paramedici. 
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Persoonsgegevens 
Per personeelslid worden o.a. volgende gegevens gevraagd (of dienen gecontroleerd te 
worden) : 
Kwalificatie : keuze maken uit 
x Verpleegkundige A1 
x Verpleegkundige A2 
x Verpleegassistent(e) 
x Verzorgingspersoneel 
x Kinesitherapeut 
x Ergotherapeut 
x Logopedist 
x Personeel voor reactivering (A1 – zie lijst in financieringsbesluit ROB-
RVT-CDV van 6 november 2003 ) 
x Andere : A1 + universitair 
x Andere : A2 (logistiek en administratief) 
x Andere met een barema lager dan A2. 
Type contract : keuze maken uit 
x Loontrekkende (inclusief statutairen in een openbaar bestuur) 
x Interim-contract 
x Zelfstandige met een ondernemingscontract 
x Loontrekkend of statutair verantwoordelijke van de inrichting/dienst 
x Zelfstandig beheerder 
x Loontrekkende Sociale Maribel 
x Vervanger opleidingsproject “400” verpleegkundigen. 
Prestatiegegevens 
x Uren : het aantal uren/week zoals dat blijkt uit het contract. 
x Gegevens over gepresteerd aantal dagen/uren per trimester (Hier 
wordt een onderscheid gemaakt tussen de voltijdsen en degenen die 
deeltijds werken : bij de voltijdsen wordt enkel het aantal gepresteerde 
dagen opgevraagd en voor de deeltijdsen wordt enkel het aantal 
gepresteerde uren opgevraagd in dat trimester) 
x Gegevens eindeloopbaan en vrijstelling van arbeidsprestaties 
Aangifte van het aantal gefactureerde dagen per trimester/ Per type inrichting (ROB of 
RVT) : 
x het aantal gefactureerde dagen per categorie van afhankelijkheid, 
opgesplitst in aantal dagen rechthebbenden en aantal dagen niet-
rechthebbenden.  
FOD Economie, KMO, Middenstand en Energie 
Rusthuizen kunnen niet vrij de dagprijs bepalen die zij wensen aan te rekenen. Het 
rusthuis moet een dossier voor prijsverhogingaanvraag indienen bij de FOD Economie, 
KMO, Middenstand en Energie (ministerie van economische zaken) die hierover zijn 
akkoord moet geven. Dit aanvraagdossier dient o.a. een becijferde verantwoording van 
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de gevraagde verhoging en de evolutie van de kostprijselementen te bevatten. De 
bevoegde administratie (Algemene Inspectie van de Prijzen en de Mededinging) kan 
eventueel bijkomende informatie in winnen bij de instelling en kan sommige elementen 
in een prijzendossier weigeren waardoor de prijsverhoging slechts gedeeltelijk wordt 
aanvaard. 
Bovendien bestaat er sinds 2003 een nota die een lijst van elementen bevat die hetzij in 
de dagprijs, hetzij als supplement of als voorschot ten gunste van derden kunnen 
worden aangerekend. De lijst van elementen die in de dagprijs moet aanwezig zijn is een 
basisminimum. Dit betekent dat iedere instelling kan beslissen om meer elementen op 
te nemen in de dagprijs en eventueel een all-inprijs aan te rekenen.  
Vlaamse overheid 
De procedures en normen voor erkenning en verlenging van erkenning ROB/RVT 
worden voornamelijk gespecificeerd in volgende besluiten : 
x Besluit van de Vlaamse regering van 17 juli 1985 (B.S. 30/08/1985) tot 
vaststelling van de normen waaraan een serviceflatgebouw, een 
woningcomplex met dienstverlening of een rusthuis moet voldoen om 
voor erkenning in aanmerking te komen. 
x Besluit van de Vlaamse regering van 18 februari 1997 (B.S. 17/05/1997) 
tot vaststelling van de procedure voor de erkenning en de sluiting van 
rust- en verzorgingstehuizen, psychiatrische verzorgingstehuizen, 
initiatieven van beschut wonen en samenwerkingsverbanden van 
psychiatrische instellingen en diensten. 
x Koninklijk besluit van 21 september 2004 (B.S. 28/10/2004) houdende 
vaststelling van de normen voor de bijzondere erkenning als rust- en 
verzorgingstehuis of als centrum voor dagverzorging  
Verder zijn ook nog de norminterpretaties van belang. De administratie streeft een 
gelijke beoordeling in alle dossiers na. Hiertoe dienen de voorzieningen te worden 
gecontroleerd aan de hand van een eenvormige norminterpretatie die toelaat om 
rechtsonzekerheid te vermijden omwille van het feit dat de erkenningsnormen niet 
steeds even duidelijk zijn. 
Een aanvraag tot (voorlopige) erkenning of verlenging van erkenning dient, op straffe 
van onontvankelijkheid, vergezeld te zijn van een aantal documenten en gegevens, zoals 
gestipuleerd in bovenstaande besluiten.  Een voorlopige erkenning (eerste aanvraag) 
geldt voor een termijn van één jaar en kan op gemotiveerd verzoek van de inrichtende 
macht eenmaal met maximaal één jaar verlengd worden. De beslissing tot erkenning 
vermeldt het aantal bedden of plaatsen waarvoor de erkenning toegekend wordt. De 
erkenning wordt verleend voor een termijn van ten hoogste zes jaar en kan worden 
verlengd.  Elke wijziging die zich in de loop van de erkenningstermijn voordoet omtrent 
de gegevens opgenomen in de documenten die bij de aanvraag vergezeld werden, dient 
onverwijld te worden meegedeeld aan de administratie.  Wat betreft evenwel de 
wijzigingen in de personeelsgegevens van de voorziening, volstaat een jaarlijkse opgave 
binnen drie maanden na verstrijken van het kalenderjaar. 
Op deze manier beschikt de Vlaamse overheid over een aanzienlijk aantal gegevens 
betreffende ROB/RVT. Bovendien dienen nog een aantal documenten, vergunningen, 
overeenkomsten en verslagen in de instelling ter beschikking van de inspectie gehouden 
te worden. De voor dit onderzoek relevante categorieën van de zaken die bevraagd 
worden, worden hieronder gerapporteerd.   
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I. IDENTIFICATIE VAN DE VOORZIENING EN DE VERANTWOORDELIJKE 
(BEHEERSINSTANTIE) 
II. ERKENNINGSTOESTAND  
III. ORGANISATIE VAN DE VOORZIENING  
x Coördinerend en raadgevend arts  
IV. AANBOD EN BEWONERSPROFIEL  
x Bewonersprofiel  
x Evolutie van de gemiddelde bezettingsgraad en verblijfsduur (2001, 2002, 2003 en 2004) 
x Dagprijzen 
V. NALEVING VAN DE ERKENNINGSNORMEN  
(BESLUIT VLAAMSE REGERING 17/07/1985 en K.B. 21/09/2004)   
x Algemene normen 
x Architectonische normen  
x Functionele normen  
x Organisatorische normen 
o Medicatie  
o Doelgroepen  
 Dementerende bewoners:  
 Zijn in de voorziening andere doelgroepen aanwezig?  
o Personeelskader  
Verder dienen een aantal documenten ter beschikking van de Inspectie te 
worden gehouden in de voorziening (het inspectiebezoek met het oog op het 
onderzoek van deze aanvraag tot verlenging van erkenning wordt vooraf aangekondigd). 
Kopie: 
x Score zorgafhankelijkheid van de bewoners d.d. inspectiebezoek, 
opgesplitst per ROB – RVT statuut, met vermelding van aantal 
dementerende bewoners, aantal bewoners jonger dan 60 jaar, aantal 
bewoners in erkend kortverblijf en aantal gehospitaliseerde bewoners. 
x Nominatieve personeelslijst van alle medewerkers d.d. inspectiebezoek, 
met eenduidige vermelding van jobtime en kwalificatie per 
personeelslid, geordend per functie, en met aanduiding van de 
personen die langdurig afwezig zijn, in tweevoud. 
Ter inzage: 
x Personeelsregisters en individuele personeelsdossiers: diploma of 
getuigschrift, arbeidsovereenkomst of raadsbesluit, bewijs goed zedelijk 
gedrag. 
x Overeenkomst met de coördinerend en raadgevend arts. 
x Geneesmiddelenformularium. 
x Het kwaliteitshandboek  
x Het kwaliteitsplan 
Behalve de vragenlijst die moet ingevuld worden bij aanvraag tot (voorlopige) erkenning 
of verlenging van erkenning en de hierop volgende inspecties (cfr. supra), dienen 
rusthuizen ook rekening te houden met periodieke inspecties.  Na het invoeren van de 
kwaliteitsdecreten zijn aan de erkenningsnormen ook nog Sectorspecifieke Minimale 
Kwaliteitseisen (SMK’s) toegevoegd die eveneens periodiek gecontroleerd worden.  
Deze inspecties gebeuren (gemiddeld) om de zes maanden (eventueel frequenter, bij 
voorbeeld naar aanleiding van een klacht) en hebben als eerste opdracht het 
inspecteren van de erkennings- en kwaliteitsnormen (SMK’s). 
Een eerste versie van het inspectierapport wordt steeds voorgelegd aan het betrokken 
rusthuis (met mogelijkheid tot reactie). Daarna wordt een definitief verslag opgemaakt 
voor de afdelingen die bevoegd zijn voor de erkenningen (eveneens met kopie aan het 
rusthuis). De inspectie stelt vast of de instelling de opgelegde normen al dan niet 
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respecteert, maar is niet bevoegd voor de erkenning. De bevoegdheid van de afdeling 
inspectie en toezicht eindigt bij het overmaken van het inspectierapport aan de afdeling 
welzijnszorg die de verdere procedure (bv. erkenning,  sanctionering) autonoom 
afwerkt. 
Verder dienen rusthuizen ook te voldoen aan normen betreffende de boekhouding, de 
minimumindeling van het rekeningenstelsel en de jaarrekening. Deze normen zijn 
recentelijk gewijzigd (januari 2006).   
Waalse overheid 
De programmering, erkenningsnormen, klachtenprocedures boekhoudnormen, 
minimumindeling van het rekeningenstelsel en de jaarrekening worden gedetailleerd 
vastgelegd in onderstaande decreet en besluit. 
x Decreet van 5 Juni 1997. Décret relatif aux maisons de repos, 
résidences-services et aux centres d'accueil de jour pour personnes 
âgées et portant création du Conseil wallon du troisième âge. (B.S. 
26/06/1997). 
x Besluit van 3 december 1998. Arrêté du Gouvernement wallon portant 
exécution du décret du 5 juin 1997 relatif aux maisons de repos, 
résidences-services et aux centres d'accueil de jour pour personnes 
âgées et portant création du Conseil wallon du troisième âge (B.S. 
27/01/1999). 
GEGEVENS DIE VIA DE VI GERAPPORTEERD WORDEN (IMA) 
Het IMA (Intermutualistisch Agentschap) beschikt via de verzekeringsinstellingen (VI) 
over uitgebreide informatie op individueel niveau. Hieronder worden een aantal 
variabelen die relevant kunnen zijn voor het onderzoeksproject gerapporteerd. 
Gegevens populatie (IMA) 
x Nummer VI 
x Geboortejaar 
x Geslacht 
x NIS-code 
x KG1  
x KG2  
x Code gerechtigde of persoon ten laste (titularis, echtgeno(o)t(e) of 
samenwonende, descendent, ascendent) 
x Bijdragebetalend / kosteloos (persoon ten laste, betaalt geen 
persoonlijke bijdrage, betaalt persoonlijke bijdrage, niet van toepassing) 
x Aard en bedrag inkomens (n.v.t., persoon in het genot van 
bestaansminimum of gelijkwaardig voordeel, persoon met een inkomen 
< of = 12 maal het bestaansminimum voor gezinshoofden, personen die 
een volledige bijdrage betalen, personen met een jaarlijks belastbaar 
bruto-gezinsinkomen < 1.000.000 BEF, personen met inkomen < 
grensbedrag voor WIGW) 
x Forfait B verpleegkundige zorgen (ja/neen) 
x Forfait C verpleegkundige zorgen (ja/neen) 
x Kinesitherapie E of fysiotherapie (ja/neen) 
x Toelage voor de integratie van gehandicapten, cat. III of IV (ja/neen) 
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x Toelage voor hulp aan ouderen, cat. III, IV of V (ja/neen) 
x Uitkering hulp aan derden (ja/neen) 
x Uitkering voor primaire arbeidsongeschiktheid of invaliditeitsuitkering 
(ja/neen) 
x Forfaitaire uitkering hulp aan derden (ja/neen) 
x Recht MAF gezin (sociale MAF, inkomensMAF, fiscale MAF) 
x Categorie MAF gezin (verhoogde tegemoetkoming, tegemoetkoming 
voor gehandicapten, laag inkomen, bescheiden inkomen, fiscaal) 
x Recht MAF individu (geen individueel recht, verhoogde 
tegemoetkoming, tegemoetkoming voor gehandicapten, verhoogde 
kinderbijslag) 
x Terugbetaling en plafond gezin (geen terugbetaling, terugbetaling op 
basis van plafond 450, terugbetaling op basis van plafond 650) 
x Terugbetaling en plafond individu (geen terugbetaling, kind min 16 jaar 
– plafond 650, kind verhoogde kinderbijslag – plafond 450) 
x Datum recht MAF 
x Recht op een gewaarborgd inkomen, inkomensgarantie voor ouderen 
of op het leefloon (ja/neen) 
x Recht op toelage van gehandicapten (ja/neen) 
x Recht op hulp van OCMW (ja/neen) 
Factureringsgegevens gezondheidszorg en Farmanet (VI’s) 
De factureringsgegevens gezondheidszorg en Farmanet zijn beschikbaar op het niveau 
van respectievelijk de nomenclatuurcode (van de geneeskundige verstrekkingen) en de 
productcode (product en verpakking). Hier kan een onderscheid gemaakt worden 
tussen ZIV-terugbetalingen en remgelden en/of supplementen op de betreffende codes.  
Tevens is ook de prestatiedatum van een medische verstrekking en de afleveringsdatum 
van een geneesmiddel gekend. Wat betreft de Farmanet-gegevens dient er echter 
voorbehoud gemaakt te worden daar niet alle aankopen van geneesmiddelen door dit 
systeem geregistreerd worden (b.v. producten aangeleverd door ziekenhuisofficina’s en 
zogenaamde OTC-producten).  Onderzoek dat enkel gebaseerd is op de Farmanet-
gegevens zal dus het werkelijke verbruik en de werkelijke kosten voor de bewoners 
onderschatten. 
Dankzij onderstaande forfaits is het voor IMA mogelijk om uit de populatiegegevens de 
rusthuisbewoners te selecteren. 
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RVT-ROB-dagcentra 
 RVT 
  Forfait B5 
  RVT Kat. C 
  RVT Kat. Cd 
  RVT forfait B4 
  RVT palliatieve / RVT forfait arts 
 ROB 
  KAT O 
  KAT A 
  KAT B 
  KAT C 
  ROB (niet erkend) 
  ROB KAT C 
  ROB palliatief 
 Dagcentra : tegemoetkoming in de centra voor dagverzorging 
BESLUIT  
Uit dit overzicht blijkt dat de rusthuizen onderworpen zijn aan een groot aantal 
politieke en administratieve overheden. De complexe Belgische staatsstructuur en meer 
specifiek de gedeelde federale en regionale bevoegdheden betreffende de rusthuissector 
en hun bewoners geeft aanleiding tot zowel een duplicatie als tot een versnippering van 
verplichte rapporteringen aan de diverse overheden. 
In het kader van de administratieve vereenvoudiging zijn er wel reeds een aantal aan te 
moedigen initiatieven genomen om nodeloze dubbele bevragingen of inspecties te 
vermijden.  Zo is op federaal niveau de jaarlijkse statistische RVT-enquête van de FOD 
Volksgezondheid, Veiligheid van de Voedselketen en Leefmilieu opgeschort omdat een 
groot aantal van de zaken die bevraagd werden in deze enquête reeds gekend zijn door 
bv. RIZIV, de Gemeenschappen en Gewesten of de FOD Economie, KMO, Middenstand 
en Energie. De nieuwe enquête (in voorbereiding) zal uitsluitend betrekking hebben op 
informatie die door geen andere instantie is ingezameld en zal meer gericht zijn op de 
organisatorische aspecten en het kwaliteitsbeleid van de instelling.  
Toch blijven er nog steeds aanzienlijke overlappingen bestaan en zijn een groot aantal 
(voor deze studie) relevante variabelen gekend door de diverse overheden, 
overheidsinstellingen en verzekeringsinstellingen.  Vooral wat betreft 
instellingskenmerken en personeelskenmerken lijken deze gegevens zeer volledig te zijn. 
In het kader van dit onderzoek dient vermeld te worden dat belangrijke gegevens op 
bewonersniveau (bv. gedetailleerde indicatie van de gezondheidstoestand van de 
bewoners en geneesmiddelenconsumptie die niet door Farmanet gecapteerd wordt) en 
informatie betreffende het geneesmiddelendistributieproces en de kwaliteitsbewaking 
ervan onmogelijk uit bestaande gegevensbronnen verzameld of afgeleid kunnen worden. 
Deze lacunes maken een uitgebreid veldonderzoek onvermijdelijk om de 
onderzoeksvragen op een adequate en wetenschappelijk verantwoorde wijze te kunnen 
beantwoorden. 
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BIJLAGE BIJ APPENDIX 2 
Jaarlijkse statistische RVT-enquête FOD Volksgezondheid, Veiligheid van de Voedselketen en 
Leefmilieu 
De hieronder gerapporteerde inhoud van deze RVT-enquête heeft betrekking op de 
enquêtes zoals die in het verleden werden gebruikt om de rusthuizen te bevragen en is 
niet langer actueel. De opsomming is gelimiteerd tot gegevens die relevant kunnen zijn 
voor het onderzoeksproject. 
1. Identificatie van de instelling 
x RIZIV-nummer 
x Juridisch statuut 
x Naam instelling 
x Postcode en gemeente 
x Naam inrichtende macht 
x Postcode en gemeente 
2. Kenmerken m.b.t. architectonische en financiële gegevens 
x Lokalisatie van de RVT-bedden (apart/in rusthuis/in ziekenhuis) 
x Afzonderlijke eenheid 
x Aantal bedden RVT  
x Aantal bedden rusthuis 
x Aantal bedden ziekenhuis 
x Dagverzorging : capaciteit, aantal gebruikers en aantal verblijfsdagen 
x Kort verblijf : capaciteit, aantal gebruikers en aantal verblijfsdagen 
x Supplementen 
o All-in 
o Indien neen, welke zijn de supplementen?  
 Incontinentiemateriaal 
 Linnen 
 Geneesmiddelen 
 Dr. Honoraria 
 Kapper 
 Pedicure 
 Andere 
3. Gegevens m.b.t. organisatie en werking 
x Aantal toeleverende apotheken : privé / ziekenhuis / beiden 
x Aantal artsen aangewezen door de inrichtende macht 
x Aantal bezoekende huisartsen 
x Vrijwilligers (ja/neen, aantal uren) 
4. Kenmerken m.b.t. het verplegend, verzorgend en paramedisch personeel 
x Aantal hoofdverpleegkundigen per diploma (gegradueerde vpk. +, gegradueerde vpk., 
gebrevetteerde vpk., zh. assistenten) 
x Aantal FTE hoofdverpleegkundigen per diploma (gegradueerde vpk. +, gegradueerde 
vpk., gebrevetteerde vpk., zh. assistenten) 
x Aantal verpleegkundigen (gegradueerde vpk. +, gegradueerde vpk., gebrevetteerde vpk., 
zh. assistenten) 
x Aantal FTE verpleegkundigen (gegradueerde vpk. +, gegradueerde vpk., gebrevetteerde 
vpk., zh. assistenten) 
x Aantal  verzorgend personeel 
x Aantal FTE verzorgend personeel 
x Aantal kinesisten 
x Aantal FTE kinesisten 
x Aantal ergotherapeuten 
x Aantal FTE ergotherapeuten  
x Aantal logopedisten 
x Aantal FTE logopedisten 
x Aantal sociaal personeel  
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x Aantal FTE sociaal personeel  
x Aantal stagiairs werkzaam in het RVT  
o Stagiairs-verpleegkundigen 
o Stagiairs-verzorgend personeel 
o Stagiairs-kine. en param. Personeel 
x Aantal personeelsleden per nacht (+ kwalificatie en bestemd voor?) 
5. Gegevens m.b.t. de bewoners 
x Aantal RVT-bewoners op 31/12 per leeftijdsklasse (-50 jaar; 50 t.e.m. 60 jaar; 61 t.e.m. 
70 jaar; 71 t.e.m. 80 jaar; 81 t.e.m. 90 jaar; 91 t.e.m. 100 jaar; +100 jaar) en geslacht 
x Gemiddelde leeftijd van de bewoners per geslacht 
x Aantal bewoners per zorgbehoeftencategorie (B, C, Cd), opgesplitst per geslacht 
x Aantal opnames 
x Herkomst bij opname (aantallen) 
o Thuis 
o Rusthuis 
o Ander RVT 
o Ziekenhuis 
o Ergens anders 
o Onbekend 
x Totaal aantal definitieve ontslagen 
x Bestemming na ontslag (aantallen) 
o Naar huis 
o Naar rusthuis 
o Ander rvt 
o Naar ziekenhuis 
o Andere bestemming 
o Onbekend 
o Overleden 
x Aantal bewoners tijdelijk opgenomen in het ziekenhuis 
x Bezettingsgraad 
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APPENDIX 3: SELECTIE RESIDENTEN IN ROB/RVT  
De gegevens zijn afkomstig uit drie bestanden voor het jaar 2004: de populatiegegevens 
(kenmerken van de residenten), Farmanet (ambulante geneesmiddelen) en 
factureringsgegevens, door het IMA aan het RIZIV/INAMI ter beschikking gesteld.  
De drie bestanden kunnen met elkaar gekoppeld worden aan de hand van een 
identificatienummer van de patiënt. De residenten in een ROB/RVT werden 
geselecteerd door de selectie van alle personen met gepresteerde uitgaven in 2004 
voor pseudocodes die verwijzen naar een ROB- of RVT-forfait (zie tabel 1).  
Tabel 1 : Selectie pseudocodes 
Categorie Pseudocodes 
ROB O 763195, 763291 
ROB A 763210, 763313 
ROB B 763232, 763335 
ROB C 763254, 763350 
ROB Cd 763276, 763372 
RVT B 763033, 763114 
RVT C 763055, 763136 
RVT Cd 763070, 763151 
RVT Cc 763092, 763173 
Niet erkend 741411 
 
Vervolgens heeft het RIZIV/INAMI de individuele gegevens geaggregeerd tot op het 
niveau van de instellingen (ROB, ROB/RVT, RVT) en aan het KCE overgemaakt. Indien 
een patiënt in de loop van 2004 in meerdere instellingen verbleef, werd zij toegewezen 
aan de instelling met de hoogste uitgaven voor de codes in tabel1.  
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APPENDIX 4: NATIONAL DATA ON 
PHARMACEUTICAL CONSUMPTION OF NURSING 
HOME RESIDENTS (FARMANET) 
All tables in Appendix 4 are based on Farmanet (made available by IMA and 
RIZIV/INAMI).  
Table A4.1 : Top 100 of drugs used in Belgian rest and nursing facilities, 
based on calculated DDDs. 
 
ATC Non-proprietary name DDD 
Health insurance 
cost (€) 
Out-of-pocket 
(€) 
1 C01DX12 MOLSIDOMINE 10346605 3666181 843581 
2 A02BC01 OMEPRAZOL 6580042 4061590 908280 
3 C03CA01 FUROSEMIDE 5349921 580875 264653 
4 C01DA02 NITROGLYCERINE 5229171 2196152 514432 
5 C08CA01 AMLODIPINE 4701052 2285735 531982 
6 N06AB04 CITALOPRAM 3980098 2759236 1055847 
7 C09AA03 LISINOPRIL 3598074 732684 224749 
8 A02BA02 RANITIDINE 2928329 1465731 351167 
9 R05CB01 ACETYLCYSTEINE 2769150 328826 395995 
10 C03CA02 BUMETANIDE 2613340 314634 72914 
11 C03DA01 SPIRONOLACTON 2323722 857438 342685 
12 N06AB06 SERTRALINE 2219502 2151098 524880 
13 C03EA04 ALTIZIDE MET KALIUMSPARENDE MIDDELEN 2043440 343836 81065 
14 N06AB10 ESCITALOPRAM 1964088 1790218 440918 
15 H02AB04 METHYLPREDNISOLON 1904333 761748 73407 
16 N04BA02 LEVODOPA MET DECARBOXYLASEREMMER 1852161 1428546 351597 
17 B01AB06 NADROPARINE 1847711 3787019 713780 
18 B01AB05 ENOXAPARINE 1797405 3456816 689716 
19 C07AB07 BISOPROLOL 1768479 560757 196219 
20 N06AB05 PAROXETINE 1761320 1704212 403382 
21 C09AA04 PERINDOPRIL 1756380 1167768 281763 
22 H03AA01 LEVOTHYROXINE 1746660 150487 36770 
23 C10AA01 SIMVASTATINE 1693369 672099 119986 
24 C01AA05 DIGOXINE 1629942 70848 16625 
25 C01BD01 AMIODARON 1547272 267663 157457 
26 N07CA01 BETAHISTINE 1498568 86081 332545 
27 B01AC04 CLOPIDOGREL 1472968 2659393 429987 
28 R06AE07 CETIRIZINE 1457730 206087 312783 
29 N06AX05 TRAZODON 1447740 713682 399436 
30 A10AD01 HUMANE INSULINE 1412069 1441603 0 
31 C10AA05 ATORVASTATINE 1295532 810532 105162 
32 M05BA04 ALENDRONINEZUUR 1290604 1375538 177645 
33 A10BA02 METFORMINE 1271712 240509 4000 
34 R03AK03 FENOTEROL MET ANDERE MIDD. VOOR 
OBSTRUCT. AANDOENINGEN VD 
LUCHTWEGEN 
1264972 1099821 257631 
35 N05AX08 RISPERIDON 1237929 3996850 676510 
36 N06AX16 VENLAFAXINE 1229508 1610023 365127 
37 C09AA05 RAMIPRIL 1177792 357036 85310 
38 N02AX02 TRAMADOL 1131576 1329777 678981 
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39 N05AH03 OLANZAPINE 1083985 4536708 471396 
40 C09AA01 CAPTOPRIL 1059526 352373 117484 
41 C07AB03 ATENOLOL 950345 218226 68450 
42 C08CA05 NIFEDIPINE 932259 452433 112572 
43 C03BA11 INDAPAMIDE 880760 123437 60707 
44 C07AA07 SOTALOL 811725 107948 62054 
45 R03AK06 SALMETEROL MET ANDERE MIDD. VOOR 
OBSTRUCT. AANDOENINGEN VD 
LUCHTWEGEN 
787350 1147941 176812 
46 G04BD04 OXYBUTYNINE 780008 51728 202123 
47 N06AX11 MIRTAZAPINE 779190 789534 193807 
48 J01CR02 AMOXICILLINE MET ENZYMREMMER 772107 838175 210319 
49 N06AB03 FLUOXETINE 758412 458481 120435 
50 M04AA01 ALLOPURINOL 750468 145508 35045 
51 C08DB01 DILTIAZEM 742564 386029 105187 
52 A10BB08 GLIQUIDON 741390 265833 0 
53 N06DA02 DONEPEZIL 735668 1974384 188440 
54 A10BB09 GLICLAZIDE 720845 306335 36187 
55 R03BB01 IPRATROPIUM BROMIDE 711103 299289 71447 
56 C09AA02 ENALAPRIL 708509 136713 36094 
57 C09CA01 LOSARTAN 682738 459770 92126 
58 C03EA01 HYDROCHLOORTHIAZIDE MET 
KALIUMSPARENDE MIDDELEN 
640496 71601 29193 
59 A02BC04 RABEPRAZOL 639758 1057575 252317 
60 R06AE09 LEVOCETIRIZINE 634880 140884 173327 
61 N02AB03 FENTANYL 617783 2562695 356400 
62 C02AC05 MOXONIDINE 599560 320281 76998 
63 N03AG01 VALPROINEZUUR 593766 935282 13 
64 C10AA03 PRAVASTATINE 549360 434908 42754 
65 R03DA04 THEOFYLLINE 532320 63994 14838 
66 C09CA04 IRBESARTAN 519372 285826 50663 
67 C09CA03 VALSARTAN 516852 241127 41911 
68 C07AB02 METOPROLOL 497601 177355 45283 
69 N05AD01 HALOPERIDOL 480025 254516 55831 
70 N05AX07 PROTHIPENDYL 479071 135622 32808 
71 C01AA08 METILDIGOXINE 457900 37008 8708 
72 C10AB05 FENOFIBRAAT 454636 99867 33275 
73 A02BC02 PANTOPRAZOL 454230 742088 132554 
74 J01XE02 NIFURTOINOL 449156 119077 27724 
75 M01AC01 PIROXICAM 436033 183079 111734 
76 N03AB02 FENYTOINE 435536 62787 0 
77 C09AA06 QUINAPRIL 419614 189239 38305 
78 C07AG02 CARVEDILOL 416426 335100 89253 
79 C08CA02 FELODIPINE 406920 114090 40747 
80 H03BB02 THIAMAZOL 395300 18965 4403 
81 C09CA06 CANDESARTAN 393008 148048 30715 
82 S01AA13 FUSIDINEZUUR 388938 27851 6564 
83 G03CA04 ESTRIOL 381090 76717 18415 
84 C03BA04 CHLOORTALIDON 378660 11692 2802 
85 B01AA07 ACENOCOUMAROL 363124 38516 9667 
86 A10BB12 GLIMEPIRIDE 352365 124384 0 
87 N06AA09 AMITRIPTYLINE 340114 79913 18797 
88 A03AB06 OTILONIUM BROMIDE 340030 48996 159349 
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89 C01BC03 PROPAFENON 336125 162538 39589 
90 S01ED01 TIMOLOL 335925 63388 16386 
91 N06DA04 GALANTAMINE 330533 883197 85737 
92 L02BA01 TAMOXIFEN 328279 236530 10 
93 J01DC02 CEFUROXIM 324234 481653 113855 
94 R03BA05 FLUTICASON 317018 241368 52077 
95 S01ED02 BETAXOLOL 313550 87414 21467 
96 M01AC06 MELOXICAM 312225 184420 43726 
97 A10BX02 REPAGLINIDE 303435 241582 0 
98 A10AC01 HUMANE INSULINE 302763 315796 0 
99 N03AF01 CARBAMAZEPINE 299190 139548 54382 
100 C07BB07 BISOPROLOL MET THIAZIDEN 285332 82754 31170 
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Table A4.2 : Overview of the drugs prescribed in the ATC1 class of 
cardiovascular drugs.  A lower boundary of 400,000 DDDs was used.  For 
several drug classes, further details of the molecules used are provided.  A 
cut-off of 10% of the market share based on DDD is used.  
 
ATC Class or non-proprietary name DDD 
Health 
insurance 
cost (€) 
Out-of-
pocket 
(€) 
% within 
drug 
class 
C01DX 
OVERIGE VASODILATANTIA BIJ 
HARTZIEKTEN 10346605 3666181 843581  
C01DX12 MOLSIDOMINE 10346605 3666181 843581  
C09AA ACE-REMMERS, ENKELVOUDIG 8889274 3027213 805993  
C09AA03 LISINOPRIL 3598074 732684 224749 40 
C09AA04 PERINDOPRIL 1756380 1167768 281763 20 
C09AA05 RAMIPRIL 1177792 357036 85310 13 
C09AA01 CAPTOPRIL 1059526 352373 117484 12 
C03CA SULFONAMIDEN 8015551 950378 350108  
C03CA01 FUROSEMIDE 5349921 580875 264653 67 
C03CA02 BUMETANIDE 2613340 314634 72914 33 
C08CA DIHYDROPYRIDINEDERIVATEN 6722495 3355252 805498  
C08CA01 AMLODIPINE 4701052 2285735 531982 70 
C08CA05 NIFEDIPINE 932259 452433 112572 14 
C01DA ORGANISCHE NITRATEN 5422761 2228674 522262  
C01DA02 NITROGLYCERINE 5229171 2196152 514432 96 
C10AA 
HMG-CoA REDUCTASEREMMERS 
(STATINES) 3710363 2014643 284464  
C10AA01 SIMVASTATINE 1693369 672099 119986 46 
C10AA05 ATORVASTATINE 1295532 810532 105162 35 
C10AA03 PRAVASTATINE 549360 434908 42754 15 
C07AB BETA-BLOKKERS, SELECTIEVE 3658144 1127417 367006  
C07AB07 BISOPROLOL 1768479 560757 196219 48 
C07AB03 ATENOLOL 950345 218226 68450 26 
C07AB02 METOPROLOL 497601 177355 45283 14 
C03EA 
"LOW-CEILING" DIURETICA MET K-
SPARENDE MIDDELEN 2723808 421850 111825  
C03EA04 ALTIZIDE MET KALIUMSPARENDE MIDDELEN 2043440 343836 81065 75 
C03EA01 
HYDROCHLOORTHIAZIDE MET 
KALIUMSPARENDE MIDDELEN 640496 71601 29193 24 
C09CA 
ANGIOTENSINE-II-ANTAGONISTEN, 
ENKELVOUDIG 2511320 1336613 252344  
C09CA01 LOSARTAN 682738 459770 92126 27 
C09CA04 IRBESARTAN 519372 285826 50663 21 
C09CA03 VALSARTAN 516852 241127 41911 21 
C09CA06 CANDESARTAN 393008 148048 30715 16 
C09CA07 TELMISARTAN 280532 129822 20800 11 
C03DA ALDOSTERONANTAGONISTEN 2375153 968687 369222  
C03DA01 SPIRONOLACTON 2323722 857438 342685  
C01AA DIGITALISGLYCOSIDEN 2171642 110224 25913  
C01AA05 DIGOXINE 1629942 70848 16625 75 
C01AA08 METILDIGOXINE 457900 37008 8708 21 
C01BD ANTI-ARITMICA (KLASSE III) 1547272 267663 157457  
C01BD01 AMIODARON 1547272 267663 157457  
C03BA SULFONAMIDEN 1259420 135129 63509  
C03BA11 INDAPAMIDE 880760 123437 60707 70 
C03BA04 CHLOORTALIDON 378660 11692 2802 30 
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C07AA BETA-BLOKKERS, NIET-SELECTIEVE 1097932 187939 83922  
C07AA07 SOTALOL 811725 107948 62054  
C07AA05 PROPRANOLOL 255874 71328 19731  
C02AC 
IMIDAZOLINE-
RECEPTORAGONISTEN 782500 372261 89348  
C02AC05 MOXONIDINE 599560 320281 76998 77 
C08DB BENZOTHIAZEPINEDERIVATEN 742564 386029 105187  
C10AB FIBRATEN 605596 159348 48078  
C01BC ANTI-ARITMICA (KLASSE IC) 502520 277378 99255  
C01BC03 PROPAFENON 336125 162538 39589 67 
C01BC04 FLECAINIDE 166395 114840 59666 33 
C09BA ACE-REMMERS MET DIURETICA 444780 260318 64135  
C07AG ALFA- EN BETA-BLOKKERS 421314 338724 90134  
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Table A4.3 : Overview of the drugs prescribed in the ATC1 class of drugs for 
the neural system.  A lower boundary of 400,000 DDDs was used.  For 
several drug classes, further details of the molecules used are provided.  A 
cut-off of 10% of the market share based on DDD was used. 
ATC Class or non-proprietary name DDD 
Health 
insurance 
cost (€) 
Out-of-
pocket 
(€) 
% within 
drug class 
N06AB 
SELECTIEVE SEROTONINE-
HEROPNAMEREMMERS 10747890 8904211 2561419  
N06AB04 CITALOPRAM 3980098 2759236 1055847 37 
N06AB06 SERTRALINE 2219502 2151098 524880 21 
N06AB10 ESCITALOPRAM 1964088 1790218 440918 18 
N06AB05 PAROXETINE 1761320 1704212 403382 16 
N06AX OVERIGE ANTIDEPRESSIVA 3698526 3284548 999764  
N06AX05 TRAZODON 1447740 713682 399436 39 
N06AX16 VENLAFAXINE 1229508 1610023 365127 33 
N06AX11 MIRTAZAPINE 779190 789534 193807 21 
N04BA DOPA EN –DERIVATEN 1858250 1455835 354903  
N05AX 
OVERIGE ANTIPSYCHOTICA 
(NEUROLEPTICA) 1833865 4166492 716872  
N05AX08 RISPERIDON 1237929 3996850 676510 68 
N05AX07 PROTHIPENDYL 479071 135622 32808 26 
N07CA ANTIVERTIGO PREPARATEN 1498568 86081 332545  
N07CA01 BETAHISTINE 1498568 86081 332545  
N02AX OVERIGE OPIOIDEN 1430572 1649141 793659  
N02AX02 TRAMADOL 1131576 1329777 678981 79 
N02AX01 TILIDINE 244404 269266 64598 17 
N05AH DIAZEPINEN, OXAZEPINEN EN THIAZEPINEN 1278495 5227852 532350  
N05AH03 OLANZAPINE 1083985 4536708 471396 85 
N05AH04 QUETIAPINE 158940 600943 40697 12 
N06DA CHOLINESTERASEREMMERS 1270223 3459896 346329  
N06DA02 DONEPEZIL 735668 1974384 188440 58 
N06DA04 GALANTAMINE 330533 883197 85737 26 
N06DA03 RIVASTIGMINE 204022 602315 72152 16 
N05AD BUTYROFENONDERIVATEN 933346 537184 120778  
N05AD01 HALOPERIDOL 480025 254516 55831 51 
N05AD05 PIPAMPERON 208712 90576 20649 22 
N05AD03 MELPERON 143149 140511 32957 15 
N06AA 
NIET-SELECTIEVE MONOAMINE-
HEROPNAMEREMMERS 690947 209213 49328  
N06AA09 AMITRIPTYLINE 340114 79913 18797 49 
N06AA16 DOSULEPINE 144720 57500 13538 21 
N06AA04 CLOMIPRAMINE 94406 40725 9761 14 
N02AB FENYLPIPERIDINEDERIVATEN 617984 2562995 356468  
N02AB03 FENTANYL 617783 2562695 356400  
N03AG VETZUURDERIVATEN 599757 955955 13  
N03AG01 VALPROINEZUUR 593766 935282 13  
N03AB HYDANTOINEDERIVATEN 463186 66836 0  
N03AB02 FENYTOINE 435536 62787 0  
N04AA TERTIAIRE AMINEN 425068 78731 17451  
N04AA08 DEXETIMIDE 229040 33646 7434 54 
N04AA04 PROCYCLIDINE 73380 16585 3709 17 
N04AA02 BIPERIDEEN 71628 17450 3933 17 
N04AA01 TRIHEXYFENIDYL 51020 11049 2375 12 
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Table A4.4 : Overview of the drugs prescribed in the ATC1 class of drugs for 
the gastrointestinal system.  A lower boundary of 50,000 DDDs was used.  
For several drug classes, further details of the molecules used are provided.  
A cut-off of 10% of the market share based on DDD was used. 
ATC Class or non-proprietary name DDD 
Health 
insurance 
cost (€) 
Out-of-
pocket 
(€) 
% within 
drug 
class 
A02BC INHIBITOREN VAN DE PROTONPOMP 8027236 6414726 1382747  
A02BC01 OMEPRAZOL 6580042 4061590 908280 82 
A02BC04 RABEPRAZOL 639758 1057575 252317 8 
A02BA H2-RECEPTORBLOKKERENDE MIDDELEN 2944330 1475664 353683  
A02BA02 RANITIDINE 2928329 1465731 351167  
A10BB SULFONYLUREUMDERIVATEN 2020750 782432 36187  
A10BB08 GLIQUIDON 741390 265833 0 37 
A10BB09 GLICLAZIDE 720845 306335 36187 36 
A10BB12 GLIMEPIRIDE 352365 124384 0 17 
A10AD 
MIDDELLANGWERKENDE MET SNELWERKENDE 
INSULINES 1426881 1457781 0  
A10BA BIGUANIDEN 1271712 240509 4000  
A10BA02 METFORMINE 1271712 240509 4000  
A03AB 
SYNTHETISCHE ANTICHOLINERGICA, 
KWATERNAIRE AMMONIUMVERBINDINGEN 363029 50840 165060  
A03AB06 OTILONIUM BROMIDE 340030 48996 159349  
A10BX OVERIGE ORALE HYPOGLYKEMIERENDE MIDDELEN 303435 241582 0  
A10BX02 REPAGLINIDE 303435 241582 0  
A10AC 
MIDDELLANGWERKENDE INSULINES EN 
ANALOGEN 302763 315796 0  
A10AB SNELWERKENDE INSULINES EN ANALOGEN 272775 284144 0  
A03AA 
SYNTHETISCHE PARASYMPATHICOLYTICA, ESTERS 
MET TERTIAIRE AMINOGROEP 269154 12926 50054  
A03AA04 MEBEVERINE 269154 12926 50054  
A07EC MESALAZINE EN VERWANTE VERBINDINGEN 179365 156631 39312  
A07EC02 MESALAZINE 131540 136336 34580  
A06AD OSMOTISCH WERKENDE LAXANTIA 63379 10404 2380  
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Table A4.5 : Overview of the drugs prescribed in the ATC1 class of drugs for 
the respiratory system.  A lower boundary of 50,000 DDDs was used.  For 
several drug classes, further details of the molecules used are provided.  A 
cut-off of 10% of the market share based on DDD was used. 
ATC Class or non-proprietary name DDD 
Health 
insurance 
cost (€) 
Out-of-
pocket 
(€) 
% within 
drug 
class 
R05CB MUCOLYTICA 2815731 419322 417250  
R05CB01 ACETYLCYSTEINE 2769150 328826 395995  
R03AK 
SYMPATHICOMIMETICA MET ANDERE MIDD. 
VOOR COPD 2504037 2966200 577482  
R03AK03 FENOTEROL + 1264972 1099821 257631 51 
R03AK06 SALMETEROL + 787350 1147941 176812 31 
R03AK04 SALBUTAMOL + 256835 383443 90131 10 
R03AK07 FORMOTEROL + 194880 334994 52908 8 
R06AE PIPERAZINEDERIVATEN 2092610 346972 486109  
R06AE07 CETIRIZINE 1457730 206087 312783 70 
R06AE09 LEVOCETIRIZINE 634880 140884 173327 30 
R03BB PARASYMPATHICOLYTICA 944108 611745 129195  
R03BB01 IPRATROPIUM BROMIDE 711103 299289 71447 75 
R03BB04 TIOTROPIUM BROMIDE 209700 305585 56175 22 
R06AX 
OVERIGE ANTIHISTAMINICA VOOR 
SYSTEMISCH GEBRUIK 652105 148996 173108  
R06AX13 LORATADINE 119896 17238 31008  
R03BA GLUCOCORTICOIDEN 635707 674015 156106  
R03BA05 FLUTICASON 317018 241368 52077 50 
R03BA02 BUDESONIDE 226502 360486 86769 36 
R03BA01 BECLOMETASON 92188 72161 17260 15 
R03DA XANTHINEDERIVATEN 532608 64031 14848  
R03DA04 THEOFYLLINE 532320 63994 14838  
R03AC SELECTIEVE BETA-2-SYMPATHICOMIMETICA 414670 279698 65631  
R03AC02 SALBUTAMOL 181985 56639 13354 44 
R03AC12 SALMETEROL 52680 49559 11308 13 
R03AC13 FORMOTEROL 179955 173495 40968 43 
      
R01AD CORTICOSTEROIDEN 266231 97912 23700  
R01AD08 FLUTICASON 112163 44086 10714 42 
R01AD09 MOMETASON 106505 41892 10148 40 
R01AD05 BUDESONIDE 33228 8036 1897 12 
R03DC LEUKOTRIEENRECEPTORANTAGONISTEN 170218 207544 48037  
R03DC03 MONTELUKAST 125642 158936 36732 74 
R03DC01 ZAFIRLUKAST 44576 48608 11305 26 
R03BC 
ANTI-ALLERGISCHE MIDDELEN, EXCL. 
CORTICOSTEROIDEN 57346 44117 25777  
R03BC01 CROMOGLICINEZUUR 57346 44117 25777  
R03CC SELECTIEVE BETA-2-SYMPATHICOMIMETICA 51887 17648 3939  
R03CC11 TULOBUTEROL 29170 8573 1922 56 
R03CC03 TERBUTALINE 15348 6436 1448 30 
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APPENDIX 5: GEOGRAPHICAL VARIATION OF 
PHARMACEUTICAL CONSUMPTION OF NURSING 
HOME RESIDENTS IN BELGIUM 
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APPENDIX 6: SEARCH STRATEGY OF THE 
LITERATURE REVIEW 
To limit the output to the appropriate setting of nursing homes, we developed the 
following profile: 
x Home for the elderly  
o  ("Homes for the Aged"[MESH] OR ("Nursing Homes"[MESH] 
AND ("Aged"[MESH] OR "Geriatrics"[MeSH]))) 
We constructed search profiles for each of the five following concepts: 
x Institutional characteristics  
o “Health Services Research” OR “Health Facility Size” OR “Health 
Manpower” OR “Nursing Staff” OR “Personnel Staffing and 
Scheduling” OR “Health Facilities, Proprietary” OR “Privacy” OR 
“Paternalism” OR “Patient Participation” OR “Population 
Dynamics”  
x Needs of residents 
o “Needs Assessment” OR “Nursing Assessment” OR “Geriatric 
Assessment” OR “Diagnosis-Related Groups” 
x Medication usage  
o “Drug Therapy” OR “Drug Utilization” OR “Economics, 
Pharmaceutical” OR “Drug Costs” OR  “Insurance, 
pharmaceutical services” OR “Community Pharmacy Services” 
OR “Pharmacy Services, Hospital” OR “Pharmacology, Clinical”  
OR “Drug Utilisation[Free text] 
x Medication Management Systems  
o “Pharmaceutical Services” OR “Drug Delivery Systems” OR 
“Community Pharmacy Services” OR “Medication Systems” OR 
“Medication Errors” OR   “Insurance, Pharmaceutical Services” 
OR “Pharmacy Services, Hospital” 
x Quality of care 
o “Quality Indicators, Health Care” OR “Quality Assurance, Health 
Care” OR “Total Quality Management” OR “Utilization Review” 
OR “Patient Care Management” OR “Management Quality 
Circles” OR “Patient care team” 
Each of the five concepts was then combined with the profile for the nursing homes. 
The same strategy was repeated (with adaptation of the keywords, when appropriate) 
in  
x International Pharmaceutical Abstracts (IPA) from Thomson 
Corporation 
x Embase (Elseviers Publishers) 
The databases were searched from 1995 to date. 
The recall of this search strategy (more than 2000 articles) was then screened on the 
basis of the abstract to select 200 relevant articles by two reviewers (Verrue M and 
Bauwens M), who discussed their selections among each other until consensus was 
reached. These articles were read in full text and a search of the cited references was 
carried out to identify other articles which might not have been detected by the search 
strategy. A selection of 40 publications, considered highly relevant by the two 
reviewers, was used as the starting point for a finishing search cycle using the Science 
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Citation Index (the Institute of Scientific Information) through Web of Science, and the 
“related articles” algorithm in PUBMED. The final selection of relevant publications 
(175) is listed in the reference list.  
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APPENDIX 7: INSTRUMENTS FOR THE 
ASSESSMENT OF FUNCTIONAL STATUS OF 
RESIDENTS AND QUALITY OF CARE IN NURSING 
HOMES 
RESOURCE UTILIZATION GROUPS VERSION III (RUG-III) 
RUG-III classifies a resident into one of 44 distinct groups. The system incorporates 
three dimensions in describing and grouping a resident.  
The first dimension is represented by seven major clinical categories. These categories 
are devised as a hierarchy with decreasing cost intensity:  
x special rehabilitation: residents receiving different degrees of physical, 
occupational, or speech therapy 
x extensive services: residents with respirator/ventilator care, parenteral 
feeding suctioning, or tracheostomy 
x special care: e.g. residents with burns, coma, multiple sclerosis, 
pressure ulcers stage 3 or 4, quadriplegia, septicaemia, IV medications, 
or tube feeding 
x clinically complex: e.g. residents with aphasia, cerebral palsy, 
dehydration, hemiplegia, pneumonia, static ulcer, terminal illness, 
urinary tract infection, dialysis, or four or more physician visits per 
month 
x impaired cognition: e.g. residents with impaired decision-making, 
orientation problems, short-term memory problems 
x behaviour problems: e.g. residents with physical abuse, verbal abuse, or 
wandering 
x reduced physical functions: residents who do not meet the conditions 
of earlier categories . 
The second dimension, used to subdivide the major categories, is based on an ADL 
(Activities of Daily Living) Index, a summary measure of functional capability in four 
ADLs: bed mobility, transfers, eating and toilet use.  
The ADL Index ranges from 4 to 18, the lowest value (4) indicating independence in all 
four ADLs, and the highest value total dependency in these same four ADLs.  
The third dimension forms tertiary splits in the classification and incorporates particular 
services; rehabilitation provided by nurses, or problems, presence of depression.  
Depression is used as tertiary splits in the “clinically complex'' category, and “nursing 
rehabilitation'' as tertiary splits in “impaired cognition'', “behaviour problems'' and 
“reduced physical functions''.  
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DUTCH CARE DEPENDENCY SCALE 
The CDS provides a framework for the care dependency status of institutionalized 
elderly people. The CDS measures 15 human needs. For example, the response 
alternatives of the item ‘eating and drinking’ are:  
x Resident is unable to take food and drink 
x Resident is unable to prepare food and drink unaided; resident is able 
to put food and drink into his/her mouth 
x Resident is able to prepare and put food and drink into his/her mouth 
unaided with supervision; has difficulty determining quantity 
x Resident is able to eat and drink unaided with some supervision 
x Resident is able to prepare meals and to satisfy his/her need for food 
and drink unaided 
The care dependency is assessed on a five-point Likertscale. Nurses rated all items by 
selecting one criterion out of the five criteria.  
A CDS sum-score can be computed by adding the item score of the 15 items. The 
theoretical range for the CDS sum-score will be from 15 to 75. Low scores on the scale 
items indicate that the patient is completely dependent on care; high scores indicate 
that the patient is almost independent of care. 
Care Dependency Scale items and item descriptions  
1. Eating/drinking  The extent to which the resident is able to satisfy his/her 
need for food and drink 
2. Incontinence  The extent to which the resident is able to control the 
discharge of urine and faeces voluntarily 
3. Body posture  The extent to which the resident is able to adopt a position 
appropriate to a certain activity 
4. Mobility  The extent to which the resident is able to move about 
unaided 
5. Day/night pattern  The extent to which the resident is able to maintain an 
appropriate day/night cycle unaided 
6. Getting (un)dressed  The extent to which the resident is able to get dressed and 
undressed unaided 
7. Body temperature  The extent to which the resident is able to protect his/her 
body temperature against external influences unaided 
8. Hygiene  The extent to which the resident is able to take care of 
his/her personal hygiene unaided 
9. Avoidance of danger  The extent to which the resident is able to assure his/her 
own safety unaided 
10. Communication  The extent to which the resident is able to communicate 
11. Contact with others  The extent to which the resident is able to appropriately 
make, maintain and end social contacts 
12. Sense of rules/values  The extent to which the resident is able to observe rules by 
him/herself 
13. Daily activities  The extent to which the resident is able to structure daily 
activities within the facility unaided 
14. Recreational activities  The extent to which the resident is able to participate in 
activities outside the facility unaided 
15. Learning ability  The extent to which the resident is able to acquire 
knowledge and/or skills and/or to retain that which was 
previously learned unaided 
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FUNCTIONAL AUTONOMY MEASUREMENT SYSTEM (PROVINCE OF 
QUEBEC, CANADA) 
The SMAF (Système de mesure de l’autonomie fonctionnelle) is a 29-item scale 
developed according to the WHO classification of disabilities. It measures functional 
ability in five areas: ADL (7 items), mobility (6 items), communication (3 items), mental 
functions (5 items) and IADL (8 items). Each item is scored on a 5-point scale for a 
maximum total score of 87. An increase in the score represents a decrease in functional 
ability. Its reliability and validity have been tested in several studies.  
The ISO-SMAF classification leads to the identification of 14 profiles based on the 
results on the 5 dimensions of the SMAF scale. These ISO-SMAF profiles can be 
grouped into four broad categories: IADL disabilities only, mobility problems 
predominant, mental problems predominant, severe and mixed disabilities.  
These ISO-SMAF profiles are associated with a specific amount of nursing and support 
services. They are also associated with costs of services according to the type of 
dwelling.  
The main objective of Tousignant M et al. (2003) was to apply the ISOSMAF 
classification to funding long-term care facilities. The second objective was to compare 
the results of this new funding methodology with the formal methods in use in the 
Province of Quebec. The results show that funding the facilities based on the severity of 
the disabilities of their residents in regard to functional autonomy highlights the under-
funding of a facility when compared to the usual funding methodology based on the 
number of beds and hours of care.  
Using the ISO-SMAF profiles, it is possible to establish a picture of the facility in terms 
of the case-mix of residents. From this picture, administrators, decisionmakers or 
admission regulation boards can compare the disability profile of the residents of a 
specific facility to the others, or the facility to the area. 
THE RESIDENT ASSESSMENT INSTRUMENT FOR NURSING HOMES 
(RAI) 
The Resident Assessment Instrument (RAI) is a method for comprehensive functional 
assessment of nursing home residents, with the object to guide the development of 
individualized care plans. It is of course an instrument for the assessment of the 
functional status of individual residents but is also an instrument to assess the nature 
and quality of all the relevant processes of care within an institution to assess their 
quality improvement performance and plans. 
RAI consists of: 
x a Minimum Data Set (MDS) 
x an identification of problem areas 
x specific Resident Assessment Protocols (RAPs) 
x a user’s manual 
The MDS is a core of assessment items that provides a comprehensive picture of each 
resident’s functional, cognitive and emotional status and a variety of other areas, 
including resident’s strengths, preferences and needs. The full MDS assessment is 
repeated yearly. In addition, a quarterly review is done with a subset of MDS 
assessment items.  
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Minimum Data Set items (MDS) 
x Background and customary routines 
x Communication–hearing patterns 
x Physical functioning and structural problems 
x Mood and behaviour patterns 
x Disease diagnoses 
x Oral–nutritional status 
x Skin condition 
x Special treatments and procedures 
x Cognitive patterns 
x Vision patterns 
x Continence 
x Activity pursuit patterns 
x Health conditions 
x Oral–dental status 
x Medication use 
Problem areas are identified by applying a set of algorithms to a resident’s MDS data 
that will suggest problems, risks for development of a problem, or potentials for 
improved function.  
The 18 condition-focused RAPs specify additional assessment of identified problem 
areas in the resident’s status. The protocols are intended to more directly link the MDS 
information to care plan decisions. Facility staff then use the more specialized 
assessment guidelines found in the RAPs to identify potentially treatable causes and 
focus decisions about the resident’s plan of care and services. 
Resident Assessment Protocols (RAPs) 
x Delirium 
x Visual function 
x ADL functional–rehabilitative potential 
x Psychosocial well-being 
x Behaviour problem 
x Falls 
x Feeding tubes 
x Dental care 
x Psychotropic drugs 
x Cognitive loss–dementia 
x Communication 
x Urinary incontinence and indwelling catheter 
x Mood state 
x Activities 
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x Nutritional status 
x Dehydration–fluid maintenance 
x Pressure ulcers 
x Physical restraints 
The user’s manual provides detailed specifications about how to complete the MDS and 
RAP assessment process (e.g. interviewing staff, residents and family members, 
reviewing records), and contains item definitions, examples of coding options and 
clinical guidelines for using the RAPs to develop care plans. 
While the Resident Assessment Instrument (RAI) was originally designed as a 
multidimensional assessment tool aimed at improving clinical practice, it can also 
provide the foundation for a comprehensive data base that can be used to assess and 
monitor the quality of care. Using data from four sites (in Denmark, Iceland, Italy and 
the USA) and eight indicators of quality that could be derived from single assessments, 
Howes et al. (1997) demonstrated how quality might be measured and compared using 
the RAI. They did show how this data base can provide invaluable information to 
providers about the quality of care within their facilities. It can also allow consumers 
and purchasers to evaluate the relative performance of different providers.  
Achterberg et al. (2001) found that the RAI has led to better case history and better 
care plans, which could mean the resident needs are better assessed. Having a better 
care plan does however, not necessarily mean the resident is better off (for example in 
aspects of quality of life, well-being and health outcomes). 
ACOVE (ASSESSING CARE OF VULNERABLE ELDERS) QUALITY 
CRITERIA 
The ACOVE criteria are the results of an explicit method for developing process quality 
indicators for vulnerable elders based on systematic literature reviews and several levels 
of expert opinion in USA. The 236 indicators developed with this method covered a 
range of domains (Screening, Prevention, Diagnosis, Treatment, Follow up, Continuity) 
and conditions (cf table 2) met in the vulnerable elders. 
It is a helpful tool to assess the quality of care and prescribing in the elders, and 
especially under-prescribing (cf the 40 items on specific medication that should be 
prescribed under mentioned conditions). 
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APPENDIX 8: UK COMMISSION FOR SOCIAL CARE 
INSPECTION OF NATIONAL MINIMUM 
STANDARDS ON MEDICATION CARE IN HOMES 
FOR OLDER PEOPLE: MEDICATION WITHIN THE 
HOMEa 
Service users, where appropriate, are responsible for their own medication, and are 
protected by the home’s policies and procedures for dealing with medicines.  
x The registered person ensures that there is a policy and staff adhere to 
procedures, for the receipt, recording, storage, handling, administration 
and disposal of medicines, and service users are able to take 
responsibility for their own medication if they wish, within a risk 
management framework.  
x The service user, following assessment as able to self-administer 
medication, has a lockable space in which to store medication, to which 
suitably trained, designated care staff may have access with the service 
user’s permission.  
x Records are kept of all medicines received, administered and leaving 
the home or disposed of to ensure that there is no mishandling. A 
record is maintained of current medication for each service user 
(including those self-administering).   
x Medicines in the custody of the home are handled according to the 
requirements of the Medicines Act 1968, guidelines from the Royal 
Pharmaceutical Society, the requirements of the Misuse of Drugs Act 
1971 and nursing staff abide by the UKCC Standards for the 
administration of medicines.  
x Controlled Drugs administered by staff are stored in a metal cupboard, 
which complies with the Misuse of Drugs (Safe Custody) Regulations 
1973.  
x Medicines, including Controlled Drugs, for service users receiving 
nursing care, are administered by a medical practitioner or registered 
nurse.  
x In residential care homes, all medicines, including Controlled Drugs, 
(except those for self-administration) are administered by designated 
and appropriately trained staff. The administration of Controlled Drugs 
is witnessed by another designated, appropriately rained member of 
staff. The training for care staff must be accredited and must include: 
basic knowledge of how medicines are used and how to recognise and 
deal with problems in use; the principles behind all aspects of the 
home’s policy on medicines handling and records.  
x Receipt, administration and disposal of Controlled Drugs are recorded 
in a Controlled Drugs register.  
x The registered manager seeks information and advice from a 
pharmacist regarding medicines policies within the home and medicines 
dispensed for individuals in the home.  
x Staff monitor the condition of the service user on medication and call 
in the GP if staff are concerned about any change in condition that may 
                                                     
a UK Commission for Social Care Inspection; “Handled with care? Managing medication for residents 
of care homes and children’s homes – a follow up study”;  
February 2006, CSCI – 112, special study report 
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be a result of medication, and prompt the review of medication on a 
regular basis.  
x When a service user dies, medicines should be retained for a period of 
seven days in case there is a coroner’s inquest.  
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APPENDIX 9: PROTOCOL FOR SCORING THE 
MEDICATION MANAGEMENT SYSTEMS  
QUESTIONNAIRE FOR THE BOARD  
TOPICS ANSWERING POSSIBILITIES SCORE 
Medication management   
Quality coordinator Yes 0 
 No -1 
Quality handbook Yes  0 
 No -1 
Number of written agreements 0-4 -1 
 5-9 0 
  10 +1 
Evaluation of medication process Never or less than once a 
year 
-3 
 Annually 0 
 At least every 6 months +2 
Self-reported medication error system Yes +1 
 No -1 
Actions to prevent errors Yes +2 
 No -2 
Formulary   
Formulary present Yes 0 
 No -3 
Use of formulary advised in regulations for 
visiting GPs Yes 
0 
 No -3 
Formulary electronically available Yes +1 
 No 0 
Electronic prescribing system Yes +1 
 No 0 
Formulary drugs as 1st choice in electronic 
prescribing system Yes 
+2 
 No 0 
Pharmacy   
Delivery of medication Per resident with name 0 
 Per resident without name -2 
 1 bag with name -1 
 1 bag without name -3 
Other activities of pharmacist 0-3 0 
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 4-5 +1 
 > 5 +2 
QUESTIONNAIRE FOR SENIOR NURSE OF THE WARD  
TOPICS ANSWERING POSSIBILITIES SCORE 
Work procedures   
Number of written agreements 0-4 -1 
 5-9 0 
  10 +1 
Formulary   
Formulary present Yes 0 
 No -2 
New GP informed about formulary Systematically 0 
 Sporadically -1 
 Never -3 
GP can prescribe non-formulary drugs 
without motivating Yes 
0 
 No +2 
Nurse points GP at prescribing non-
formulary drugs Systematically 
+3 
 Sporadically +1 
 Never 0 
Formulary visibly present at prescribing 
place Yes 
0 
 No -2 
Formulary systematically (at every 
prescription) presented at GP  Yes, to all GPs 
+3 
 Yes, only to GPs receptive 
to it 
+1 
 No 0 
Communication   
Evaluation of medication record Systematically +3 
 Sporadically 0 
Medication record   
Medication record Handwritten 0 
 Electronic +2 
Degree of informatisation Only medication record is 
electronic 
0 
 Entire patient record is 
electronic 
+1 
Items on medication record < the legally obliged items -3 
 = the legally obliged items 0 
 > the legally obliged items +1 
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Frequency new medication record < 1 x / month -1 
 Per (half) month or week 0 
 At every change +1 
Two person-check on correctness of 
medication record Yes 
+2 
 No -1 
Order of chronic medication after 
prescription   Yes 
0 
 No -2 
Check of dispensed medication Yes 0 
 
No 
-2 
Medication storage   
Separate room for medication storage 
Yes  
+1 
 
No 
0 
Medication cupboard locked 
Yes  
0 
 
No 
-2 
Separate lockable storage for stupefaction 
Yes  
0 
 
No 
-3 
Separate refrigerator for drugs 
Yes  
0 
 
No 
-2 
Check on the amount of stock  
Yes 
0 
 
No 
-1 
Check on expiration dates of stock 
Yes 
0 
 
No 
-2 
Emergency kit 
Yes 
0 
 
No 
-3 
Resident autonomy in medication  
management 
  
Medication record 
Yes 
+1 
 
No 
0 
Check on amount of stock 
Yes 
+1 
 
No 
0 
Check on expiration date 
Yes 
+1 
 
No 
0 
Preparation of medication   
Record used to prepare medication 
Medication record 
0 
 
Other 
-1 
Time period for which medication is 
prepared  Per week 
-3 
 
Per half week 
-3 
 
Per day 
0 
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Who prepares medication 
Nurse 
0 
 
Other 
-1 
Documentation of the name of the person 
preparing the medication Yes 
0 
 
No 
-1 
Check of prepared medication 
No 
-2 
 
Yes, by the same person  
0 
 
Yes, by another person 
+2 
Preparation immediately before 
administration  Yes for all mentioned drugs 
(drugs requiring cool 
storage, solutions, 
effervescent tablets, 
sachets) 
0 
 
No for 1 or more of the 
mentioned drugs 
-2 
Check of prepared medication  
immediately before administration No 
-2 
 
Yes, by the same person  
0 
 
Yes, by another person 
+2 
Tablets out of blister 
No 
0 
 
Yes, but medication 
prepared for max. 24 hours 
0 
 
Yes and medication 
prepared for more than 24 
hours 
- 3 
Administration of medication   
Who administrates medication 
Nurse 
0 
 
Other 
-1 
Documentation of the name of the person 
administrating medication Yes 
0 
 
No 
-1 
Control on medication  intake for mentally 
fit residents  Yes 
+1 
 
No 
-1 
Information sources used to check if drug 
forms are crushable None 
-3 
 
Patient package inserts 
0 
 
Medical coordinator (CRA) 
0 
 
Pharmacist 
+1 
 
Other 
+1 
Information about medication   
Information for nurses 
None 
-2 
 
Gecomm. GM-repertorium 
0 
 
Compendium 
0 
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Both 
+1 
Information from pharmacist 
Yes 
+2 
 
No 
-1 
Information from doctor 
Yes 
+2 
 
No 
-1 
Patient education about the indication 
Systematically 
+2 
 
Only for some drugs 
+1 
 
Only on request 
0 
 
No 
0 
Patient education about side-effects 
Systematically 
+2 
 
Only for some drugs 
+1 
 
Only on request 
0 
 
No 
0 
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APPENDIX 10: DETAILS OF THE PRESCRIBING 
QUALITY PROBLEM RESULTS 
Table 4.1. Beers criteria  
Results of the Beers Criteria (N=1720)  
Criterium 
number 
ATCcode Active substance 
Number of 
cases 
1 N02AC04 dextropropoxyphene  5 
2 M01AB01 Indometacin 0 
3 N02AD01 Pentazocine 0 
4 G04BD04 Oxybutynin 78 
5 N05CD01 Flurazepam 10 
6 N06AA09 Amitriptyline 28 
7 N05BA06 Lorazepam 9 
8 N05BA04 Oxazepam 0 
9 N05BA12 Alprazolam 0 
10 N05BA01 Diazepam 29 
11 N05BA05 clorazepate potassium 20 
12 C01BA03 disopyramide 4 
13 C01AA05 Digoxin 128 
14 B01AC07 dipyridamole 27 
15 C02AB01 methyldopa (levorotatory) 3 
16 R06AA02 diphenhydramine 0 
17 R06AA20 dimenhydrinaat 1 
18 R06AD02 promethazine 1 
19 C04AE01 ergoloid mesylates 34 
20 C04AX01 Cyclandelate 1 
21 B03AA07 ferrous sulfate 0 
22 A08AA10 Sibutramine 1 
23 M01AE02 Naproxen 0 
24 M01AE12 Oxaprozin 1 
25 M01AC01 Piroxicam 15 
26 A06AB CONTACT LAXATIVES 0 
27 C01BD01 Amiodarone 70 
28 C04AX01 Cyclandelate 1 
29 J01XE NITROFURAN DERIVATIVES 0 
30 C02CA04 Doxazosin 0 
31 G03B ANDROGENS 0 
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32 C08CA05 Nifedipine 38 
33 C02AC01 Clonidine 9 
34 A06AA SOFTENERS, EMOLLIENTS 0 
35 A02BA01 Cimetidine 1 
36 N06BA10 Fenetylline 0 
37 G03CA ESTROGENS 0 
38 N06AB03 Fluoxetine 21 
Table 4.2. Bednurs Criteria  
Bednurse criteria (N=1730) 
Number of 
patients 
Heart failure and verapamil 4 
Heart failure and diltiazem 39 
Heart failure and nonselective betablockers 59 
Heart failure and nonselective betablockers/thiazides 0 
Combination antihypertensives and NSAIDS 3 
Combination diuretics and NSAIDS 68 
Combination betablocker and NSAIDs 38 
Combination amitryptiline and doxepine 28 
Combination antiparkinson and Phenothiazines 7 
Long acting benzo: diazepam 29 
Long acting benzo: clorazepate 20 
Long acting benzo: clobazam 1 
Long acting benzo: loclazepate 3 
Long acting benzo: cloxazolam 11 
Long acting benzo: clonazepam 31 
Long acting benzo: prazepam 43 
Long acting benzo: nordazepam 1 
Long acting benzo: nitrazepam 2 
Long acting benzo: flunitrazepam 14 
Inappropriate: alimemazine 8 
Inappropriate: promethazine 1 
Inappropriate: pentazocine 0 
Chronic NSAID 132 
Combination Iron and NSAID 5 
Combination Iron and antithrombotics  46 
Heart failure and only monotherapy 191 
Combination ACE and Potassium or potassium saving diuretic 75 
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Combination Psychotropics: N05+N06  594 
Combination Psychotropics: N05+N05 1 
Combination Psychotropics: N06+N06 194 
Chronic use of antipsychotics (all patients)  437 
Table 4.3. Drug drug Interactions (N=2510) 
GM1 ATC1 GM2 ATC2 
Number
of 
patients 
C01AA05 Digoxin C03C HIGH-CEILING DIURETICS 62 
B01AA03 Warfarin H03 THYROID THERAPY 1 
C10AA HMG COA REDUCTASE INHIBIT C10AB04 Gemfibrozil 0 
C08DA01 Verapamil C07 BETA BLOCKING AGENTS 0 
B01AA03 Warfarin C01BD01 Amiodarone 7 
C03D POTASSIUM-SPARING AGENTS A12BA POTASSIUM 1 
C01AA05 Digoxin C08DA01 Verapamil 1 
C01AA05 Digoxin C01BD01 Amiodarone 9 
C02AC01 Clonidine C07 BETA BLOCKING AGENTS 4 
J01FA MACROLIDES C10AA HMG COA REDUCTASE INHIBIT 0 
N02CC01 Sumatriptan N06AB SELECTIVE SEROTONIN REUPT 0 
L01BA01 Methotrexate M01 ANTIINFLAMMATORY AND ANTI 1 
L04AX03 Methotrexate M01 ANTIINFLAMMATORY AND ANTI 2 
C01AA05 Digoxin C01BC03 Propafenone 0 
C01AA05 Digoxin C01BA01 Quinidine 0 
B01AA03 Warfarin A10BB SULFONAMIDES, UREA DERIVA 5 
B01AA03 Warfarin C01BA01 Quinidine 0 
N05AN01 Lithium M01 ANTIINFLAMMATORY AND ANTI 0 
B01AA03 Warfarin J02AC01 Fluconazole 0 
C08DA01 Verapamil N03AF01 Carbamazepine 0 
B01AA03 Warfarin N03AA BARBITURATES AND DERIVATI 0 
B01AA03 Warfarin A02BA01 Cimetidine 0 
R03DA XANTHINES J01MA FLUOROQUINOLONES 0 
B01AA03 Warfarin P03AB01 Clofenotane 0 
B01AA03 Warfarin J01XD01 Metronidazole 0 
B01AA03 Warfarin R03DC01 Zafirlukast 0 
B01AA03 Warfarin J01FA01 Erythromycin 0 
N06AA NON SELECTIVE MONOAMINE R C02AC01 Clonidine 0 
L01BA01 Methotrexate A10BB SULFONAMIDES, UREA DERIVA 0 
G04BE03 Sildenafil C01DA ORGANIC NITRATES 0 
C08DA01 Verapamil C01BA01 Quinidine 0 
N04BD01 Selegiline N06AB SELECTIVE SEROTONIN REUPT 3 
A08AA10 Sibutramine N06AB SELECTIVE SEROTONIN REUPT 0 
N03AF01 Carbamazepine J01FA MACROLIDES 0 
C01AA05 Digoxin L04AA01 Ciclosporin 0 
R03DA XANTHINES J01FA MACROLIDES 0 
B01AA03 warfarin L01BC06 Capecitabine 0 
R03DA XANTHINES A02BA01 Cimetidine 0 
M04AA01 allopurinol L04AX01 Azathioprine 0 
KCE reports 47 Medication use in Nursing Homes 167 
 
L04AA01 ciclosporin N03AB02 Phenytoin 0 
L01BA01 methotrexate B01AC06 acetylsalicylic acid 0 
L01BA01 methotrexate N02BA01 acetylsalicylic acid 0 
L04AX03 methotrexate B01AC06 acetylsalicylic acid 1 
L04AX03 methotrexate N02BA01 acetylsalicylic acid 0 
J04AB02 rifampicin H02AB GLUCOCORTICOIDS 0 
J02AB02 ketoconazole A02BA H2-RECEPTOR ANTAGONISTS 0 
C01BD01 amiodarone C01BA01 Quinidine 0 
N04BD01 selegiline N06AX16 Venlafaxine 0 
C10AA02 lovastatin L04AA01 Ciclosporin 0 
B01AA03 warfarin G03B ANDROGENS 0 
J04AB02 rifampicin G03A HORMONAL CONTRACEPTIVES F 0 
G02AB ERGOT ALKALOIDS J01FA MACROLIDES 0 
N06AG MONOAMINE OXIDASE TYPE A N06AB SELECTIVE SEROTONIN REUPT 0 
N06AG MONOAMINE OXIDASE TYPE A N06BA CENTRALLY ACTING SYMPATHO 0 
N06AG MONOAMINE OXIDASE TYPE A N02CC01 Sumatriptan 0 
N06AG MONOAMINE OXIDASE TYPE A N06AA NON SELECTIVE MONOAMINE R 0 
N06AF MONOAMINE OXIDASE INHIBIT N06AB SELECTIVE SEROTONIN REUPT 0 
N06AF MONOAMINE OXIDASE INHIBIT N06BA CENTRALLY ACTING SYMPATHO 0 
N06AF MONOAMINE OXIDASE INHIBIT N02CC01 Sumatriptan 0 
N06AF MONOAMINE OXIDASE INHIBIT N06AA NON SELECTIVE MONOAMINE R 0 
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APPENDIX 11: DESCRIPTION OF THE 
ENDOGENOUS VARIABLES INCLUDED IN THE 
MUTIVARIATE ANALYSIS 
In this appendix, descriptive statistics are given for 74 institutions for data on medicines 
(data on medicines insufficient for 2 institutions) and 72 institutions for data on quality 
of prescribing (data on clinical problems missing for 2 extra institutions).  Per 
institution, for a number of variables, the mean of all residents was calculated.  
The figures and data below describe the variation of these means over the institutions. 
For instance, for the total number of medication lines on the registration chart of 
residents, the mean total number of medication lines per resident ranged from 5.8 to 
12.1 in the 74 institutions. The median of these means was 7.9. 
In this appendix, we give the basic statistics of the 7 endogenous variables, representing 
volume, expenditures and appropriateness of prescribing:  
x Average number drugs per resident (MEDICTOT) 
x Average number chronic systemic drugs per resident (MNSYST) 
x Average expenditures in ex-pharmacy retail price (publieksprijs) of 
reimbursed chronic drugs per month per resident (MNPPCHRE) 
Average co-payment for chronic reimbursed drugs per month per 
resident (MNREMCHR) 
x Average out of pocket payment of non-reimbursed drugs per month 
per resident (MNPPNONR) 
x Percentage of cheap drugs (PCGOEDKO) 
x Average sum-score of quality problems of prescribing per resident 
(TOTQUALM) 
In addition, for each of these variables the variance within each stratum (OCMW-small; 
OCMM-large, Private-small; Private-large) and within the province (Antwerpen, Oost-
Vlaanderen, Hainaut) is given.  
Nursing homes with OCMW status are nursing homes run by the Local Community 
Social Service, while private institutions are either run by non-for profit charity 
associations or for-profit institutions. Nursing homes with more then 90 beds were 
considered large nursing homes.   
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1. Average number drugs per resident (MEDICTOT) and average number 
of systemic drugs (MNSYST) 
 
 
 MEDICTOT MNSYST 
 Mean  8.070592  7.283634 
 Median  7.946909  7.197222 
 Maximum  12.06667  10.63333 
 Minimum  5.823529  5.108108 
 Std. Dev.  1.299964  1.170890 
 Skewness  0.658885  0.599517 
 Kurtosis  3.302355  3.422868 
   
 Jarque-Bera  5.636131  4.984211 
 Probability  0.059721  0.082736 
   
 Sum  597.2238  538.9889 
 Sum Sq. Dev.  123.3632  100.0818 
   
 Observations  74  74 
 
5
6
7
8
9
10
11
12
13
MEDICTOT MNSYST
170 Medication use in Nursing Homes KCE reports 47 
 
 
 
Included observations: 74     
STRATUM  Mean  Median  Max  Min.  Std. Dev.  Obs. 
OCMWkl 8.584003 8.725000 10.62857 6.825000 1.176552 15 
OCMWgr 7.746302 7.655172 12.06667 5.823529 1.478451 17 
PRIVEkl 7.895631 7.935484 10.89744 6.269231 1.112478 19 
PRIVEgr 8.119985 8.142857 11.22581 5.897436 1.354352 23 
All 8.070592 7.946909 12.06667 5.823529 1.299964 74 
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Mean       8.070592
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Minimum  5.823529
Std. Dev.   1.299964
Skewness   0.658885
Kurtosis   3.302355
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Probability  0.059721
5
6
7
8
9
10
11
12
13
OCMWkl OCMWgr PRIVEkl PRIVEgr
M
E
D
IC
TO
T
STRATUM
KCE reports 47 Medication use in Nursing Homes 171 
 
 
Included observations: 74     
PROV  Mean  Median  Max  Min.  Std. Dev.  Obs. 
antw 8.064149 8.266667 10.89744 6.250000 1.250787 27 
Oostvl 8.083828 7.958333 10.62857 6.424242 1.064642 25 
Heneg 8.063459 7.716667 12.06667 5.823529 1.625354 22 
All 8.070592 7.946909 12.06667 5.823529 1.299964 74 
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Included observations: 76     
STRATUM  Mean  Median  Max  Min.  Std. Dev.  Obs. 
OCMWkl 7.675142 7.600000 9.486486 5.108108 1.251412 15 
OCMWgr 6.797712 6.846154 10.63333 5.179487 1.228337 17 
PRIVEkl 7.223733 7.366667 9.538462 5.447368 1.013599 19 
PRIVEgr 7.451082 7.352941 10.56667 5.727273 1.220923 25 
All 7.292319 7.197222 10.63333 5.108108 1.196721 76 
 
 
0
2
4
6
8
10
5 6 7 8 9 10
Series: MNSYST
Sample 1 76
Observations 76
Mean       7.292319
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Std. Dev.   1.196721
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Kurtosis   3.232358
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Probability  0.108819
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Included observations: 76     
PROV  Mean  Median  Max  Min.  Std. Dev.  Obs. 
Antw 7.054220 6.846154 9.538462 5.108108 1.219326 27 
Oostvl 7.374408 7.297297 9.486486 5.939394 0.920084 25 
Heneg 7.474670 7.262677 10.63333 5.606061 1.413299 24 
All 7.292319 7.197222 10.63333 5.108108 1.196721 76 
 
2. Expenditures for medication  
x Average expenditures in ex-pharmacy retail price (publieksprijs) of reimbursed chronic drugs 
per month per resident (MNPPCHRE)  
x Average co-payment for chronic reimbursed drugs per month per resident (MNREMCHR) 
x Average out of pocket payment of non-reimbursed drugs per month per resident 
(MNPPNONR) 
x Percentage of cheap drugs (PCGOEDKO) 
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 MNPPCHRE MNREMCHR MNPPNONR PCGOEDKO 
 Mean  110.2141  23.38544  27.09559  28.88044 
 Median  106.2466  22.97883  26.29417  28.60963 
 Maximum  194.4050  36.54556  46.03676  55.88235 
 Minimum  42.08627  14.30778  14.88654  13.23529 
 Std. Dev.  27.70399  4.861624  7.359154  6.830823 
 Skewness  0.495071  0.290648  0.579133  0.946244 
 Kurtosis  3.448293  2.798354  2.704729  5.560663 
     
 Jarque-Bera  3.740929  1.198796  4.524424  30.41551 
 Probability  0.154052  0.549142  0.104120  0.000000 
     
 Sum  8376.272  1777.294  2059.265  2079.392 
 Sum Sq. Dev.  57563.31  1772.654  4061.786  3312.870 
     
 Observations  76  76  76  72 
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Average expenditures in ex-pharmacy retail price of reimbursed chronic 
drugs  per month/ per resident (MNPPCHRE) 
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Included observations: 76     
STRATUM  Mean  Median  Max  Min.  Std. Dev.  Obs. 
OCMWkl 117.8412 109.2755 155.8690 85.43979 24.68307 15 
OCMWgr 103.4918 98.59017 178.2454 64.19471 29.32677 17 
PRIVEkl 110.2639 114.3802 152.6149 65.95356 22.60458 19 
PRIVEgr 110.1712 105.7747 194.4050 42.08627 31.90774 25 
All 110.2141 106.2466 194.4050 42.08627 27.70399 76 
 
Included observations: 76     
PROV  Mean  Median  Max  Min.  Std. Dev.  Obs. 
antw 111.5153 109.4136 166.7330 71.19371 25.46530 27 
Oostvl 108.9190 106.7186 155.7294 64.19471 24.82187 25 
Heneg 110.0993 105.0544 194.4050 42.08627 33.51044 24 
All 110.2141 106.2466 194.4050 42.08627 27.70399 76 
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Average co-payment for chronic reimbursed drugs per month per 
resident (MNREMCHR) 
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Included observations: 76     
STRATUM  Mean  Median  Max  Min.  Std. Dev.  Obs. 
OCMWkl 24.14244 23.92000 36.54556 14.30778 5.573664 15 
OCMWgr 21.09091 20.80724 33.57172 14.35793 4.954997 17 
PRIVEkl 23.86815 23.62727 32.76816 17.10400 4.340401 19 
PRIVEgr 24.12467 24.17033 32.95267 15.20935 4.516689 25 
All 23.38544 22.97883 36.54556 14.30778 4.861624 76 
 
Included observations: 76     
PROV  Mean  Median  Max  Min.  Std. Dev.  Obs. 
antw 23.01375 22.71138 32.76816 14.30778 5.021002 27 
Oostvl 22.27301 21.70769 36.54556 14.35793 5.201810 25 
Heneg 24.96238 24.84044 33.57172 16.89273 4.029355 24 
All 23.38544 22.97883 36.54556 14.30778 4.861624 76 
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Payment of non-reimbursed drugs per month per resident (MNPPNONR) 
 
 
 
0
1
2
3
4
5
6
7
8
15 20 25 30 35 40 45
Series: MNPPNONR
Sample 1 76
Observations 76
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Included observations: 76     
STRATUM  Mean  Median  Max  Min.  Std. Dev.  Obs. 
OCMWkl 26.12293 24.82952 41.47162 14.88654 7.086075 15 
OCMWgr 29.29872 26.84605 46.03676 16.63204 8.009410 17 
PRIVEkl 25.35087 24.57481 43.51378 15.16221 6.459627 19 
PRIVEgr 27.50703 26.67746 43.90917 16.34971 7.698875 25 
All 27.09559 26.29417 46.03676 14.88654 7.359154 76 
 
 
 
Included observations: 76     
PROV  Mean  Median  Max  Min.  Std. Dev.  Obs. 
antw 26.48898 26.10152 41.47162 14.88654 5.869651 27 
Oostvl 25.05044 24.57481 41.18750 15.16221 6.510198 25 
Heneg 29.90837 29.61801 46.03676 16.63204 8.955073 24 
All 27.09559 26.29417 46.03676 14.88654 7.359154 76 
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Percentage of cheap drugs (PCGOEDKO) 
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Observations 72
Mean       28.88044
Median   28.60963
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Std. Dev.   6.830823
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Kurtosis   5.560663
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Probability  0.000000
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Included observations: 72     
STRATUM  Mean  Median  Max  Min.  Std. Dev.  Obs. 
OCMWkl 28.79186 27.74566 55.88235 19.11765 8.344837 15 
OCMWgr 31.30409 32.96703 40.74074 16.85393 6.901014 17 
PRIVEkl 29.03448 26.66667 46.66667 19.79167 6.555714 19 
PRIVEgr 26.84234 27.58621 36.78161 13.23529 5.544033 21 
All 28.88044 28.60963 55.88235 13.23529 6.830823 72 
 
 
 
Included observations: 72     
PROV  Mean  Median  Max  Min.  Std. Dev.  Obs. 
antw 31.84964 30.79502 55.88235 19.79167 7.018133 26 
Oostvl 28.35437 27.74566 46.66667 17.74194 6.861920 25 
Heneg 25.83058 25.88235 34.66667 13.23529 5.098916 21 
All 28.88044 28.60963 55.88235 13.23529 6.830823 72 
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3. Appropriateness of prescribing  
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Included observations: 72     
STRATUM  Mean  Median  Max  Min.  Std. Dev.  Obs. 
OCMWkl 3.607134 3.558824 4.838710 2.206897 0.864444 15 
OCMWgr 3.335831 3.400000 4.333333 2.440000 0.579643 17 
PRIVEkl 3.310118 3.272727 4.709677 2.090909 0.726061 19 
PRIVEgr 3.395364 3.388889 4.823529 2.565217 0.564539 21 
All 3.402931 3.351471 4.838710 2.090909 0.677271 72 
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Included observations: 72     
PROV  Mean  Median  Max  Min.  Std. Dev.  Obs. 
antw 3.157819 3.016667 4.838710 2.142857 0.731312 26 
Oostvl 3.672229 3.600000 4.823529 2.333333 0.594083 25 
Heneg 3.385810 3.481481 4.470588 2.090909 0.606024 21 
All 3.402931 3.351471 4.838710 2.090909 0.677271 72 
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APPENDIX 12: DETAILS OF THE MULTIVARIATE 
ANALYSIS (REGRESSION RESULTS FOR 
ENDOGENOUS VARIABLES) 
Average number drugs per resident 
Dependent variable :  MEDICTOT     
Variable Coef. St. err. t-stat Prob.
(Constant) -2.353 2.896 -0.812 0.421
Dovl -1.188 0.375 -3.171 0.003
Dhen -0.823 0.508 -1.620 0.112
Docmw -0.389 0.348 -1.116 0.270
dprivefprof -1.364 0.531 -2.569 0.013
Apogroot 1.442 0.617 2.340 0.024
qsumPHARM -0.162 0.151 -1.074 0.288
qsumMRECORD_mean -0.054 0.054 -1.011 0.317
qsumADMM_mean -0.105 0.115 -0.911 0.367
qsumINFO_mean 0.098 0.070 1.398 0.169
percRVTbeddenvlgKCE 0.026 0.014 1.876 0.067
percfemale 0.075 0.031 2.437 0.019
percKatzScoreC -0.022 0.016 -1.393 0.170
RbewVPK -0.344 0.079 -4.378 0.000
RbewVstaf 1.184 0.286 4.133 0.000
Polypath 0.790 0.342 2.308 0.025
Totzorg 0.749 0.277 2.705 0.009
pcOCMW -0.015 0.009 -1.786 0.080
 
R² R²-adjusted St. err. of est. Durbin-Watson   
0.598 0.455 0.929994177 1.821   
      
 Sum of Squares Df Mean Square F-stat Prob. 
Regression 61.709 17 3.63 4.197 0 
Residual 41.515 48 0.865     
Total 103.224 65       
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Average number chronic systemic drugs per resident 
Dependent variable :  MNSYST       
Variable Coef. St. err. t-stat Prob. 
(Constant) -1.291 2.368 -0.545 0.588 
dovl -0.521 0.272 -1.914 0.061 
dhen -0.425 0.393 -1.082 0.284 
docmw -0.364 0.250 -1.455 0.152 
dprivefprof -0.883 0.432 -2.046 0.046 
apogroot 0.873 0.478 1.829 0.074 
qsumSTORAGE_mean -0.048 0.046 -1.036 0.305 
qsumADMM_mean -0.148 0.085 -1.746 0.087 
qsumINFO_mean 0.086 0.056 1.540 0.130 
percRVTbeddenvlgKCE 0.020 0.009 2.131 0.038 
percfemale 0.037 0.023 1.589 0.118 
RbewVPK -0.205 0.064 -3.227 0.002 
RbewVstaf 1.037 0.229 4.534 0.000 
pcA1new -0.024 0.022 -1.130 0.264 
polypath 0.921 0.261 3.524 0.001 
totzorg 0.463 0.218 2.126 0.039 
pcOCMW -0.013 0.007 -1.932 0.059 
 
R² R²-adjusted St. err. of est. Durbin-Watson   
0.656 0.544 0.74939 1.918   
      
 Sum of Squares df Mean Square F-stat Prob. 
Regression 52.455 16 3.278 5.838 0 
Residual 27.518 49 0.562     
Total 79.973 65       
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Average price (publieksprijs) of reimbursed chronic drugs per month per 
resident 
Dependent variable :  MNPPCHREIMB     
Variable Coef. St. err. t-stat Prob. 
(Constant) 35.068 30.841 1.137 0.261 
Dhen 13.851 9.273 1.494 0.142 
Dprivefprof -16.284 11.855 -1.374 0.176 
Aantal bedden -0.208 0.079 -2.624 0.012 
Aantal afdelingen 5.232 2.516 2.080 0.043 
Procent bew behandeld dr CRA 0.626 0.175 3.585 0.001 
Bew per ext huisarts 3.908 1.716 2.277 0.028 
Apomonop 5.791 6.377 0.908 0.368 
Procent bew afz factuur private kosten 0.165 0.152 1.083 0.285 
QsumFORM 3.474 1.854 1.873 0.067 
qsumSTORAGE_mean -1.320 1.268 -1.041 0.303 
qsumPREPMED_mean 1.011 1.116 0.905 0.370 
qsumADMM_mean -2.363 2.136 -1.106 0.274 
qsumINFO_mean 2.007 1.444 1.390 0.171 
RbewVPK -5.170 1.695 -3.050 0.004 
RbewVstaf 10.345 5.614 1.843 0.072 
pcA1new -1.593 0.583 -2.733 0.009 
Polypath 10.677 6.843 1.560 0.126 
Totzorg 13.966 5.708 2.447 0.018 
PcOCMW -0.596 0.221 -2.693 0.010 
 
R² R²-adjusted St. err. of est. Durbin-Watson   
0.534 0.342 18.98516 2.025   
      
 Sum of Squares df Mean Square F-stat Prob. 
Regression 19019.21 19 1001.011 2.777 0 
Residual 16580.073 46 360.436     
Total 35599.282 65       
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Average co-payment for chronic reimbursed drugs per month per 
resident 
Dependent variable :  MNREMCHREIMB     
Variable Coef. St. err. t-stat Prob. 
(Constant) -14.176 8.852 -1.601 0.116 
Dovl -3.626 1.128 -3.215 0.002 
Dhen -3.256 1.358 -2.397 0.021 
Dprivefprof -4.103 1.530 -2.681 0.010 
Apoziek -4.597 2.813 -1.634 0.109 
Apogroot 1.713 1.827 0.938 0.353 
Apomonop 1.254 0.884 1.419 0.163 
Procent bew afz factuur private kosten -0.066 0.033 -1.974 0.054 
QsumPHARM -1.042 0.402 -2.595 0.013 
qsumCOM_mean 0.637 0.335 1.901 0.064 
qsumZELFMED_mean 1.344 0.476 2.827 0.007 
percRVTbeddenvlgKCE 0.199 0.034 5.844 0.000 
Percfemale 0.285 0.073 3.906 0.000 
RbewA1 -0.160 0.080 -2.002 0.051 
RbewVPK -0.626 0.227 -2.762 0.008 
RbewVstaf 5.028 0.980 5.129 0.000 
pcA1new -0.283 0.162 -1.748 0.087 
Polypath 4.675 0.797 5.867 0.000 
Prijsconc -1.760 0.946 -1.860 0.069 
PcOCMW -0.133 0.030 -4.471 0.000 
 
R² R²-adjusted St. err. of est. Durbin-Watson   
0.78 0.69 2.49415 1.81   
      
 Sum of Squares df Mean Square F-stat Prob. 
Regression 1016.801 19 53.516 8.603 0 
Residual 286.156 46 6.221     
Total 1302.958 65       
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Average out of pocket payment of non-reimbursed drugs per month per 
resident 
Dependent variable :  MNPPNONREIMB     
Variable Coef. St. err. t-stat Prob. 
(Constant) -15.516 16.813 -0.923 0.361 
Dovl -7.312 2.260 -3.235 0.002 
Docmw -2.539 2.071 -1.226 0.226 
Dprivefprof -5.360 3.248 -1.650 0.106 
Procent bew behandeld dr CRA -0.045 0.047 -0.956 0.344 
Bew per ext huisarts 1.243 0.492 2.527 0.015 
Apoziek 10.558 3.838 2.751 0.008 
Apogroot 6.850 3.669 1.867 0.068 
QsumFORM -0.671 0.474 -1.417 0.163 
qsumPROC_mean 3.409 1.265 2.695 0.010 
qsumSTORAGE_mean -0.916 0.348 -2.633 0.011 
qsumZELFMED_mean 1.195 1.046 1.142 0.259 
percRVTbeddenvlgKCE 0.122 0.070 1.755 0.086 
Percfemale 0.230 0.171 1.349 0.184 
percKatzScoreC -0.119 0.095 -1.250 0.217 
RbewVPK -1.117 0.478 -2.335 0.024 
RbewVstaf 5.143 1.470 3.498 0.001 
Totzorg 5.872 1.571 3.738 0.001 
PcOCMW -0.125 0.063 -2.000 0.051 
 
R² R²-adjusted St. err. of est. Durbin-Watson   
0.592 0.436 5.58947 2.191   
      
 Sum of Squares df Mean Square F-stat Prob. 
Regression 2132.037 18 118.447 3.791 0 
Residual 1468.384 47 31.242     
Total 3600.421 65       
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Percentage of cheap drugs 
Dependent variable :  PCGOEDKOOP     
Variable Coef. St. err. t-stat Prob. 
(Constant) 57.162 14.654 3.901 0.000 
dovl 5.497 2.307 2.383 0.021 
dhen 5.395 2.614 2.064 0.045 
docmw -3.916 1.683 -2.326 0.024 
apomonop -5.319 1.519 -3.502 0.001 
Procent bew afz factuur private kosten -0.080 0.032 -2.467 0.017 
qsumMANAG -0.187 0.185 -1.011 0.317 
qsumFORM 0.392 0.452 0.868 0.390 
qsumFORM_mean 0.418 0.243 1.722 0.092 
qsumCOM_mean 0.872 0.625 1.395 0.170 
qsumADMM_mean -0.589 0.527 -1.118 0.269 
qsumINFO_mean 0.632 0.369 1.715 0.093 
percRVTbeddenvlgKCE -0.089 0.069 -1.301 0.200 
percfemale -0.207 0.140 -1.481 0.145 
RbewA1 0.151 0.080 1.890 0.065 
RbewVPK 0.413 0.398 1.038 0.305 
RbewVstaf -4.664 1.418 -3.289 0.002 
pcdement 0.086 0.062 1.378 0.175 
totzorg -2.194 1.244 -1.764 0.084 
prijsconc 8.334 2.061 4.043 0.000 
 
R² R²-adjusted St. err. of est. Durbin-Watson   
0.612 0.452 4.4758 2.536   
      
 Sum of Squares df Mean Square F-stat Prob. 
Regression 1452.578 19 76.451 3.816 0 
Residual 921.506 46 20.033     
Total 2374.084 65       
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Average sum-score of quality problems of prescribing per resident 
Dependent variable :  TOTQUALMN     
Variable Coef. St. err. t-stat Prob. 
(Constant) 12.400 3.279 3.782 0.000 
Aantal bedden 0.003 0.001 2.294 0.026 
Procent bew behandeld dr CRA -0.008 0.004 -2.015 0.049 
Bew per ext huisarts -0.073 0.041 -1.772 0.083 
Apoziek 0.397 0.277 1.432 0.158 
Apogroot 0.267 0.291 0.919 0.362 
qsumPHARM -0.187 0.073 -2.569 0.013 
qsumPREPMED_mean -0.043 0.024 -1.786 0.080 
percRVTbeddenvlgKCE -0.009 0.006 -1.556 0.126 
Age -0.107 0.034 -3.113 0.003 
RbewA1 -0.009 0.006 -1.578 0.121 
RbewVPK -0.069 0.034 -2.040 0.047 
pcdement -0.012 0.005 -2.190 0.033 
polypath 0.550 0.161 3.421 0.001 
totzorg 0.218 0.135 1.617 0.112 
pcOCMW -0.007 0.005 -1.330 0.189 
 
R² R²-adjusted St. err. of est. Durbin-Watson   
0.638 0.529 0.44794 1.722   
      
 Sum of Squares df Mean Square F-stat Prob. 
Regression 17.674 15 1.178 5.872 0 
Residual 10.032 50 0.201     
Total 27.706 65       
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Medication management 
Dependent variable :  QSUMMANAG       
Variable Coef. St. err. t-stat Prob. 
(Constant) 34.287 24.730 1.386 0.171 
Dhen 1.694 1.452 1.167 0.248 
Apoziek -3.318 1.934 -1.715 0.092 
Apomonop 1.404 1.176 1.194 0.238 
Age -0.298 0.271 -1.100 0.276 
RbewA1 -0.177 0.084 -2.103 0.040 
pcA1new -0.235 0.179 -1.316 0.194 
Pcdement -0.038 0.035 -1.110 0.272 
Polypath 1.640 1.238 1.324 0.191 
Totzorg -1.079 1.071 -1.007 0.318 
Prijsconc -1.717 1.203 -1.427 0.159 
PcOCMW 0.034 0.035 0.982 0.331 
 
R² R²-adjusted St. err. of est. Durbin-Watson   
0.19 0.025 3.55633 2.06   
      
 Sum of Squares df Mean Square F-stat Prob. 
Regression 160.021 11 14.547 1.15 0.34 
Residual 682.963 54 12.647     
Total 842.985 65       
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Formulary 
Dependent variable :  QSUMFORM       
Variable Coef. St. err. t-stat Prob. 
(Constant) -7.856 10.898 -0.721 0.474 
Dovl 0.585 0.540 1.083 0.284 
Dhen -1.777 0.635 -2.799 0.007 
Dprivefprof 1.939 0.835 2.323 0.024 
Procent bew afz factuur private kosten -0.027 0.009 -2.996 0.004 
Age 0.148 0.120 1.229 0.224 
Percfemale -0.045 0.041 -1.082 0.284 
RbewA1 -0.040 0.033 -1.187 0.240 
RbewVPK 0.249 0.098 2.556 0.013 
pcA1new -0.110 0.070 -1.567 0.123 
Pcdement 0.017 0.016 1.094 0.279 
PcOCMW 0.024 0.015 1.593 0.117 
 
 
R² R²-adjusted St. err. of est. Durbin-Watson   
0.635 0.561 1.41392 2.155   
      
 Sum of Squares df Mean Square F-stat Prob. 
Regression 188.166 11 17.106 8.557 0 
Residual 107.956 54 1.999     
Total 296.121 65       
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Pharmacist 
Dependent variable :  QSUMPHARM       
Variable Coef. St. err. t-stat Prob. 
(Constant) 1.409 1.124 1.253 0.216 
Aantal bedden 0.006 0.002 2.639 0.011 
Procent bew behandeld dr CRA -0.012 0.006 -1.801 0.077 
Bew per ext huisarts -0.099 0.067 -1.469 0.148 
Apoziek 1.119 0.442 2.534 0.014 
Apogroot 0.723 0.506 1.428 0.159 
Apomonop 0.396 0.268 1.477 0.146 
percKatzScoreC 0.021 0.011 1.938 0.058 
RbewVPK -0.177 0.063 -2.813 0.007 
RbewVstaf 0.316 0.200 1.575 0.121 
Pcdement -0.024 0.009 -2.587 0.013 
Polypath -0.734 0.272 -2.695 0.009 
Totzorg 0.319 0.221 1.446 0.154 
Prijsconc -0.620 0.239 -2.597 0.012 
 
 
R² R²-adjusted St. err. of est. Durbin-Watson   
0.489 0.361 0.7873 1.912   
      
 Sum of Squares df Mean Square F-stat Prob. 
Regression 30.799 13 2.369 3.822 0 
Residual 32.232 52 0.62     
Total 63.03 65       
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Sum of quality scores of medication management on board level 
Dependent variable :  QSUMTOTDIR       
Variable Coef. St. err. t-stat Prob. 
(Constant) 8.400 5.122 1.640 0.107 
dprivefprof 2.808 2.260 1.243 0.219 
apomonop 1.432 1.295 1.106 0.274 
percKatzScoreC 0.061 0.048 1.275 0.207 
RbewA1 -0.164 0.080 -2.049 0.045 
pcA1new -0.268 0.182 -1.472 0.147 
pcdement -0.080 0.044 -1.824 0.073 
prijsconc -2.038 1.426 -1.429 0.158 
pcOCMW 0.063 0.031 1.997 0.051 
 
R² R²-adjusted St. err. of est. Durbin-Watson   
0.208 0.097 4.07701 1.754   
      
 Sum of Squares df Mean Square F-stat Prob. 
Regression 249.528 8 31.191 1.876 0.082 
Residual 947.457 57 16.622     
Total 1196.985 65       
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